0001043961-17-000009.txt : 20170518 0001043961-17-000009.hdr.sgml : 20170518 20170518143441 ACCESSION NUMBER: 0001043961-17-000009 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 56 CONFORMED PERIOD OF REPORT: 20170331 FILED AS OF DATE: 20170518 DATE AS OF CHANGE: 20170518 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TRANSGENOMIC INC CENTRAL INDEX KEY: 0001043961 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 911789357 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36439 FILM NUMBER: 17854543 BUSINESS ADDRESS: STREET 1: 12325 EMMET ST CITY: OMAHA STATE: NE ZIP: 68164 BUSINESS PHONE: 4027385480 MAIL ADDRESS: STREET 1: 12325 EMMET STREET CITY: OMAHA STATE: NE ZIP: 68164 10-Q 1 tbio-20170331x10q.htm 10-Q Document

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 _______________________________
 FORM 10-Q
 _______________________________

(Mark One)
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the quarterly period ended March 31, 2017
OR 
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from _____ to _____
Commission File Number: 000-36439
 _______________________________
TRANSGENOMIC, INC.
(Exact name of registrant as specified in its charter)
 _______________________________

Delaware
 
91-1789357
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification No.)
 
 
 
12325 Emmet Street, Omaha, Nebraska
 
68164
(Address of principal executive offices)
 
(Zip Code)
(402) 452-5400
(Registrant’s telephone number, including area code)
 _______________________________
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes   x No   o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).   Yes   x No   o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
 
o
Accelerated filer
 
o
Non-accelerated filer
 
o  (Do not check if a smaller reporting company)
Smaller reporting company
 
x
Emerging growth company
 
o
 
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes   o    No   x
As of April 30, 2017, the number of shares of common stock outstanding was 26,863,062.


TRANSGENOMIC, INC.
INDEX
 
 
 
 
 
 
 
 
Page No.    
 
 
 
 
PART I.
 
 
 
 
 
Item 1.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6
 
 
 
 
Item 2.
 
 
 
 
 
Item 3.
 
Quantitative and Qualitative Disclosures About Market Risk
 
 
 
 
Item 4.
 
 
 
 
 
PART II.
 
 
 
 
 
Item 1.
 
 
 
 
 
Item 1A.
 
 
 
 
 
Item 6.
 
 
 
 
 

2

PART I. FINANCIAL INFORMATION 
Item 1.
Financial Statements
TRANSGENOMIC, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED BALANCE SHEETS
(Dollars in thousands, except share data)
 
March 31,
 
 
 
2017
 
December 31,
 
(unaudited)
 
2016
ASSETS
 
 
 
CURRENT ASSETS:
 
 
 
Cash and cash equivalents
$
59

 
$
110

Accounts receivable, net
279

 
225

Inventories
15

 
24

Other current assets
190

 
105

Assets held for sale
24

 
31

Total current assets
567

 
495

 
 
 
 
PROPERTY AND EQUIPMENT, NET
127

 
144

 
 
 
 
OTHER ASSETS:
 
 
 
Intangibles, net
531

 
562

Other assets
4

 
58

 
$
1,229

 
$
1,259

LIABILITIES AND STOCKHOLDERS’ DEFICIT
 
 
 
CURRENT LIABILITIES:
 
 
 
Current maturities of long-term debt
$
7,368

 
$
7,814

Accounts payable
8,509

 
6,541

Accrued compensation
192

 
224

Accrued expenses
3,398

 
3,546

Deferred revenue
133

 
170

Other current liabilities
1,529

 
1,529

Total current liabilities
21,129

 
19,824

LONG TERM LIABILITIES:
 
 
 
Common stock warrant liability
615

 
582

Other long-term liabilities
128

 
203

Total liabilities
21,872

 
20,609

STOCKHOLDERS’ DEFICIT:
 
 
 
Preferred stock, $0.01 par value, 15,000,000 shares authorized, 214,705 shares issued and outstanding
2

 
2

Common stock, $0.01 par value, 150,000,000 shares authorized, 26,863,062 shares at March 31, 2017 and 26,446,927 shares at December 31, 2016 issued and outstanding
268

 
264

Additional paid-in capital
206,342

 
205,877

Accumulated deficit
(227,255
)
 
(225,493
)
Total stockholders’ deficit
(20,643
)
 
(19,350
)
 
$
1,229

 
$
1,259


See notes to unaudited condensed consolidated financial statements.

3

TRANSGENOMIC, INC. AND SUBSIDIARY
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Dollars in thousands, except per share data)
 
 
Three Months Ended
 
March 31,
 
2017
 
2016
NET SALES
$
658

 
$
236

COST OF GOODS SOLD
459

 
505

Gross profit (loss)
199

 
(269
)
OPERATING EXPENSES:
 
 
 
Selling, general and administrative
1,620

 
1,704

Research and development
134

 
270

 
1,754

 
1,974

OPERATING LOSS FROM CONTINUING OPERATIONS
(1,555
)
 
(2,243
)
OTHER INCOME (EXPENSE):
 
 
 
Interest expense, net
(247
)
 
(169
)
Warrant revaluation
(33
)
 
321

 
(280
)
 
152

LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES
(1,835
)
 
(2,091
)
INCOME TAX EXPENSE (BENEFIT)
—

 
—

LOSS FROM CONTINUING OPERATIONS
(1,835
)
 
(2,091
)
INCOME (LOSS) FROM DISCONTINUED OPERATIONS, NET OF TAXES
73

 
(1,173
)
NET LOSS
(1,762
)
 
(3,264
)
 
 
 
 
PREFERRED STOCK DIVIDENDS
—

 
(393
)
 
 
 
 
NET LOSS FROM CONTINUING OPERATIONS AVAILABLE TO COMMON STOCKHOLDERS
(1,835
)
 
(2,484
)
NET INCOME (LOSS) FROM DISCONTINUED OPERATIONS AVAILABLE TO COMMON STOCKHOLDERS
73

 
(1,173
)
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS
$
(1,762
)
 
$
(3,657
)
 
 
 
 
BASIC AND DILUTED LOSS PER COMMON SHARE FROM CONTINUING OPERATIONS
$
(0.07
)
 
$
(0.12
)
BASIC AND DILUTED INCOME (LOSS) PER COMMON SHARE FROM DISCONTINUED OPERATIONS
$
—

 
$
(0.06
)
BASIC AND DILUTED LOSS PER COMMON SHARE
$
(0.07
)
 
$
(0.18
)
BASIC AND DILUTED WEIGHTED-AVERAGE SHARES OF COMMON STOCK OUTSTANDING
26,779,835

 
20,323,333


See notes to unaudited condensed consolidated financial statements.

4

TRANSGENOMIC, INC. AND SUBSIDIARY
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Dollars in thousands) 
 
Three Months Ended 
 March 31,
 
2017
 
2016
CASH FLOWS USED IN OPERATING ACTIVITIES:
 
 
 
Net loss
$
(1,762
)
 
$
(3,264
)
Less income (loss) from discontinued operations, net of tax
73

 
(1,173
)
Loss from continuing operations
(1,835
)
 
(2,091
)
 
 
 
 
Adjustments to reconcile net loss to net cash flows used in operating activities:
 
 
 
Depreciation and amortization
48

 
83

Stock-based compensation and change in liability of stock appreciation rights
(24
)
 
110

Provision for losses on doubtful accounts
1

 
21

Warrant revaluation
33

 
(321
)
Loss on settlement of lease termination
358

 
—

Deferred interest
—

 
17

Changes in operating assets and liabilities:
 
 
 
Accounts receivable
(55
)
 
73

Inventories
9

 
6

Other assets
(45
)
 
41

Accounts payable
1,967

 
1,230

Accrued expenses and other liabilities
(587
)
 
(481
)
Net cash used in operating activities, continuing operations
(130
)
 
(1,312
)
Net cash provided by (used in) operating activities, discontinued operations
80

 
(612
)
Net cash used in operating activities
(50
)
 
(1,924
)
CASH FLOWS USED IN INVESTING ACTIVITIES:
 
 
 
Purchases of property and equipment
—

 
(19
)
Change in other assets
—

 
(7
)
Net cash used in investing activities
—

 
(26
)
CASH FLOWS (USED IN) PROVIDED BY FINANCING ACTIVITIES:
 
 
 
Principal payments on capital lease obligations
(1
)
 
(1
)
Issuance of preferred stock and warrants, net of costs of $219
—

 
1,779

Proceeds from debt
—

 
500

Principal payments on debt
—

 
(550
)
Net cash flows (used in) provided by financing activities
(1
)
 
1,728

NET CHANGE IN CASH AND CASH EQUIVALENTS
(51
)
 
(222
)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD
110

 
444

CASH AND CASH EQUIVALENTS AT END OF PERIOD
$
59

 
$
222

SUPPLEMENTAL CASH FLOW INFORMATION
 
 
 
Cash paid during the period for interest
$
—

 
$
—

SUPPLEMENTAL DISCLOSURE OF NON-CASH INFORMATION
 
 
 
Initial valuation of warrant issued in conjunction with Private Placement
$
—

 
$
1,827

Conversion of convertible promissory notes
499

 
—

Debt settled with issuance of preferred stock and warrants
—

 
199

See notes to unaudited condensed consolidated financial statements.

5


TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
Three Months Ended March 31, 2017 and 2016

1. BUSINESS DESCRIPTION
Business Description

Transgenomic, Inc., and Subsidiary, (“we”, “us”, “our”, the “Company” or “Transgenomic”) is a biotechnology company advancing personalized medicine for the detection and treatment of cancer and integrated diseases through our proprietary molecular technologies and clinical and research services. A key goal is to bring our Multiplexed ICE COLD-PCR (“MX-ICP”) product to the clinical market through strategic partnerships and licensing agreements, enabling the use of blood and other bodily fluids for more effective and patient-friendly diagnosis, monitoring and treatment of cancer.

MX-ICP is technology proprietary to Transgenomic. It is a reagent that improves the ability to detect genetic mutations. This technology has been validated internally on all currently available sequencing platforms, including Sanger, Next Gen Sequencing and Digital PCR. By enhancing the level of detection of genetic mutations and suppressing the normal or wild-type DNA, several benefits are provided.

Historically, our operations were organized and reviewed by management along our major product lines and presented in two business segments: Laboratory Services and Genetic Assays and Platforms. Beginning with the quarter ended September 30, 2015, our operations are now organized as one business segment, our Laboratory Services segment, and during the fourth quarter of 2015, we began including a portion of our Laboratory Services segment as discontinued operations, this has continued through March 31, 2017.

Our current Laboratory Services business consists of our laboratory in Omaha, Nebraska, which is focused on providing genetic analytical services related to Oncology and pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical and biotechnology companies. Our laboratory employs a variety of genomic testing service technologies, including our proprietary MX-ICP technology. Our laboratory in Omaha is certified under the Clinical Laboratory Improvement Amendments (“CLIA”) as a high complexity laboratory and is accredited by the College of American Pathologists.

Our condensed consolidated balance sheets, statements of operations and statements of cash flows for all periods presented reflect our former Genetic Assays and Platforms activities and Patient Testing business as discontinued operations (See Note 3 - “Discontinued Operations”).

Going Concern

The condensed consolidated financial statements have been prepared using accounting principles generally accepted in the United States of America applicable for a going concern, which assume that we will realize our assets and discharge our liabilities in the ordinary course of business. We have incurred substantial operating losses and have used cash in our operating activities for the past few years. As of March 31, 2017, we had negative working capital of $20.6 million and we were also not in compliance with our loan agreement due to the fact that events of default existed, including our failure to make certain required monthly interest payments to the lenders. The Company’s ability to continue as a going concern is dependent upon a combination of completing its planned merger with Precipio Diagnostics, LLC (“Precipio”), generating additional revenue, improving cash collections, potentially selling underutilized assets and/or product lines related to discontinued operations and, if needed, raising necessary financing to meet its obligations and pay its liabilities arising from normal business operations when they come due. Following the planned merger, Transgenomic will change its name to Precipio, Inc. (“New Precipio”). On February 17, 2017, Transgenomic received written notification from the staff of Nasdaq that, as a result of Transgenomic’s inability to maintain certain Nasdaq continued listing requirements, Nasdaq had determined to delist Transgenomic’s shares from Nasdaq. Accordingly, trading in Transgenomic’s shares was suspended, and on February 22, 2017, Transgenomic’s shares began trading on the OTCQB exchange under the ticker “TBIO”. As discussed below upon completion of the merger, the New Precipio common stock will be required to meet the Nasdaq listing standards. As a result of the merger, New Precipio is expected to meet Nasdaq's initial listing requirements. In addition, at the time of the merger the Company intends to execute a reverse stock split. The outcome of these matters cannot be predicted with any certainty at this time and raises substantial doubt that the Company will be able to continue as a going concern for the next twelve months from the date of issuance of these condensed financial statements. These condensed consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern. There is no assurance that the Company will complete the merger in a timely manner or at all. The merger agreement is subject to many closing conditions and termination rights. The Company

6
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three Months Ended March 31, 2017 and 2016


also cannot be certain that additional financing, if needed, will be available on acceptable terms, or at all, and its failure to raise capital when needed could limit its ability to continue its operations.
Merger Agreement
On October 12, 2016, Transgenomic, New Haven Labs Inc., a wholly owned subsidiary of Transgenomic (“Merger Sub” and, together with Transgenomic, the “Transgenomic Parties”), and Precipio entered into an Agreement and Plan of Merger (as amended by the Merger Agreement Amendment (as defined below) the “Merger Agreement”) pursuant to which Precipio will become a wholly owned subsidiary of Transgenomic (the “Merger”), on the terms and subject to the conditions set forth in the Merger Agreement. On February 2, 2017, Transgenomic, Merger Sub and Precipio entered into a First Amendment to Agreement and Plan of Merger (the “Merger Agreement Amendment”), which provided for, among other things, the revision of the exchange ratio set forth in the Merger Agreement, the waiver and removal of certain closing conditions and the authorization of certain actions taken by each of Transgenomic and Precipio since the date the Merger Agreement. The parties expect the Merger to close in the second quarter of 2017.
Upon the effectiveness of the Merger (the “Effective Time”), (i) the outstanding common units of Precipio will be converted into the right to receive approximately 160.6 million shares of common stock of New Precipio (“New Precipio common stock”), together with cash in lieu of fractional units, which will result in Precipio common unit holders owning approximately 52% of the issued and outstanding shares of New Precipio common stock on a fully diluted basis, taking into account the issuance of shares of convertible preferred stock of New Precipio (“New Precipio preferred stock”) in the Merger and the private placement as discussed below (the “fully diluted New Precipio common stock”) and (ii) the outstanding preferred units of Precipio will be converted into the right to receive approximately 24.1 million shares of New Precipio preferred stock with an aggregate face amount equal to $3.0 million (based upon the purchase price of the new preferred stock of New Precipio in the new preferred stock financing), which will result in the Precipio preferred unit holders owning approximately 8% of the fully diluted New Precipio common stock.
Upon completion of the merger, New Precipio will be required to meet the initial listing requirements to qualify its shares for listing and begin trading of its shares on Nasdaq. These initial listing requirements are more difficult to achieve than the continued listing requirements.  Pursuant to the Merger Agreement, Transgenomic agreed to use its commercially reasonable efforts to cause the shares of Transgenomic common stock being issued in the merger to be approved for listing on Nasdaq at or prior to the effective time of the merger. Based on information currently available to Transgenomic, Transgenomic anticipates that its stock will be unable to meet the $4.00 (or, to the extent applicable, $3.00) minimum bid price initial listing requirement at the closing of the merger unless it effects a reverse stock split. On October 31, 2016, the stockholders of Transgenomic authorized the Transgenomic Board to effect a reverse stock split of the shares of Transgenomic common stock at a ratio of between one-for-ten to one-for-thirty, such ratio to be determined by our Board of Directors (the “Reverse Split Proposal”). The Reverse Split Proposal was described in detail in our definitive proxy statement filed with the Securities and Exchange Commission on September 22, 2016, as supplemented on October 13, 2016.  In addition, often times a reverse stock split will not result in a trading price for the affected common stock that is proportional to the ratio of the split.


2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation.
The accompanying condensed consolidated financial statements are presented in conformity with GAAP. Supplemental cash flows from discontinued operations are presented in Note 3 - “Discontinued Operations”. We have evaluated events occurring subsequent to March 31, 2017 for potential recognition or disclosure in the condensed consolidated financial statements and concluded there were no subsequent events that required recognition or disclosure.
The condensed consolidated balance sheet as of December 31, 2016 was derived from our audited balance sheet as of that date. There has been no change in the balance sheet from December 31, 2016. The accompanying condensed consolidated financial statements as of and for the three months ended March 31, 2017 and 2016 are unaudited and reflect all adjustments (consisting of only normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the interim periods. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2016

7
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three Months Ended March 31, 2017 and 2016


contained in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the “SEC”) on April 13, 2017. The results of operations for the interim periods presented are not necessarily indicative of the results for fiscal year 2017.
Principles of Consolidation.
The condensed consolidated financial statements include the accounts of Transgenomic, Inc. and our wholly owned subsidiary. All inter-company balances and transactions have been eliminated in consolidation.
Risks and Uncertainties.
Certain risks and uncertainties are inherent in our day-to-day operations and in the process of preparing our financial statements. The more significant of those risks are presented below and throughout the notes to the unaudited condensed consolidated financial statements.
Fair Value.
Unless otherwise specified, book value approximates fair value. The common stock warrant liability is recorded at fair value. See Note 8 - “Fair Value” for additional information.
Cash and Cash Equivalents and Other Current Assets.
Cash and cash equivalents include cash and investments with original maturities at the date of acquisition of three months or less. Other current assets as of March 31, 2017 of $0.2 million include prepaid assets of $0.1 million and other receivables of $0.1 million.
Concentrations of Cash.
From time to time, we may maintain a cash position with financial institutions in amounts that exceed federally insured limits. We have not experienced any losses on such accounts as of March 31, 2017.
 
Property and Equipment.
Depreciation expense in continuing operations related to property and equipment was less than $0.1 million for each of the three month periods ended March 31, 2017 and 2016. Depreciation expense during each period includes depreciation related to equipment acquired under capital leases.
Intangible Assets.
Amortization expense for intangible assets was less than $0.1 million during the three month periods ended March 31, 2017 and 2016. Amortization expense for intangible assets is expected to be $0.1 million for each of the years ending December 31, 2017, 2018 and less than $0.1 million for each of the years ending December 31, 2019, 2020 and 2021.
Stock-Based Compensation.
All stock-based awards to date have exercise prices equal to the market price of our common stock on the date of grant and have ten-year contractual terms. Unvested awards as of March 31, 2017 had vesting periods of up to three years from the date of grant. None of the awards outstanding at March 31, 2017 are subject to performance or market-based vesting conditions.
During the three months ended March 31, 2017 and 2016, we recorded compensation expense for all stock awards of zero and $0.1 million, respectively, within selling, general and administrative expense. As of March 31, 2017, the unrecognized compensation expense related to unvested stock awards was less than $0.1 million, which is expected to be recognized over a weighted-average period of one year.
Included in our stock awards outstanding as of March 31, 2017 were fully vested stock appreciation rights (“SARs”) to purchase 83,333 shares of our common stock. The SARs were issued solely to our executive officers and vested over three years from the date of grant.
Net Sales Recognition.

8
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three Months Ended March 31, 2017 and 2016


Revenue is realized and earned when all of the following criteria are met:
•
Persuasive evidence of an arrangement exists;
•
Delivery has occurred or services have been rendered;
•
The seller’s price to the buyer is fixed or determinable; and
•
Collectability is reasonably assured.

In our Omaha, Nebraska laboratory, we perform services on a project by project basis. When we receive payment in advance, we initially defer the revenue and recognize it when we deliver the service. These projects typically do not extend beyond one year. At each of March 31, 2017 and December 31, 2016, deferred net sales associated with pharmacogenomics research projects included in the balance sheet in deferred revenue were $0.1 million and $0.2 million, respectively.

Net sales from Patient Testing laboratories are reported as part of discontinued operations (See Note 3 - “Discontinued Operations”) and are recognized on an individual test basis and, since collectability is not reasonably assured, are recognized when cash is received. There are no deferred net sales associated with our Patient Testing services.

Taxes collected from customers and remitted to government agencies for specific net sales producing transactions are recorded net with no effect on the income statement.
Loss Per Share.
Basic loss per share is calculated based on the weighted-average number of common shares outstanding during each period. Diluted loss per share includes shares issuable upon exercise of outstanding stock options, warrants or conversion rights that have exercise or conversion prices below the market value of our common stock. Options, warrants and conversion rights pertaining to 4,425,218 and 12,970,881 shares of our common stock have been excluded from the computation of diluted loss per share at March 31, 2017 and 2016, respectively, because the effect is anti-dilutive due to the net loss.
Recent Accounting Pronouncements.
In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers. This guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to a customer. ASU No. 2014-09 will replace most existing revenue recognition guidance in generally accepted accounting principles in the U.S. when it becomes effective. In July 2015, the FASB decided to defer the effective date of this new accounting guidance by one year. As a result, ASU No. 2014-09 will be effective for us for all annual and interim reporting periods beginning after December 15, 2017 and early adoption would be permitted as of the original effective date. The new standard permits the use of either the retrospective or cumulative effect transition method. We do not expect to early adopt this guidance and we have not selected a transition method. We are currently evaluating the impact this guidance will have on our financial condition, results of operations and cash flows.

In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard amends the recognition of lease assets and lease liabilities by lessees for those leases currently classified as operating leases and amends disclosure requirements associated with leasing arrangements. The new standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2018. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition, and provides for certain practical expedients. Transition will require application of the new guidance at the beginning of the earliest comparative period presented. We are currently assessing the impact that the adoption of this ASU will have on our consolidated financial statements.
In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The new standard simplifies several aspects related to the accounting for share-based payment transactions, including the accounting for income taxes, statutory tax withholding requirements, forfeitures and classification on the statement of cash flows. This guidance is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2016. The Company adopted ASU No. 2016-09 as of January 1, 2017. The adoption of this guidance does not have a material effect on the Company’s financial position and results of operations.

In August 2016, FASB issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments. ASU No. 2016-15 eliminates the diversity in practice related to the classification of certain cash receipts and payments in the statement of cash flows by adding or clarifying guidance on eight specific cash flow issues. ASU No. 2016-15 is effective for fiscal years

9
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three Months Ended March 31, 2017 and 2016


beginning after December 15, 2017, and for interim periods within that fiscal year. We do not believe ASU No. 2016-15 will have a material effect on our financial position and results of operations.

In January 2017, FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business. ASU No. 2017-01adds guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The new guidance is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company does not believe ASU No. 2017-01 will have a material effect on its financial position and results of operations.


3. DISCONTINUED OPERATIONS

In March 2016, we halted testing services in our Patient Testing laboratory in New Haven, Connecticut. As a result of this action, as of December 31, 2015, our Patient Testing business met the criteria to be reported as discontinued operations. The related assets, liabilities, results of operations and cash flows for the Patient Testing business are classified as assets held for sale, liabilities held for sale and discontinued operations for all periods presented.
Results of the discontinued operations consisted of the following:
 
Three months ended March 31,
(Dollars in thousands)
2017
 
2016
Net sales
$
68

 
$
1,103

Cost of goods sold
15

 
1,183

Gross profit (loss)
53

 
(80
)
Selling, general and administrative expense
(65
)
 
1,025

Research and development expense
—

 
68

Operating income (loss) from discontinued operations
118

 
(1,173
)
Loss on settlement of liability
(45
)
 
—

Income (loss) from discontinued operations before income taxes
73

 
(1,173
)
Income tax expense
—

 
—

Income (loss) from discontinued operations, net of taxes
$
73

 
$
(1,173
)

At March 31, 2017 and December 31, 2016, the Company had assets of the discontinued operations of less than $0.1 million which were classified as assets held for sale in the condensed consolidated balance sheets.

4.         DEBT

10
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three Months Ended March 31, 2017 and 2016


 
 
Dollars in Thousands
 
 
March 31, 2017
 
December 31, 2016
Revolving Line of Credit(1)
 
$
3,243

 
$
3,243

Term Loan(2)
 
4,000

 
4,000

Convertible Promissory Notes (3)
 
125

 
571

Total debt
 
7,368

 
7,814

Current portion of long-term debt
 
(7,368
)
 
(7,814
)
Long-term debt, net of current maturities
 
$
—

 
$
—

 
(1)
Revolving Line of Credit. Amounts advanced under the Revolving Line accrue interest at an annual rate equal to the greater of (a) 6.25% or (b) the Wall Street Journal prime rate plus 3%. The current interest rate is 6.75%. As discussed below under Additional Terms, the interest rate is subject to increase if there is a default under the Loan Agreement. Interest is payable on a monthly basis, with the balance payable at the maturity of the Revolving Line. Under the Loan Agreement, we pay the Lenders a commitment fee of $20,000 on each one-year anniversary of March 13, 2013, the Effective Date, during the term of the Revolving Line. In addition, a fee of 0.5% per annum is payable quarterly on the unused portion of the Revolving Line. The Revolving Line matures on November 1, 2017.

(2)
Term Loan. We received $4.0 million under the Term Loan on the Effective Date. Pursuant to the terms of the Loan Agreement, as amended, the maturity date of the Loan Agreement was extended until November 1, 2017 and no principal payments on the Term Loan are due until such date. The current interest rate is 9.1%. As discussed below, the interest rate is subject to increase if there is a default under the Loan Agreement.

We will pay the Lenders an additional final payment of $120,000, at maturity or prepayment of the Term Loan, which has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016. In addition, if we repay the Term Loan prior to maturity, we will pay the Lenders a prepayment penalty of 1% of the total outstanding balance under the Term Loan.

Additional Terms.
The Loan Agreement contains affirmative and negative covenants. Under the Loan Agreement, we agreed not to (i) pledge or otherwise encumber our assets other than to the Lenders, (ii) enter into additional borrowings or guarantees, (iii) repurchase our capital stock, or (iv) enter into certain mergers or acquisitions without the Lenders’ consent. Additionally, the Loan Agreement contains a subjective acceleration clause at the discretion of the Lenders. As of March 31, 2017, we were not in compliance with the Loan Agreement, as amended, due to the fact that events of default existed, including our failure to make certain required monthly interest payments.

To secure the repayment of any amounts borrowed under the Revolving Line and the Term Loan, we granted the Lenders a security interest in all of our assets. The occurrence of an event of default under the Loan Agreement could result in the acceleration of our obligations under the Loan Agreement, would increase the applicable interest rate under the Revolving Line or Term Loan (or both) by 5% and would permit the Lenders to exercise remedies with respect to the collateral under the Loan Agreement. At March 31, 2017, our applicable interest rates have been increased by 5%.

(3) Convertible Promissory Notes. The Notes accrue interest at a rate of 6% per year and matured on December 31, 2016.

Revolving Line and Term Loan.

On March 13, 2013 (the “Effective Date”), we entered into a Loan and Security Agreement with affiliates of Third Security, LLC, a related party, (the “Lenders”) for (a) a revolving line of credit (the “Revolving Line”) with borrowing availability of up to $4.0 million, subject to reduction based on our eligible accounts receivable, and (b) a term loan (the “Term Loan” and, together with the Revolving Line, the “Loan Agreement”) of $4.0 million. From the Effective Date through 2015, there were a number of amendments to the Loan Agreement.
On January 6, 2016, we entered into an eighth amendment to the Loan Agreement (the “Eighth Amendment”). The Eighth Amendment, among other things, (a) provided that the Lenders waived specified events of default under the terms of the Loan Agreement, (b) reduced our future minimum revenue covenants under the Loan Agreement, (c) extended the maturity date of the Loan Agreement until November 1, 2017, and (d) provided for the repayment of an overadvance of $750,000 previously provided by the Lenders to us pursuant to the Loan Agreement.

11
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three Months Ended March 31, 2017 and 2016



During the first quarter of 2016, the overadvance that existed at December 31, 2015 was repaid to the Lenders and $0.2 million was received from certain of the Lenders and another lender affiliate in connection with the equity offering made on January 6, 2016.

On June 6, 2016, we entered into a ninth amendment to the Loan Agreement (the “Ninth Amendment”). The Ninth Amendment, among other things, (a) provided that the Lenders waived specified events of default under the terms of the Loan Agreement, (b) amended the prepayment terms of the Loan Agreement, (c) provided for the reduction of amounts available under the Revolving Line upon the prepayment or repayment of certain amounts by us, (d) removed the minimum liquidity ratio and minimum net revenue financial covenants applicable to us under the Loan Agreement, (e) amended the circumstances pursuant to which we may engage in certain sales or transfers of our business or property without the consent of the Lenders, and (f) capitalized certain amounts owed by us to the Lenders and added such overdue amounts to the outstanding principal amount of the Revolving Line.
 
On February 2, 2017, we entered into a termination and tenth amendment to the Loan Agreement (the “Tenth Amendment”). The Tenth Amendment, among other things, (i) provides that the Lenders will waive specified events of default under the terms of the Loan Agreement until the effective time of the Merger (or the termination of the Merger Agreement in accordance with its terms), (ii) provides for the conversion of all outstanding indebtedness owed to the Lenders under the Loan Agreement (the “Outstanding Indebtedness”) into shares of Transgenomic common stock and preferred stock (collectively, the “Conversion Shares”) effective as of the closing date of the Merger and (iii) the termination of the Loan Documents (as defined in the Loan Agreement) and the termination and release of all security interests and liens of the Lenders in the Collateral (as defined in the Loan Agreement) in each case immediately following the conversion of the Outstanding Indebtedness into Conversion Shares.

The effectiveness of certain provisions in the Tenth Amendment, including provisions relating to conversion of the Conversion Shares and termination of the Loan Documents, is conditioned on, among other things, the consummation of the Merger, and, in the event that the Merger is not consummated, these provisions in the Loan Agreement Amendment will terminate.

In connection with the Tenth Amendment, the Lenders have agreed to convert the outstanding principal and accrued interest under the Loan Agreement into (i) approximately 10.4 million shares of New Precipio common stock immediately prior to the effectiveness of the Merger at a price equal to $0.50 per share and (ii) 24.1 million shares of New Precipio preferred stock. As of March 31, 2017, the outstanding amount owed under the Loan Agreement was approximately $7.2 million of principal and $0.8 million of accrued interest. The issuance of the Conversion Shares is subject to the approval of the Transgenomic stockholders in accordance with NASDAQ Capital Market listing rules.

Convertible Promissory Notes.

On December 31, 2014, we entered into an Unsecured Convertible Promissory Note Purchase Agreement (the “Note Purchase Agreement”) with an accredited investor (the “Investor”), pursuant to which we agreed to issue and sell to the Investor in a private placement an unsecured convertible promissory note (the “Initial Note”). We issued the Initial Note in the aggregate principal amount of $750,000 to the Investor on December 31, 2014. Pursuant to the terms of the Initial Note, interest accrued at a rate of 6% per year and the Initial Note was set to mature on December 31, 2016. The Initial Note has been converted in full into 502,786 shares of our common stock, in accordance with the terms of the Initial Note.

On January 15, 2015, we entered into the Note Purchase Agreement with seven accredited investors (the “Additional Investors”) and, on January 20, 2015, issued and sold to the Additional Investors, in a private placement, notes (the “Additional Notes”) in an aggregate principal amount of $925,000. We also issued, to our placement agent for the Notes, a convertible promissory note in an aggregate principal amount equal to 5% of the proceeds received by us, or $46,250 (the “Agent Note”). The Additional Notes and Agent Note have the same terms and conditions as the Initial Note. As of December 31, 2016, $400,000 of the aggregate principal amount of the Additional Notes and Agent Note, and accrued interest thereon, had been converted into an aggregate of 281,023 shares of our common stock.

On the Maturity Date, the then outstanding aggregate amount owed on the Additional Notes and Agent Note of approximately $0.6 million, including accrued interest, became due. Pursuant to the terms of the Initial Note, our failure to pay any principal or interest within 10 days of the date such payment is due will constitute an event of default (the “Prospective Event of Default”).

On January 10, 2017, the Additional Investors and our placement agent executed a waiver of the Prospective Event of Default, pursuant to which, they agreed to waive the Prospective Event of Default on the condition that the Company and the Additional Investors enter into definitive documentation evidencing the terms for an extended maturity date of the Additional Notes and the Agent Note on or before January 16, 2017 (the “Waiver Deadline”).


12
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three Months Ended March 31, 2017 and 2016


On January 13, 2017, all but one Additional Investor exercised their conversion rights relating to their respective Additional Notes, including the Agent Note, and converted an aggregate principal amount of $0.4 million, and accrued interest of less than $0.1 million, into 416,135 shares of our common stock. The Waiver Deadline was extended with respect to the remaining Additional Investor who did not exercise conversion rights (the “Non-Converting Investor”) so that the parties could continue to discuss a resolution of the Prospective Event of Default relating to such Non-Converting Investor’s Additional Note with an outstanding principal amount due of $0.1 million.

On January 17, 2017, the Non-Converting Investor agreed to extend the Maturity Date of its Additional Note pursuant to an amendment to the Additional Note (the “Amendment”). The Amendment provides that two-thirds of the outstanding principal amount of the Additional Note must be paid upon the earlier to occur of the close of the Company’s merger with Precipio Diagnostics, LLC or June 16, 2017 (such applicable date, the “Deferred Maturity Date”).  The remaining one-third of the principal amount outstanding on the Additional Note must be paid on the six month anniversary of the Deferred Maturity Date (the “Extended Maturity Date”).

5. CONTINGENCIES

We are subject to a number of claims of various amounts that arise out of the normal course of our business. In addition to the claims described in this Note, we are delinquent on the payment of outstanding accounts payable amounting to approximately $0.6 million with certain of our vendors and suppliers who have taken or have threatened to take legal action to collect such outstanding amounts.
On February 25, 2016, the Board of Regents of the University of Nebraska (“UNMC”) filed a lawsuit against us in the District Court of Douglas County, Nebraska, for breach of contract and seeking recovery of $0.7 million owed by us to UNMC. A $0.4 million liability has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016. We and UNMC entered into a settlement agreement dated February 6, 2017, which included, among other things, a mutual general release of claims, and our agreement to pay $0.4 million to UNMC in installments over a period of time. As of March 15, 2017, the initial payment due to UNMC under the settlement agreement is delinquent. We and UNMC are currently in discussions to extend the date of the initial payment due to UNMC.
In addition, on April 13, 2016, Fox Chase Cancer Center (“Fox Chase”) filed a lawsuit against us in the Court of Common Pleas of Philadelphia County, First Judicial District of Pennsylvania Civil Trial Division (the “Court of Common Pleas”), alleging, among other things, breach of contract, tortious interference with present and prospective contractual relations, unjust enrichment, fraudulent conversion and conspiracy and seeking punitive damages in addition to damages and other relief. This lawsuit relates to a license agreement we entered into with Fox Chase in August 2000, as amended (the “License Agreement”), as well as the assignment of certain of our rights under the License Agreement to Integrated DNA Technologies, Inc. (“IDT”) pursuant to the Surveyor Kit Patent, Technology and Inventory Purchase Agreement we entered into with IDT effective as of July 1, 2014 (the “IDT Agreement”). Pursuant to the terms of the IDT Agreement, we agreed to indemnify IDT with respect to certain of the claims asserted in the Fox Chase proceeding. On July 8, 2016, the Court of Common Pleas sustained our preliminary objections to several of Fox Chase’s claims and dismissed the claims for tortious interference, fraudulent conversion, conspiracy, punitive damages and attorney’s fees.  Accordingly, the case has been narrowed so that only certain contract claims and an unjust enrichment claim remain pending against us. We believe that we have good and substantial defenses to the claims asserted by Fox Chase. We are unable to determine whether any loss will occur or to estimate the range of such potential loss; therefore, no amount of loss has been accrued by us as of the date of filing of this Quarterly Report on Form 10-Q. Furthermore, there is no guarantee that we will prevail in this suit or receive any damages or other relief if we do prevail.
On June 23, 2016, the Icahn School of Medicine at Mount Sinai (“Mount Sinai”) filed a lawsuit against us in the Supreme Court of the State of New York, County of New York, alleging, among other things, breach of contract and, alternatively, unjust enrichment and quantum merit, and seeking recovery of $0.7 million owed by us to Mount Sinai for services rendered. We and Mount Sinai entered into a settlement agreement dated October 27, 2016, which included, among other things, a mutual general release of claims, and our agreement to pay approximately $0.7 million to Mount Sinai in installments over a period of time. A $0.7 million liability has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016. Effective as of February 1, 2017, we and Mount Sinai agreed to amend the terms of our settlement agreement to extend the date of the initial payment due to Mount Sinai.
On December 19, 2016, Todd Smith (“Smith”) filed a lawsuit against us in the District Court of Douglas County Nebraska, alleging breach of contract and seeking recovery of $2.2 million owed by us to Smith for costs and damages arising from a breach of our obligations pursuant to a lease agreement between the parties. On April 7, 2017, we entered into a settlement agreement with Smith related to the early termination of our lease for our Omaha, Nebraska facility. The agreement included, among other things, a mutual general release of claims, and our agreement to pay approximately $0.6 million to Smith in installments over a period of time. A $0.6 million liability has been recorded and is reflected in accrued expenses at March 31, 2017. The accrued

13
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three Months Ended March 31, 2017 and 2016


liability includes $0.4 million recorded as a net loss on the settlement and is included in other expense in our condensed consolidated statements of operations for the three months ended March 31, 2017.
On February 21, 2017, XIFIN, Inc. (“XIFIN”) filed a lawsuit against us in the District Court for the Southern District of California alleging breach of written contract and seeking recovery of approximately $0.27 million owed by us to XIFIN for damages arising from a breach of our obligations pursuant to a Systems Services Agreement between us and XIFIN, dated as of February 22, 2013, as amended and restated on September 1, 2014. On April 5, 2017, the court clerk entered default against us. On May 5, 2017, XIFIN filed an application for entry of default judgment against us. A $0.3 million and $0.2 million liability has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016, respectively.
We and Science Park Development Corporation (“SPDC”) entered into that certain Lease dated as of December 31, 2011, as modified by the First Amendment to Lease dated as of June 18, 2013, as further modified by a letter agreement dated as of February 2, 2015, as modified by the Second Amendment to Lease dated as of June 26, 2015 (the “ SPDC Lease”). In November 2016, SPDC alleged that we defaulted on our obligations under the SPDC Lease. Specifically, SPDC alleges that we failed to pay approximately $0.4 million in rental payments due under the SPDC Lease and that we vacated a portion of the leased premises in violation of the terms of the SPDC Lease. We and SPDC entered into a settlement agreement dated March 6, 2017, which included, among other things, a mutual general release of claims, and our agreement to pay approximately $0.4 million to SPDC in installments over a period of time. This liability has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016.
CPA Global provides us with certain patent management services. On February 6, 2017, CPA Global claimed that we owe approximately $0.2 million for certain patent maintenance services rendered. CPA Global has not filed claims against us in connection with this allegation. A liability of approximately $0.2 million has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016.
On March 9, 2016, counsel for Edge BioSystems, Inc. (“EdgeBio”) sent a demand letter on behalf of EdgeBio to us in connection with the terms of that certain Asset Purchase Agreement dated September 8, 2015 (the “EdgeBio Agreement”). EdgeBio alleges, among other things, that certain customers of EdgeBio erroneously remitted payments to us, that such payments should have been paid to EdgeBio and that we failed to remit these funds to EdgeBio in violation of the terms of the EdgeBio Agreement. On September 13, 2016, we received a demand for payment letter from EdgeBio’s counsel alleging that the balance due to EdgeBio is approximately $0.1 million. A liability of approximately $0.1 million has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016.
On February 17, 2017, Jesse Campbell (“Campbell”) filed a lawsuit individually and on behalf of others similarly situated against us in the District Court for the District of Nebraska alleging we have a materially incomplete and misleading proxy relating to a potential merger and that the merger agreement’s deal protection provisions deter superior offers.  As a result, he alleges that we have violated Sections 14(a) and 20(a) of the Exchange Act and Rule 14a-9 promulgated thereafter.  Although we intend to defend the lawsuit, there can be no assurance regarding the ultimate outcome of this case. Given the uncertainty of litigation, the legal standards that must be met for, among other things, class certification and success on the merits, we are unable to estimate the amount of loss, or range of possible loss, at this time that may result from this action. In the event that a settlement is reached related to these matters, the amount of such settlement may be material to our results of operations and financial condition and may have a material adverse impact on our liquidity.

6. INCOME TAXES

Annually, we file U.S. Federal, state and foreign income tax returns.  All U.S. Federal and most state loss carryforwards remain subject to adjustment in the event of an income tax examination.
Income tax expense from continuing operations was zero for both the three months ended March 31, 2017 and 2016. We maintain a full valuation allowance on our net deferred tax assets, having concluded that we are not more likely than not going to realize the benefit of our deferred tax assets, including our net operating loss carryforwards.

7. STOCKHOLDERS’ DEFICIT

Common Stock.


14
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three Months Ended March 31, 2017 and 2016


Pursuant to our Third Amended and Restated Certificate of Incorporation, as amended, we currently have 150,000,000 shares of common stock authorized for issuance.

On January 6, 2016, we entered into a Securities Purchase Agreement (the “SPA”) with certain accredited investors (the “2016 Investors”), pursuant to which, on January 8, 2016, we sold to the 2016 Investors, and the 2016 Investors purchased from us (the “January 2016 Offering”), an aggregate of approximately $2.2 million of units (the “Units”) consisting of (a) an aggregate of 2,365,243 shares (the “A-1 Preferred Shares”) of our Series A-1 Convertible Preferred Stock (the “A-1 Preferred”), and (b) warrants (the “2016 Warrants”) to purchase up to an aggregate of 1,773,929 shares of our common stock, with an initial value of $1.8 million. The gross amount of $2.2 million included $2.0 million of cash proceeds and $0.2 million of debt settled with the issuance of preferred stock and warrants. Each Unit was sold to the 2016 Investors at a purchase price of $0.93 per Unit. The A-1 Preferred Shares are convertible into shares of our common stock at an initial rate of 1-for-1, which conversion rate is subject to further adjustment as set forth in our Certificate of Designation of Series A-1 Convertible Preferred Stock, which was filed with the Secretary of State of the State of Delaware on January 8, 2016 (the “Series A-1 Certificate of Designation”). We determined there was a beneficial conversion feature (“BCF”) in connection with this issuance and valued the BCF at $0.4 million.  The holders of the A-1 Preferred were able to convert at any time following the issuance.  Accordingly, we recorded a dividend totaling $0.4 million during 2016 related to this beneficial conversion, which was recorded against additional paid in capital. Pursuant to the terms of the Series A-1 Certificate of Designation, the holders of the A-1 Preferred Shares will generally be entitled to that number of votes as is equal to the product obtained by multiplying: (i) the number of whole shares of our common stock into which the A-1 Preferred may be converted as of the record date of such vote or consent, by (ii) 0.93, rounded down to the nearest whole number. Therefore, every 1.075269 shares of A-1 Preferred will generally initially be entitled to one vote. In May 2016, 2,150,538 of the A-1 Preferred Shares were converted into 2,150,538 shares of our common stock. At March 31, 2017, there were 214,705 A-1 Preferred Shares outstanding.

The 2016 Warrants were immediately exercisable upon issuance, have a term of five years and have an exercise price of $1.21 per share of our common stock. Each 2016 Warrant includes both cash and “cashless exercise” features and an exchange feature whereby the holder of the 2016 Warrant may exchange (the “Exchange Right”) all or any portion of the 2016 Warrant for a number of shares of our common stock equal to the quotient obtained by dividing the “Exchange Amount” by the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrant is exchanged (the “Exchange Price”). Under the 2016 Warrants, the “Exchange Amount” is based upon a Black Scholes option pricing model, and the aggregate Exchange Amount under all of the 2016 Warrants will be $1.4 million, subject to adjustment to the extent that the risk-free U.S. Treasury rate fluctuates between the date of issuance of the 2016 Warrants and the date the 2016 Warrants are exchanged. Each 2016 Warrant provides that the number of shares that may be issued upon exercise of the Exchange Right is limited to the number of shares that may be purchased pursuant to the terms of the 2016 Warrant, unless we have previously obtained stockholder approval or approval from The Nasdaq Stock Market LLC to issue any additional shares of our common stock (the “Additional Shares”) pursuant to the Exchange Right (the “Required Approvals”). For any Exchange Right exercised more than 90 days following the issuance of the 2016 Warrants, if we have not obtained either of the Required Approvals, we will be required to pay the 2016 Warrant holder an amount in cash for any Additional Shares that we cannot issue without the Required Approvals based on the Exchange Amount.

The 2016 Warrants further provide that, to the extent the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrant is exchanged is less than $0.50, the Exchange Price will be deemed to be equal to $0.50, and, in addition to issuing shares of our common stock based on this Exchange Price, we will be required to pay to the 2016 Warrant holder an amount in cash equal to the product obtained by multiplying (a) $0.50 minus the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrant is exchanged, by (b) the aggregate number of shares of our common stock issued to the 2016 Warrant holder by the Company in such exchange at an Exchange Price equal to $0.50. Therefore, if the Required Approvals are obtained, based on the Exchange Amount of $1,436,882 (which, as noted above, is subject to adjustment to the extent that the risk-free U.S. Treasury rate fluctuates between the date of the issuance of the 2016 Warrants and the date the 2016 Warrants are exchanged), the maximum number of shares of our common stock issuable pursuant to the Exchange Right in the 2016 Warrants will be 2,873,765. In addition, if, for example, assuming an Exchange Amount of $1,436,882, the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrants are exchanged is $0.25, we would be required to pay to the 2016 Warrant holders cash in an aggregate amount of $718,441 in addition to issuing the 2016 Warrant holders 2,873,765 shares. During the year ended December 31, 2016, 1,006,419 of the 2016 Warrants were exchanged for 1,613,353 shares of our common stock and cash due of $0.5 million. As of March 31, 2017 and December 31, 2016, the $0.5 million due to a 2016 Investor is included in other current liabilities on our condensed consolidated balance sheet.

In accordance with the terms of the SPA, we amended that certain Series A Warrant to purchase up to an aggregate of 1,161,972 shares of our common stock previously issued by us to an affiliate of one of the 2016 Investors on July 7, 2015 (the “Original Warrant”), as previously reported by us on our Amendment No. 1 to Current Report on Form 8-K/A, filed with the SEC on July

15
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three Months Ended March 31, 2017 and 2016


7, 2015 (as so amended, the “Amended Warrant”). The Amended Warrant amends the Original Warrant to provide that the Amended Warrant is subject to the same terms and conditions as the 2016 Warrants and, therefore, includes both cash and “cashless exercise” features and an Exchange Right whereby the number of shares issuable pursuant to the Exchange Right is equal to the “Amended Warrant Exchange Amount”, which is based on a Black Scholes option pricing model, and will be $941,197, subject to adjustment to the extent that the risk-free U.S. treasury rate fluctuates between the date of issuance of the Amended Warrant and the date the Amended Warrant is exchanged. The Amended Warrant is exercisable for up to 1,161,972 shares of our common stock in the event we have obtained either of the Required Approvals with respect to the Amended Warrant. In the event the Amended Warrant holder exercises the Amended Warrant more than 90 days following the issuance of the Amended Warrant, if we have not obtained either of the Required Approvals, we will be required to pay the Amended Warrant holder an amount in cash for the shares of our common stock that we cannot issue under the Amended Warrant pursuant to such exercise without the Required Approvals based on the Amended Warrant Exchange Amount.

The Amended Warrant also provides that, to the extent the closing bid price of our common stock on the second trading day prior to the date the Amended Warrant is exchanged is less than $0.50, the Exchange Price will be deemed to be equal to $0.50, and, in addition to issuing shares of our common stock based on this Exchange Price (assuming receipt of the Required Approvals), we will be required to pay to the Amended Warrant holder an amount in cash equal to the product obtained by multiplying (a) $0.50 minus the closing bid price of our common stock on the second trading day prior to the date the Amended Warrant is exchanged, by (b) the aggregate number of shares of our common stock issued to the Amended Warrant holder by us in such exchange at an Exchange Price equal to $0.50. Therefore, if the Required Approvals are obtained, based on the Amended Warrant Exchange Amount of $941,197 (which, as noted above, is subject to adjustment to the extent that the risk-free U.S. Treasury rate fluctuates between the issuance of the Amended Warrant and the date the Amended Warrant is exchanged), the maximum number of shares of our common stock issuable pursuant to the Exchange Right in the Amended Warrant will be 1,882,395. In addition, if, for example, assuming an Amended Warrant Exchange Amount of $941,197, the closing bid price of our common stock on the second trading day prior to the date the Amended Warrant is exchanged is $0.25, we would be required to pay to the Amended Warrant holder cash in an aggregate amount of $470,599 in addition to issuing the Amended Warrant holder 1,882,395 shares.

In connection with entering into the SPA, we also entered into a Registration Rights Agreement, dated January 8, 2016, with the 2016 Investors. Pursuant to the terms of the Registration Rights Agreement, we were required to file with the SEC a registration statement to register for resale the shares of our common stock issuable upon conversion of the A-1 Preferred Shares and the shares of our common stock issuable upon exercise of the 2016 Warrants and the Amended Warrant by January 25, 2016. We filed the required registration statement with the SEC on January 25, 2016.

Craig-Hallum (the “Placement Agent”) served as the sole placement agent for the January 2016 Offering. In consideration for services rendered as the Placement Agent in the January 2016 Offering, we (1) paid to the Placement Agent cash commissions equal to approximately $140,000, or 7.0% of the gross proceeds received in the January 2016 Offering, excluding any proceeds received from Third Security, LLC or any of its affiliates; (2) issued to the Placement Agent, for a price of $50, a five-year warrant to purchase up to 107,527 shares of our common stock at an exercise price of $1.21 per share (the “Agent Warrant”), which is subject to the same terms as the 2016 Warrants except that the Agent Warrant was not exercisable until July 8, 2016 and does not contain the Exchange Right; and (3) reimbursed the Placement Agent for reasonable out-of-pocket expenses, including fees paid to the Placement Agent’s legal counsel, incurred in connection with the January 2016 Offering, which reimbursable expenses did not exceed $50,000.

The January 2016 Offering and the payment of all accrued and unpaid dividends on the Series A Preferred Stock and Series B Preferred Stock in the form of shares of our common stock at a rate of $1.00 per share of our common stock discussed under “-Conversion of Preferred Stock” below required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the February 2012 common stock and warrant sale (the “2012 Private Placement”). The exercise price of these warrants decreased to $4.39 per share and the number of shares issuable upon exercise of the warrants increased from 2,188,177 to 3,239,827.

On May 31, 2016, we issued to a vendor an aggregate of 78,000 shares of our common stock and, on June 14, 2016, we issued to a second vendor an aggregate of 64,153 shares of our common stock. Such shares of common stock were issued to the vendors in lieu of an aggregate cash amount of approximately $89,000 owed by us to such vendors for services previously performed by such vendors. We issued the shares to the vendors in transactions exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder and in reliance on similar exemptions under applicable state laws. The offering of the shares to the vendors did not involve a public offering, and no general solicitation or advertisement was made in connection with the offering of the shares to the vendors.

16
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three Months Ended March 31, 2017 and 2016



On June 7, 2016, we entered into an At the Market Offering Agreement (the “ATM Agreement”) with Craig-Hallum, as sales agent, pursuant to which we may offer and sell, from time to time, through Craig-Hallum, up to $3,500,000 of shares (the “Shares”) of our common stock. Any Shares offered and sold in the offering will be issued pursuant to our effective shelf registration statement on Form S-3 (File No. 333-201907) and the related prospectus previously declared effective by the SEC on February 13, 2015, as supplemented by a prospectus supplement, dated June 7, 2016, that we filed with the SEC pursuant to Rule 424(b)(5) under the Securities Act of 1933, as amended (the “Securities Act”). The number of shares eligible for sale under the ATM Agreement will be subject to the limitations of General Instruction I.B.6 of Form S-3.

Under the terms of the ATM Agreement, we will pay Craig-Hallum a placement fee of 3.25% of the gross sales price of the Shares, unless Craig-Hallum acts as principal, in which case we may sell Shares to Craig-Hallum as principal at a price to be agreed upon by us and Craig-Hallum. We will also reimburse Craig-Hallum for certain expenses incurred in connection with the ATM Agreement, and agreed to provide indemnification and contribution to Craig-Hallum with respect to certain liabilities, including liabilities under the Securities Act and the Securities Exchange Act of 1934, as amended.
 
The ATM Agreement was terminated during the fourth quarter of 2016 and at the time of termination we had sold 1,177,849 shares.  The average sales price per common share was $0.42 and the aggregate net proceeds from the sales totaled $0.5 million. We did not sell any shares under the ATM Agreement during the three month periods ended March 31, 2017 and 2016.

The sale of shares under the ATM Agreement required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the 2012 Private Placement. The exercise price of these warrants decreased to $4.23 per share and the number of shares issuable upon exercise of the warrants increased from 3,262,088 to 3,362,276. The 3,362,276 warrants issued in the 2012 Private Placement expired in February 2017.
Common Stock Warrants.
During the three months ended March 31, 2017, we did not issue any warrants, no warrants were exercised and 3,362,276 warrants expired. During the three months ended March 31, 2016, we issued warrants to purchase 2,933,106 shares of common stock and no warrants were exercised. The warrants issued in the three months ended March 31, 2016 included 1,051,650 warrants issued due to repricing requirements of the Private Placement and 1,881,456 warrants issued in connection with the January 2016 Offering. Warrants to purchase an aggregate of 3,334,011 shares of common stock were outstanding at March 31, 2017.
 
Warrant Holder
 
Issue Year
 
Expiration
 
Underlying
Shares
 
Exercise
Price
Various Institutional Holders(1)
 
2013
 
January 2018
 
441,655
 
$9.00
Affiliates of Third Security, LLC(1)
 
2013
 
January 2018
 
250,000
 
$9.00
Various Institutional Holders(2)
 
2014
 
April 2020
 
374,618
 
$4.00
Various Institutional Holders(3)
 
2015
 
February 2020
 
714,780
 
$2.24
Various Institutional Holders(4)
 
2015
 
December 2020
 
122,433
 
$1.66
Various Institutional Holders(5)
 
2015
 
January 2021
 
1,161,972
 
$1.21
Affiliates of Third Security, LLC(6)
 
2016
 
January 2021
 
161,026
 
$1.21
Various Institutional Holders(6)
 
2016
 
January 2021
 
107,527
 
$1.21
 
 
 
 
 
 
3,334,011
 
 

(1)
These warrants were issued in connection with an offering which was completed in January 2013.
(2)
These warrants were issued in connection with a private placement which was completed in October 2014.
(3)
These warrants were issued in connection with an offering which was completed in February 2015.
(4)
These warrants were issued in connection with an offering which was completed in July 2015.
(5)
These warrants were originally issued in connection with the offering in July 2015, and were amended in connection with the January 2016 Offering, which was completed in January 2016.

17
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three Months Ended March 31, 2017 and 2016


(6)
These warrants were issued in connection with the January 2016 Offering, which was completed in January 2016.
Preferred Stock Series A.
The Company’s Board of Directors is authorized to issue up to 15,000,000 shares of preferred stock in one or more series, from time to time, with such designations, powers, preferences and rights and such qualifications, limitations and restrictions as may be provided in a resolution or resolutions adopted by the Board of Directors. The authority of the Board of Directors includes, but is not limited to, the determination or fixing of the following with respect to shares of such class or any series thereof: (i) the number of shares; (ii) the dividend rate, whether dividends shall be cumulative and, if so, from which date; (iii) whether shares are to be redeemable and, if so, the terms and amount of any sinking fund providing for the purchase or redemption of such shares; (iv) whether shares shall be convertible and, if so, the terms and provisions thereof; (v) what restrictions are to apply, if any, on the issue or reissue of any additional preferred stock; and (vi) whether shares have voting rights. The preferred stock may be issued with a preference over the common stock as to the payment of dividends. We have no current plans to issue any additional preferred stock. Classes of stock such as the preferred stock may be used, in certain circumstances, to create voting impediments on extraordinary corporate transactions or to frustrate persons seeking to effect a merger or otherwise to gain control of the Company. For the foregoing reasons, any additional preferred stock issued by the Company could have an adverse effect on the rights of the holders of the common stock.

On December 29, 2010, we entered into a transaction with the Third Security Investors, pursuant to the terms of a Series A Convertible Preferred Stock Purchase Agreement (the “Series A Purchase Agreement”), in which we: (i) sold an aggregate of 2,586,205 shares of Series A Preferred Stock at a price of $2.32 per share; and (ii) issued Series A Warrants to purchase up to an aggregate of 1,293,102 shares of Series A Preferred Stock having an exercise price of $2.32 per share (the sale of Series A Preferred Stock and issuance of the Series A Warrants hereafter referred to together as the “Financing”). The Series A Warrants may be exercised at any time from December 29, 2010 until December 28, 2015 and contain a “cashless exercise” feature. The gross proceeds from the Series A financing were $6.0 million. The $0.2 million of costs incurred to complete the Series A financing were recorded as a reduction in the value of the Series A Preferred Stock. We used the net proceeds from the financing to acquire the FAMILION family of genetic tests from PGxHealth, a subsidiary of Clinical Data, Inc. Until the November 2011 modifications, the Series A Preferred Stock met the definition of mandatorily redeemable stock as it was preferred capital stock that was redeemable at the option of the holder through December 2015 and was reported outside of equity. The Series A Preferred Stock was to be accreted to its redemption value of $6.0 million. Until the November 2011 modifications, the Series A Warrants did not qualify to be treated as equity and, accordingly, were recorded as a liability. A preferred stock anti-dilution feature is embedded within the Series A Preferred Stock that met the definition of a derivative.

In connection with the Series A financing, we filed a Certificate of Designation of Series A Convertible Preferred Stock (the “Series A Certificate of Designation”) with the Secretary of State of the State of Delaware, designating 3,879,307 shares of our preferred stock as Series A Preferred Stock. As of December 31, 2013, the Series A Preferred Stock, including the Series A Preferred Stock issuable upon exercise of the Series A Warrants, was convertible into shares of our common stock at a rate of 4-for-1, which conversion rate is subject to further adjustment as set forth in the Series A Certificate of Designation. Giving effect to the reverse split of our stock in January 2014, the conversion rate was adjusted to 1-for-3. Certain rights of the holders of the Series A Preferred Stock are senior to the rights of the holders of our common stock. The Series A Preferred Stock has a liquidation preference equal to its original price per share, plus any accrued and unpaid dividends thereon. The holders of the Series A Preferred Stock are entitled to receive quarterly dividends, which accrue at the rate of 10% of the original price per share per annum, whether or not declared, and which shall compound annually and shall be cumulative. In any calendar quarter in which we have positive distributable cash flow as defined in the Series A Purchase Agreement, we are required to pay from funds legally available a cash dividend in the amount equal to the lesser of 50% of such distributable cash flow or the aggregate amount of dividends accrued on the Series A Preferred Stock.
Generally, the holders of the Series A Preferred Stock are entitled to vote together with the holders of common stock, as a single group, on an as-converted basis. However, the Series A Certificate of Designation provides that we shall not perform some activities, subject to certain exceptions, without the affirmative vote of a majority of the holders of the outstanding shares of Series A Preferred Stock. The holders of the Series A Preferred Stock, along with the holders of the Series B Preferred Stock, also are entitled to elect or appoint, as a single group, two directors of the Company.
In connection with the Series A financing, we also entered into a registration rights agreement with the Third Security Investors (the “Registration Rights Agreement”). Pursuant to the terms of the Registration Rights Agreement, the Company has granted certain demand, “piggyback” and S-3 registration rights covering the resale of the shares of common stock underlying the

18
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three Months Ended March 31, 2017 and 2016


Series A Preferred Stock issued pursuant to the Series A Purchase Agreement and issuable upon exercise of the Series A Warrants and all shares of common stock issuable upon any dividend or other distribution with respect thereto.
In November 2011, we entered into a transaction with the Third Security Investors, pursuant to an Agreement Regarding Preferred Stock (the “Amendment Agreement”), in which the Third Security Investors agreed to (i) waive their rights to enforce the anti-dilution and redemption features of the Series A Preferred Stock and (ii) at the next annual stockholders’ meeting, vote to amend the Series A Certificate of Designation to remove the anti-dilution and redemption features of the Series A Preferred Stock. In exchange, the Company issued shares of common stock to the Third Security Investors having an aggregate market value of $0.3 million.
As a result of the Amendment Agreement, the values of the Series A Preferred Stock and Series A Warrants, including the Series A Preferred Stock conversion feature and Series A Warrant liability, were reclassified into stockholders’ equity as of the date of the Amendment Agreement.
Preferred Stock Series B.

On March 5, 2014, we entered into a Series B Convertible Preferred Stock Purchase Agreement (the “Series B Purchase Agreement”) with affiliates of Third Security, LLC (the “2014 Third Security Investors”), pursuant to which we, in a private placement, sold and issued an aggregate of 1,443,297 shares of our Series B Preferred Stock, par value $0.01 per share (the “Series B Preferred Stock”), at a price per share of $4.85 for an aggregate purchase price of approximately $7.0 million. Each share of Series B Preferred Stock issued pursuant to the Series B Purchase Agreement was initially convertible into shares of our common stock at a rate of 1-for-1, which conversion rate was subject to further adjustment as set forth in the Certificate of Designation of Series B Convertible Preferred Stock.

In connection with the Series B financing, we also entered into a Registration Rights Agreement, dated March 5, 2014, with the 2014 Third Security Investors, pursuant to which we granted certain demand, “piggy-back” and S-3 registrations rights covering the resale of the shares of common stock underlying the Series B Preferred Stock issued pursuant to the Series B Purchase Agreement and all shares of common stock issuable upon any dividend or other distribution with respect thereto.

The Series B financing required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement. The exercise price of the warrants decreased from $12.96 per share to $11.73 per share and the number of shares issuable upon exercise of the warrants increased from 1,097,600 to 1,212,665.

Conversion of Preferred Stock - Series A and Series B.

On January 6, 2016, the Company entered into a Conversion Agreement (the “Conversion Agreement”) with the holders (the “Preferred Holders”) of all of the Company’s outstanding shares of Series A Convertible Preferred Stock, par value $0.01 per share (the “Series A Preferred Stock”), and Series B Preferred Stock, pursuant to which, among other things, the Preferred Holders: (a) elected to convert all of the outstanding shares of Series A Preferred Stock and Series B Preferred Stock into shares of our common stock, in each case in accordance with the terms thereof, and (b) agreed that all accrued and unpaid dividends on the Series A Preferred Stock and Series B Preferred Stock would be paid by the Company in shares of our common stock at a rate of $1.00 per share of our common stock (collectively, the “Conversion”).

The outstanding shares of Series A Preferred Stock were convertible into shares of our common stock at a rate of 1-for-3, and the outstanding shares of Series B Preferred Stock were convertible into shares of our common stock at a rate of 1-for-1. Prior to the entry into the Conversion Agreement, there were 2,586,205 shares of Series A Preferred Stock outstanding, which were converted into 862,057 shares of our common stock, and 1,443,297 shares of Series B Preferred Stock outstanding, which were converted into 1,443,297 shares of our common stock, for an aggregate of 2,305,354 shares of our common stock issued upon conversion of the Series A Preferred Stock and Series B Preferred Stock (the “Conversion Shares”). At the time of the entry into the Conversion Agreement, there were $3.7 million in accrued and unpaid dividends on the outstanding shares of Series A Preferred Stock, which were converted, in accordance with the Conversion Agreement, into 3,681,590 shares of our common stock, and $0.8 million in accrued and unpaid dividends on the outstanding shares of Series B Preferred Stock, which were converted, in accordance with the terms of the Conversion Agreement, into 793,235 shares of our common stock, for an aggregate of 4,474,825 shares of our common stock issued pursuant to the accrued and unpaid dividends on the Series A Preferred Stock and Series B Preferred Stock. Therefore, in connection with the full conversion of the Series A Preferred Stock and Series B Preferred Stock, plus the conversion of all accrued and unpaid dividends thereon, we issued an aggregate of 6,780,179 shares of our common stock to the Preferred Holders on January 6, 2016.

19
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three Months Ended March 31, 2017 and 2016



Following the conversion of the shares of Series A Preferred Stock and Series B Preferred Stock into common stock, no shares of Series A Preferred Stock or Series B Preferred Stock remain outstanding.
Preferred Stock Dividends.
We had no undeclared dividends for the three months ended March 31, 2017. For the three months ended March 31, 2016, we had undeclared dividends. In accordance with the FASB’s Accounting Standards Codification Topic 260-10-45-11, “Earnings per Share”, these dividends were added to the net loss per share calculation.

8. FAIR VALUE

FASB guidance on fair value measurements, which defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements for our financial assets and liabilities, as well as for other assets and liabilities that are carried at fair value on a recurring basis in our condensed consolidated financial statements.
FASB guidance establishes a three-level fair value hierarchy based upon the assumptions (inputs) used to price assets or liabilities. The three levels of inputs used to measure fair value are as follows:
Level 1—Unadjusted quoted prices in active markets for identical assets or liabilities;
Level 2—Observable inputs other than those included in Level 1, such as quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets; and
Level 3—Unobservable inputs reflecting our own assumptions and best estimate of what inputs market participants would use in pricing the asset or liability.

Debt.
Our long term debt book value approximates fair market value due to the variable interest rate it bears.

Common Stock Warrant Liabilities.

Certain of our issued and outstanding warrants to purchase shares of common stock do not qualify to be treated as equity and, accordingly, are recorded as a liability.

2012 Warrant Liability
The 2012 Warrant Liability represents the fair value of the 3.4 million warrants issued in February 2012 (as adjusted pursuant to the terms of the 2012 Warrants). We are required to record these instruments at fair value at each reporting date and changes are recorded as a non-cash adjustment to earnings. The gains or losses included in earnings are reported in other income (expense) in our condensed consolidated Statement of Operations. Management does not believe that this liability will be settled by a use of cash. The 2012 Warrants expired in February 2017 and, as such, the 2012 Warrant Liability no longer exists at March 31, 2017.
The 2012 Warrant Liability is considered a Level 3 financial instrument and is valued using a Monte Carlo simulation model. This method is well suited to valuing options with non-standard features, such as anti-dilution protection. A Monte Carlo simulation model uses repeated random sampling to simulate significant uncertainty in inputs. Assumptions and inputs used in the valuation of the common stock warrants are broken down into four sections: Static Business Inputs; Static Technical Inputs; Simulated Business Inputs; and Simulated Technical Inputs.

During the three months ended March 31, 2017 and 2016, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following:

20
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three Months Ended March 31, 2017 and 2016


 
 
Dollars in Thousands
 
 
For the Three Months Ended
 
 
March 31, 2017
 
March 31, 2016
Beginning balance at January 1
 
$
—

 
$
350

Total (gains) or losses:
 

 
 
Recognized in earnings
 
—

 
(330
)
Balance at March 31
 
$
—

 
$
20



2016 Warrant Liability
The 2016 Warrant Liability represents the fair value of the 1.8 million warrants issued in January 2016, of which, 0.8 million warrants remain outstanding as of March 31, 2017. We are required to record these instruments at fair value at each reporting date and changes are recorded as a non-cash adjustment to earnings. The gains or losses included in earnings are reported in other income (expense) in our condensed consolidated Statement of Operations.
The 2016 Warrant Liability is considered a Level 3 financial instrument and is valued using a binomial lattice simulation model. This method is well suited to valuing options with non-standard features. Assumptions and inputs used in the valuation of the common stock warrants include; our equity value, which was estimated using our stock price of $0.56 as of March 31, 2017; volatility of 115%; and a risk-free interest rate of 1.66%.
During the three months ended March 31, 2017 and 2016, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following:     
 
 
Dollars in Thousands
 
 
 
For the Three Months Ended
 
 
 
March 31, 2017
 
March 31, 2016
 
Beginning balance at January 1
 
$
582

 
$
—

 
Additions
 
—

 
1,437

 
Total (gains) or losses:
 
 
 
 
 
Recognized in earnings
 
33

 
9

 
Balance at March 31
 
$
615

 
$
1,446

 

9. STOCK OPTIONS
 
Stock Options.

The following table summarizes stock option activity under our 2006 Equity Incentive Plan (the "Plan") during the three months ended March 31, 2017:
 
 
Number of
Options
 
Weighted-Average
Exercise Price
Outstanding at January 1, 2017
738,026

 
$
3.59

Granted
—

 
—

Forfeited
(62,739
)
 
2.12

Outstanding at March 31, 2017
675,287

 
$
3.73

Exercisable at March 31, 2017
547,957

 
$
4.25

    

21
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three Months Ended March 31, 2017 and 2016


During the three months ended March 31, 2017, we did not grant any options to purchase shares of our common stock. Options to purchase an aggregate of 14,000 shares of our common stock were granted during the three months ended March 31, 2016.

As of March 31, 2017, there were 661,914 options that were vested or expected to vest with an aggregate intrinsic value of zero with a remaining weighted average contractual life of 7.2 years.

Stock Appreciation Rights (“SARs”)

As of March 31, 2017, 83,333 outstanding and exercisable SARs shares were vested or expected to vest. All outstanding SARs were issued solely to our chief executive officer. The weighted-average exercise price of these SARs was $4.32 per share and the aggregate intrinsic value was zero with a remaining weighted average contractual life of 6.5 years.

10. SUBSEQUENT EVENTS

On April 13, 2017, Transgenomic completed the sale of an aggregate of $1.15 million of promissory notes (the “Bridge Notes”) in a bridge financing pursuant to a securities purchase agreement (the “Purchase Agreement”). Transgenomic may receive additional investments of up to $100,000 in connection with the bridge financing. The financing is intended to help facilitate the completion of Transgenomic’s merger with Precipio, which is expected to close during the second quarter of 2017. Transgenomic received net proceeds of $1,031,000 from the sale of the Bridge Notes.
 
The Bridge Notes have an annual interest rate of 4% and a 90-day maturity. Transgenomic may repay the Bridge Notes at any time in cash upon payment of a 20% premium. In connection with the issuance of the Bridge Notes, Transgenomic issued warrants (the “Bridge Warrants”) to acquire 1.15 million shares of Transgenomic common stock at an exercise price of $0.50 per share, subject to anti-dilution protection. The Purchase Agreement provides certain piggyback registration rights for the holders of the Bridge Warrants for a period of six months after the closing of the bridge financing.
 
As part of the bridge financing, Transgenomic agreed to loan 50% of the net proceeds from the sale of the Bridge Notes to Precipio pursuant to a promissory note (the “Precipio Note”) with an original principal amount of up to $561,500 upon substantially the same terms and conditions as the Bridge Notes. The payment of the Precipio Note is subordinated to the payment by Precipio of its secured $500,000 bank debt pursuant to a subordination agreement.
 
Aegis Capital Corp. acted as placement agent for the bridge financing and received a placement agent fee of $84,000 and warrants (the “Aegis Warrants”) to acquire 168,000 shares of Transgenomic common stock at an exercise price of $0.50 per share. The Aegis Warrants are identical to the Bridge Warrants except that the Aegis Warrants do not have anti-dilution protection.

Item 2.
Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Information
This Quarterly Report on Form 10-Q, including this Management’s Discussion and Analysis, contains forward-looking statements. These statements are based on management’s current views, assumptions or beliefs of future events and financial performance and are subject to uncertainty and changes in circumstances. Readers of this report should understand that these statements are not guarantees of performance or results. Many factors could affect our actual financial results and cause them to vary materially from the expectations contained in the forward-looking statements. These factors include, among other things: our expected revenue, income (loss), receivables, operating expenses, supplier pricing, availability and prices of raw materials, insurance reimbursements, product pricing, sources of funding operations and acquisitions, our ability to raise funds, sufficiency of available liquidity, future interest costs, future economic circumstances, business strategy, industry conditions, our ability to execute our operating plans, the success of our cost savings initiatives, competitive environment and related market conditions, expected financial and other benefits from our organizational restructuring activities, actions of governments and regulatory factors affecting our business, retaining key employees and other risks as described in our reports filed with the Securities and Exchange Commission. In some cases these statements are identifiable through the use of words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “target,” “can,” “could,” “may,” “should,” “will,” “would” or the negative versions of these terms and other similar expressions.
You are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements we make are not guarantees of future performance and are subject to various assumptions, risks and other factors that could cause

22

actual results to differ materially from those suggested by these forward-looking statements. Actual results may differ materially from those suggested by the forward-looking statements that we make for a number of reasons, including those described in Part II, Item 1A, “Risk Factors,” of this Quarterly Report on Form 10-Q and in Part I, Item 1A, “Risk Factors,” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, which we filed with the Securities and Exchange Commission on April 13, 2017.
We expressly disclaim any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
The following discussion should be read together with our financial statements and related notes contained in this Quarterly Report on Form 10-Q and with the financial statements, related notes and Management’s Discussion and Analysis included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, which we filed with the Securities and Exchange Commission on April 13, 2017. Results for the three months ended March 31, 2017 are not necessarily indicative of results that may be attained in the future.

Overview

Transgenomic, Inc. (“we”, “us”, “our”, the “Company” or “Transgenomic”) is a biotechnology company advancing personalized medicine for the detection and treatment of cancer and integrated diseases through our proprietary molecular technologies and clinical and research services. A key goal is to bring our Multiplexed ICE COLD-PCR (“MX-ICP”) product to the clinical market through strategic partnerships and licensing agreements, enabling the use of blood and other bodily fluids for more effective and patient-friendly diagnosis, monitoring and treatment of cancer.

MX-ICP is technology proprietary to Transgenomic. It is a reagent that improves the ability to detect genetic mutations by 100 - 400 fold over existing technologies. This technology has been validated internally on all currently available sequencing platforms, including Sanger, Next Gen Sequencing and Digital PCR. By enhancing the level of detection of genetic mutations and suppressing the normal, or wild-type, DNA, several benefits are provided. It is generally understood that most current technologies are unable to consistently identify mutations that occur in less than approximately 5% of a sample. However, many mutations found at much lower levels, even as low as 0.01%, are known to be clinically relevant and can have significant consequences to a patient: both in terms of how they will respond to a given drug or treatment and how a given tumor is likely to change over time. More importantly, in our view, is the ability to significantly improve the level of detection while using blood, saliva and even urine as a source for DNA, rather than depending on painful, expensive and potentially dangerous tumor biopsies. We believe that this is an important advancement in patient care with respect to cancer detection, treatment and monitoring and can result in significant cost savings for the healthcare system by replacing invasive procedures with the simple collection of blood or other bodily fluids. By broadening the types of samples that can be used for testing and allowing all sequencing platforms to provide improved identification of low level mutations, MX-ICP has the potential to make testing more readily available and more patient friendly, enable genetic monitoring of disease progression, effectively guide treatment protocols, and reduce the overall cost of diagnosis and monitoring while significantly improving patient outcomes.

Our laboratory in Omaha, Nebraska is focused on providing genetic analytical services related to oncology and pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical and biotechnology companies. Our laboratory employs a variety of genomic testing service technologies, including our proprietary MX-ICP technology. ICE COLD-PCR is a proprietary ultra-high sensitivity platform technology with breakthrough potential to enable wide adoption of personalized, precision medicine in cancer and other diseases. It can be run in any laboratory that contains standard PCR systems. MX-ICP enables detection of multiple known and unknown mutations from virtually any sample type, including tissue biopsies, blood, urine, saliva, cell-free DNA (“cfDNA”) and circulating tumor cells (“CTCs”) at levels greater than 1,000-fold higher than standard DNA sequencing techniques. It is easy to implement and use within existing workflows. Our laboratory in Omaha is certified under the Clinical Laboratory Improvement Amendments (“CLIA”) as a high complexity laboratory and is accredited by the College of American Pathologists.

The following discussion should be read together with our financial statements and related notes contained in this Quarterly Report. Results for the three months ended March 31, 2017 are not necessarily indicative of results that may be attained in the future.

First Quarter 2017 Overview and Recent Highlights

Below is a summary of our most recent business activities:


23

•
Leading Clinical Laboratory Services Provider LifeLabs Selects ICE COLD-PCR (ICP) as Its Mutation Enrichment Platform - In January 2017, we announced a licensing agreement with leading Canadian laboratory services provider LifeLabs, which has selected our ICP technology as its mutation enrichment platform for cancer testing. LifeLabs intends to use ICP with tissue samples and is receiving a three-year non-exclusive license to the ICP technology in Canada. The three-year renewable agreement also allows LifeLabs to benefit from technology improvements and additional product launches during its term.
Uncertainties
We have historically operated at a loss and have not consistently generated sufficient cash from operating activities to cover our operating and other cash expenses. We have been able to historically finance our operating losses through borrowings or from the issuance of additional equity. At March 31, 2017, we had cash and cash equivalents of less than $0.1 million. Our ability to continue as a going concern is dependent upon a combination of completing our planned merger with Precipio, generating additional revenue, improving cash collections, potentially selling underutilized assets and/or product lines related to discontinued operations and, if needed, raising necessary financing to meet our obligations and pay our liabilities arising from normal business operations when they come due. The outcome of these matters cannot be predicted with any certainty at this time and raises substantial doubt that we will be able to continue as a going concern.

Results of Continuing Operations for The Three Months Ended March 31, 2017 and 2016
Net Sales. Net sales were as follows:
 
Dollars in Thousands
 
Three Months Ended
 
 
 
March 31,
 
Change
 
2017
 
2016
 
$    
 
%
Total Net Sales
$
658

 
$
236

 
$
422

 
179
%
Net sales increased by $0.4 million, or 179%, during the three months ended March 31, 2017 as compared to the same period in 2016. The increase in total net sales for the current year period reflects higher sales of our contract laboratory services due to a new contract that did not exist in the prior year period.
Cost of Goods Sold. Cost of goods sold includes material costs for the products that we sell and other direct costs (primarily personnel costs, rent, supplies and depreciation) associated with the operations of our laboratories.
Gross Profit. Gross profit and gross margins were as follows:
 
Dollars in Thousands
 
Three Months Ended
 
 
 
March 31,
 
Margin %
 
2017
 
2016
 
2017
 
2016
Gross Profit (Loss)
$
199

 
$
(269
)
 
30
%
 
(114
)%
Gross profit was $0.2 million, or 30% of total net sales, during the first quarter of 2017, compared to negative $0.3 million, or (114)% of total net sales, during the same quarter of 2016. The increased gross profit during the three months ended March 31, 2017 as compared to the same period of 2016 is due to increased revenues, along with a slight decrease in cost of goods sold which resulted from lower personnel costs.
Selling, General and Administrative Expenses. Selling, general and administrative expenses primarily consist of personnel costs, marketing, travel costs, professional fees, facility costs and bad debt provisions. Our selling, general and administrative costs decreased by $0.1 million to $1.6 million during the three month period ended March 31, 2017 as compared to the same period in 2016. This decrease was due to lower personnel costs, lower professional fees and lower stock compensation costs in the first quarter of 2017 as compared to the first quarter of 2016. These decreases were partially offset by increased costs related to our pending merger and an increase of approximately $0.4 million related to charges incurred as part of a settlement agreement for the early termination of our facility lease for our Omaha, Nebraska facility.
Research and Development Expenses. Research and development expenses primarily include personnel costs, intellectual property fees, patent costs, outside services, laboratory supplies and facility costs and are expensed in the period in which they are incurred. For the three months ended March 31, 2017, research and development expenses totaled $0.1 million as compared to $0.3 million for the three months ended March 31, 2016. The decrease was a result of lower personnel costs and lower laboratory

24

supply costs during the three months ended March 31, 2017 as compared to the same period in 2016. Research and development expenses totaled 20% and 114% of net sales during the three months ended March 31, 2017 and 2016, respectively.
Other Income (Expense). Other expense for the three months ended March 31, 2017 and 2016 includes interest expense of approximately $0.2 million for interest related to our debt. We also recorded expense of less than $0.1 million and income of $0.3 million for the three months ended March 31, 2017 and 2016, respectively, for the revaluation of common stock warrants, which was due to the change in fair value of the common stock warrant liability. The income and expense associated with the change in fair value of the warrants is a non-cash item.
Discontinued Operations for The Three Months Ended March 31 2017 and 2016
In March 2016, we halted testing services in our Patient Testing laboratory in New Haven, Connecticut. As a result of this action, as of December 31, 2015, our Patient Testing business met the criteria to be reported as discontinued operations. The related assets, liabilities, results of operations and cash flows for the Patient Testing business are classified as assets held for sale, liabilities held for sale and discontinued operations for all periods presented.
Revenues and net loss of the discontinued operations consisted of the following:
 
Three months ended March 31,
(Dollars in thousands)
2016
 
2016
Net sales
$
68

 
$
1,103

Net income (loss) from discontinued operations, before tax
$
73

 
$
(1,173
)
Income tax expense
—

 
—

Income (loss) from discontinued operations, net of tax
$
73

 
$
(1,173
)


Liquidity and Capital Resources
Our working capital positions at March 31, 2017 and December 31, 2016 were as follows: 
 
Dollars in Thousands
 
March 31,
2017
 
December 31,
2016
 
Change
Current assets (including cash and cash equivalents of $59 and $110, respectively)
$
567

 
$
495

 
$
72

Current liabilities
21,129

 
19,824

 
1,305

Working capital
$
(20,562
)
 
$
(19,329
)
 
$
(1,233
)

At March 31, 2017, we had cash on hand of less than $0.1 million. Our ability to continue as a going concern is dependent upon a combination of completing our planned merger with Precipio, generating additional revenue, improving cash collections, potentially selling underutilized assets and/or product lines related to discontinued operations and, if needed, raising necessary financing to meet our obligations and pay our liabilities arising from normal business operations when they come due. The outcome of these matters cannot be predicted with any certainty at this time and raises substantial doubt that we will be able to continue as a going concern. There is no assurance that we will complete the merger in a timely manner or at all. The merger agreement is subject to many closing conditions and termination rights. We also cannot be certain that additional financing, if needed, will be available on acceptable terms, or at all, and our failure to raise capital when needed could limit our ability to continue our operations.

Analysis of Cash Flows - Three Months Ended March 31, 2017 and 2016
Net Change in Cash and Cash Equivalents. Cash and cash equivalents decreased by less than $0.1 million during the three months ended March 31, 2017, compared to an decrease of $0.2 million during the three months ended March 31, 2016. These amounts include cash provided by discontinued operations of $0.1 million and cash used in discontinued operations of $0.6 million, for the three months ended March 31, 2017 and 2016, respectively.
Cash Flows From Continuing Operations

25

Cash Flows Used in Operating Activities. The cash flows used in operating activities of $0.1 million during the three months ended March 31, 2017 included a net loss of $1.8 million and a decrease in accrued expenses of $0.6 million. These were partially offset by an increase in accounts payable of $2.0 million and non-cash adjustments of $0.4 million. The cash flows used in operating activities in the first three months of 2016 included the net loss of $2.1 million and a decrease in accrued expenses and other liabilities of $0.5 million. These were partially offset by an increase in accounts receivable of $1.2 million.
Cash Flows Used in Investing Activities. Cash flows used in investing activities for continuing operations were zero and less than $0.1 million for the three months ended March 31, 2017 and 2016, respectively.
Cash Flows Provided by Financing Activities. There were no cash flows provided by financing activities for the three months ended March 31, 2017 other than capital lease payments of less than $0.1 million. Cash flows provided by financing activities during the three months ended March 31, 2016 totaled $1.7 million which included net proceeds of approximately $1.8 million from our Unit issuance and $0.5 million from borrowing on our debt. These proceeds were partially offset by payments on our debt of approximately $0.6 million

Off-Balance Sheet Arrangements
At each of March 31, 2017 and December 31, 2016, we did not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

Contractual Obligations and Commitments
There have been no material changes to our contractual obligations outside the normal course of business as compared to those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2016, filed with the Securities and Exchange Commission on April 13, 2017 except for the following.
•Our debt decreased by $0.4 million resulting from the conversion of convertible promissory notes into shares of our common stock in January 2017. See Note 4 - Debt to our accompanying condensed consolidated financial statements.
•Our operating lease obligations decreased from approximately $1.3 million to approximately $0.6 million as the result of a settlement agreement we entered into on April 7, 2017 related to the early termination of our lease for our Omaha, Nebraska facility.

Critical Accounting Policies and Estimates
Accounting policies used in the preparation of our consolidated financial statements may involve the use of management judgments and estimates. Certain of our accounting policies are considered critical as they are both important to the portrayal of our financial statements and require significant or complex judgments on the part of management. Our judgments and estimates are based on experience and assumptions that we believe are reasonable under the circumstances. Further, we evaluate our judgments and estimates from time to time as circumstances change. Actual financial results based on judgments or estimates may vary under different assumptions or circumstances. Our critical accounting policies are discussed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, filed with the Securities and Exchange Commission on April 13, 2017.

Recently Issued Accounting Pronouncements
Please refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, filed with the Securities and Exchange Commission on April 13, 2017. There have been no changes to those accounting pronouncements listed except as noted in Note 2 - “Summary of Significant Accounting Policies-Recent Accounting Pronouncements” in the Notes to Unaudited Condensed Consolidated Financial Statements contained in this Quarterly Report on Form 10-Q.

Impact of Inflation
We do not believe that price inflation or deflation had a material adverse effect on our financial condition or results of operations during the periods presented.

Item 3.    Quantitative and Qualitative Disclosures About Market Risk


26

We are a smaller reporting company, as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, and are not required to provide the information required under this item.

Item 4.
Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
Management performed, with the participation of our Chief Executive Officer and Interim Chief Financial Officer, an evaluation of the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Interim Chief Financial Officer, to allow timely decisions regarding required disclosures. Based on the evaluation, our Chief Executive Officer and Interim Chief Financial Officer concluded that, as of March 31, 2017, our disclosure controls and procedures were effective at the reasonable assurance level.
Changes in Internal Control over Financial Reporting
We have evaluated the changes in our internal control over financial reporting that occurred during the three months ended March 31, 2017 and concluded that there have not been any changes that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

27

PART II. OTHER INFORMATION
 
Item 1.
Legal Proceedings
We are subject to a number of claims of various amounts that arise out of the normal course of our business. In addition to the claims described in this Item 1, we are delinquent on the payment of outstanding accounts payable amounting to approximately $0.6 million with certain of our vendors and suppliers who have taken or have threatened to take legal action to collect such outstanding amounts.
On February 25, 2016, the Board of Regents of the University of Nebraska (“UNMC”) filed a lawsuit against us in the District Court of Douglas County, Nebraska, for breach of contract and seeking recovery of $0.7 million owed by us to UNMC. A $0.4 million liability has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016. We and UNMC entered into a settlement agreement dated February 6, 2017, which included, among other things, a mutual general release of claims, and our agreement to pay $0.4 million to UNMC in installments over a period of time. As of March 15, 2017, the initial payment due to UNMC under the settlement agreement is delinquent. We and UNMC are currently in discussions to extend the date of Transgenomic’s initial payment due to UNMC.
In addition, on April 13, 2016, Fox Chase Cancer Center (“Fox Chase”) filed a lawsuit against us in the Court of Common Pleas of Philadelphia County, First Judicial District of Pennsylvania Civil Trial Division (the “Court of Common Pleas”), alleging, among other things, breach of contract, tortious interference with present and prospective contractual relations, unjust enrichment, fraudulent conversion and conspiracy and seeking punitive damages in addition to damages and other relief. This lawsuit relates to a license agreement we entered into with Fox Chase in August 2000, as amended (the “License Agreement”), as well as the assignment of certain of our rights under the License Agreement to Integrated DNA Technologies, Inc. (“IDT”) pursuant to the Surveyor Kit Patent, Technology and Inventory Purchase Agreement we entered into with IDT effective as of July 1, 2014 (the “IDT Agreement”). Pursuant to the terms of the IDT Agreement, we agreed to indemnify IDT with respect to certain of the claims asserted in the Fox Chase proceeding. On July 8, 2016, the Court of Common Pleas sustained our preliminary objections to several of Fox Chase’s claims and dismissed the claims for tortious interference, fraudulent conversion, conspiracy, punitive damages and attorney’s fees.  Accordingly, the case has been narrowed so that only certain contract claims and an unjust enrichment claim remain pending against us. We believe that we have good and substantial defenses to the claims asserted by Fox Chase. We are unable to determine whether any loss will occur or to estimate the range of such potential loss; therefore, no amount of loss has been accrued by us as of the date of filing of this Quarterly Report on Form 10-Q. Furthermore, there is no guarantee that we will prevail in this suit or receive any damages or other relief if we do prevail.
On June 23, 2016, the Icahn School of Medicine at Mount Sinai (“Mount Sinai”) filed a lawsuit against us in the Supreme Court of the State of New York, County of New York, alleging, among other things, breach of contract and, alternatively, unjust enrichment and quantum merit, and seeking recovery of $0.7 million owed by us to Mount Sinai for services rendered. We and Mount Sinai entered into a settlement agreement dated October 27, 2016, which included, among other things, a mutual general release of claims, and our agreement to pay approximately $0.7 million to Mount Sinai in installments over a period of time. A $0.7 million liability has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016. Effective as of February 1, 2017, we and Mount Sinai agreed to amend the terms of our settlement agreement to extend the date of the initial payment due to Mount Sinai.
On December 19, 2016, Todd Smith (“Smith”) filed a lawsuit against us in the District Court of Douglas County Nebraska, alleging breach of contract and seeking recovery of $2.2 million owed by us to Smith for costs and damages arising from a breach of our obligations pursuant to a lease agreement between the parties. On April 7, 2017, we entered into a settlement agreement with Smith related to the early termination of our lease for our Omaha, Nebraska facility. The agreement included, among other things, a mutual general release of claims, and our agreement to pay approximately $0.6 million to Smith in installments over a period of time. A $0.6 million liability has been recorded and is reflected in accrued expenses at March 31, 2017. The accrued liability includes $0.4 million recorded as a net loss on the settlement and is included in other expense in our condensed consolidated statements of operations for the three months ended March 31, 2017.
On February 21, 2017, XIFIN, Inc. (“XIFIN”) filed a lawsuit against us in the District Court for the Southern District of California alleging breach of written contract and seeking recovery of approximately $0.27 million owed by us to XIFIN for damages arising from a breach of our obligations pursuant to a Systems Services Agreement between us and XIFIN, dated as of February 22, 2013, as amended and restated on September 1, 2014. On April 5, 2017, the court clerk entered default against us. On May 5, 2017, XIFIN filed an application for entry of default judgment against us. A $0.3 million and $0.2 million liability has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016, respectively.
We and Science Park Development Corporation (“SPDC”) entered into that certain Lease dated as of December 31, 2011, as modified by the First Amendment to Lease dated as of June 18, 2013, as further modified by a letter agreement dated as of

28

February 2, 2015, as modified by the Second Amendment to Lease dated as of June 26, 2015 (the “ SPDC Lease”). In November 2016, SPDC alleged that we defaulted on our obligations under the SPDC Lease. Specifically, SPDC alleges that we failed to pay approximately $0.4 million in rental payments due under the SPDC Lease and that we vacated a portion of the leased premises in violation of the terms of the SPDC Lease. We and SPDC entered into a settlement agreement dated March 6, 2017, which included, among other things, a mutual general release of claims, and our agreement to pay approximately $0.4 million to SPDC in installments over a period of time. This liability has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016.
CPA Global provides us with certain patent management services. On February 6, 2017, CPA Global claimed that we owe approximately $0.2 million for certain patent maintenance services rendered. CPA Global has not filed claims against us in connection with this allegation. A liability of approximately $0.2 million has been recorded and is reflected in accrued expenses at December 31, 2016.
On March 9, 2016, counsel for Edge BioSystems, Inc. (“EdgeBio”) sent a demand letter on behalf of EdgeBio to us in connection with the terms of that certain Asset Purchase Agreement dated September 8, 2015 (the “EdgeBio Agreement”). EdgeBio alleges, among other things, that certain customers of EdgeBio erroneously remitted payments to us, that such payments should have been paid to EdgeBio and that we failed to remit these funds to EdgeBio in violation of the terms of the EdgeBio Agreement. On September 13, 2016, we received a demand for payment letter from EdgeBio’s counsel alleging that the balance due to EdgeBio is approximately $0.1 million. A liability of approximately $0.1 million has been recorded and is reflected in accrued expenses at December 31, 2016.
On February 17, 2017, Jesse Campbell (“Campbell”) filed a lawsuit individually and on behalf of others similarly situated against us in the District Court for the District of Nebraska alleging we have a materially incomplete and misleading proxy relating to a potential merger and that the merger agreement’s deal protection provisions deter superior offers.  As a result, he alleges that we have violated Sections 14(a) and 20(a) of the Exchange Act and Rule 14a-9 promulgated thereafter.  Although we intend to defend the lawsuit, there can be no assurance regarding the ultimate outcome of this case. Given the uncertainty of litigation, the legal standards that must be met for, among other things, class certification and success on the merits, we are unable to estimate the amount of loss, or range of possible loss, at this time that may result from this action. In the event that a settlement is reached related to these matters, the amount of such settlement may be material to our results of operations and financial condition and may have a material adverse impact on our liquidity.
The outcome of legal proceedings and claims brought against us are subject to significant uncertainty. Therefore, although management considers the likelihood of such an outcome to be remote, if one or more of these legal matters were resolved against us in the same reporting period for amounts in excess of management’s expectations, our financial statements for such reporting period could be materially adversely affected. In general, the resolution of a legal matter could prevent us from offering our services or products to others, could be material to our financial condition or cash flows, or both, or could otherwise adversely affect our operating results. 

Item 1A.
Risk Factors

As disclosed in “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2016, there are a number of risks and uncertainties that may have a material effect on the operating results of our business and our financial condition. There are no additional material updates or changes to our risk factors since the filing of our Annual Report on Form 10-K for the year ended December 31, 2016.


29

Item 2.     Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 6.
Exhibits
(a)
Exhibits
2.1

 
First Amendment to Agreement and Plan of Merger, dated as of February 3, 2017, by and among the Registrant, New Haven Labs Inc. and Precipio Diagnostics, LLC (incorporated by reference to Exhibit 2.1 to the Registrant’s Current Report on Form 8-K filed on February 2, 2017).
 
 
 
10.1

 
Waiver Letter Agreement by and among the Registrant, Potomac Capital Partners, L.P., MAZ Partners LP, David Wambeke and Craig-Hallum Capital Group LLC, dated as of January 10, 2017 (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on January 17, 2017).
 
 
 
10.2

 
First Amendment to Unsecured Convertible Promissory Note by and among the Registrant and MAZ Partners LP, dated as of January 17, 2017 (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on January 20, 2017).
 
 
 
10.3

 
Termination and Tenth Amendment to Loan and Security Agreement, dated as of February 3, 2017, by and among Third Security Senior Staff 2008 LLC, as administrative agent and a lender, the other lenders party thereto and the Registrant (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on February 2, 2017).
 
 
 
10.4

 
Promissory Note, dated February 2, 2017, between the Registrant and Precipio Diagnostics, LLC (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed on February 3, 2017).
 
 
 
10.5

 
Securities Purchase Agreement, dated as of April 13, 2017, by and between the Registrant and the investors set forth on Schedule A attached thereto (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on April 17, 2017).
 
 
 
10.6

  
Form of Promissory Note, issued by the Registrant to certain investors, dated as of April 13, 2017 (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed on April 17, 2017).
 
 
 
10.7

 
Form of Warrant to Purchase Common Stock, issued by the Registrant to certain investors, dated as of April 13, 2017 (incorporated by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed on April 17, 2017).
 
 
 
10.8

 
Precipio Diagnostics, LLC Subordinated Promissory Note, issued by Precipio to the Registrant, dated as of April 13, 2017 (incorporated by reference to Exhibit 10.4 to the Registrant’s Current Report on Form 8-K filed on April 17, 2017).
 
 
 
10.9

 
Subordination Agreement, dated as of April 13, 2017, by and between the Registrant and Webster Bank, National Association (incorporated by reference to Exhibit 10.5 to the Registrant’s Current Report on Form 8-K filed on April 17, 2017).
 
 
 
31.1

 
Certification of Paul Kinnon, President, Chief Executive Officer and Interim Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, as amended.
 
 
 
32.1

  
Certification of Paul Kinnon, President, Chief Executive Officer and Interim Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, as amended.
 
 
 
101.INS

 
XBRL Instance Document
 
 
 
101.SCH

 
XBRL Taxonomy Extension Schema Document
 
 
 
101.CAL

 
XBRL Taxonomy Extension Calculation Linkbase Document
 
 
 
101.DEF

 
XBRL Taxonomy Extension Definition Linkbase Document
 
 
 
101.LAB

 
XBRL Taxonomy Extension Label Linkbase Document
 
 
 
101.PRE

 
XBRL Taxonomy Extension Presentation Linkbase Document
 
 
 

30

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
 
 
 
 
 
TRANSGENOMIC, INC.
 
 
 
 
Date:
May 18, 2017
By:
/S/ PAUL KINNON



Paul Kinnon
President, Chief Executive Officer and Interim Chief Financial Officer (Principal Executive Officer and Principal Financial Officer)
 
 
 
 

31
 EX-31.1 2 tbio-ex311_20170331x10q.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER
I, Paul Kinnon, certify that:
1.
I have reviewed this Quarterly Report on Form 10-Q of Transgenomic, Inc. (the Registrant);
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and I have:
a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiary, is made known to me by others within those entities, particularly during the period in which this report is being prepared;
b)
Designed such internal control over financial reporting, or caused internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
Disclosed in this report any change in the Registrant's internal control over financial reporting that occurred during the Registrant's most recent fiscal quarter (the Registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and
5.
I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the Registrant's auditors and the audit committee of the Registrant's board of directors (or persons performing the equivalent function):
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting.


/s/ PAUL KINNON
 
Paul Kinnon
President, Chief Executive Officer and Interim Chief Financial Officer (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)
Date: May 18, 2017


EX-32.1 3 tbio-ex321_20170331x10q.htm EXHIBIT 32.1 Exhibit


Exhibit 32.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350
In connection with the accompanying Quarterly Report on Form 10-Q of Transgenomic, Inc. for the period ended March 31, 2017, I, Paul Kinnon, Chief Executive Officer and Interim Chief Financial Officer of Transgenomic, Inc., hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge, that:
(1)
Such Quarterly Report on Form 10-Q of Transgenomic, Inc. for the period ended March 31, 2017, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
The information contained in such Quarterly Report on Form 10-Q of Transgenomic, Inc. for the period ended March 31, 2017, fairly presents, in all material respects, the financial condition and results of operations of Transgenomic, Inc.
 
/s/ PAUL KINNON
 
Paul Kinnon
President, Chief Executive Officer and Interim Chief Financial Officer (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)

Date: May 18, 2017
A signed original of the certification required by Section 906 has been provided to Transgenomic, Inc. and will be retained by Transgenomic, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.



EX-101.INS 4 tbio-20170331.xml XBRL INSTANCE DOCUMENT 0001043961 2017-01-01 2017-03-31 0001043961 2017-04-30 0001043961 2017-03-31 0001043961 2016-12-31 0001043961 2016-01-01 2016-03-31 0001043961 us-gaap:SegmentContinuingOperationsMember 2017-01-01 2017-03-31 0001043961 us-gaap:SegmentContinuingOperationsMember 2016-01-01 2016-03-31 0001043961 us-gaap:SegmentDiscontinuedOperationsMember 2017-01-01 2017-03-31 0001043961 us-gaap:SegmentDiscontinuedOperationsMember 2016-01-01 2016-03-31 0001043961 2015-12-31 0001043961 2016-03-31 0001043961 tbio:PrecipioMember us-gaap:CommonStockMember 2017-02-02 2017-02-02 0001043961 tbio:PrecipioMember us-gaap:PreferredStockMember 2017-02-02 2017-02-02 0001043961 2015-01-01 2015-09-29 0001043961 us-gaap:MinimumMember us-gaap:CommonStockMember 2016-10-31 0001043961 us-gaap:MaximumMember us-gaap:CommonStockMember 2016-10-31 0001043961 tbio:PharmacogenomicServicesMember 2016-12-31 0001043961 tbio:PharmacogenomicServicesMember 2017-03-31 0001043961 us-gaap:ExecutiveOfficerMember 2017-01-01 2017-03-31 0001043961 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-01-01 2017-03-31 0001043961 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-01-01 2016-03-31 0001043961 us-gaap:MaximumMember 2017-01-01 2017-03-31 0001043961 us-gaap:SegmentDiscontinuedOperationsMember tbio:GeneticAssaysandPlatformsandPatientTestingMember 2017-01-01 2017-03-31 0001043961 us-gaap:SegmentDiscontinuedOperationsMember tbio:GeneticAssaysandPlatformsandPatientTestingMember 2016-01-01 2016-03-31 0001043961 us-gaap:SegmentDiscontinuedOperationsMember 2017-03-31 0001043961 us-gaap:ConvertibleNotesPayableMember 2017-03-31 0001043961 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2017-03-31 0001043961 tbio:TermLoanMember 2017-03-31 0001043961 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2016-12-31 0001043961 tbio:TermLoanMember 2016-12-31 0001043961 us-gaap:ConvertibleNotesPayableMember 2016-12-31 0001043961 us-gaap:RevolvingCreditFacilityMember tbio:ThirdSecurityLlcAndAffiliatesMember us-gaap:LineOfCreditMember 2013-03-13 0001043961 us-gaap:ConvertibleNotesPayableMember 2016-01-01 2016-12-31 0001043961 us-gaap:ConvertibleNotesPayableMember tbio:AgentNoteMember 2015-01-20 0001043961 tbio:TermLoanMember 2017-01-01 2017-03-31 0001043961 us-gaap:ConvertibleNotesPayableMember tbio:AdditionalNotePrivatePlacementMember 2016-12-31 2016-12-31 0001043961 us-gaap:ConvertibleNotesPayableMember tbio:AgentNoteMember 2017-01-13 0001043961 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2016-01-01 2016-03-31 0001043961 us-gaap:ConvertibleNotesPayableMember 2016-01-06 0001043961 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2017-01-01 2017-03-31 0001043961 tbio:PrecipioMember us-gaap:ConvertibleCommonStockMember 2017-02-02 2017-02-02 0001043961 tbio:PrecipioMember 2017-02-02 0001043961 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember tbio:WallStreetJournalPrimeRateMember 2017-01-01 2017-03-31 0001043961 us-gaap:ConvertibleNotesPayableMember tbio:AdditionalNotePrivatePlacementMember 2016-01-01 2016-12-31 0001043961 us-gaap:ConvertibleNotesPayableMember 2017-01-01 2017-03-31 0001043961 tbio:PrecipioMember 2017-03-31 0001043961 us-gaap:ConvertibleNotesPayableMember tbio:AgentNoteMember 2017-01-13 2017-01-13 0001043961 tbio:AdditionalNotePrivatePlacementMember 2015-01-15 0001043961 tbio:PrecipioMember us-gaap:ConvertiblePreferredStockMember 2017-02-02 2017-02-02 0001043961 us-gaap:ConvertibleNotesPayableMember 2014-12-31 0001043961 tbio:ThirdSecurityLlcAndAffiliatesMember tbio:TermLoanMember 2013-03-13 0001043961 us-gaap:ConvertibleNotesPayableMember tbio:AdditionalNotePrivatePlacementMember 2015-01-20 0001043961 tbio:PrecipioMember 2017-01-01 2017-03-31 0001043961 tbio:AdditionalNotesMember us-gaap:ConvertibleNotesPayableMember 2017-01-17 0001043961 tbio:MountSinaiMember 2016-10-27 2016-10-27 0001043961 tbio:CPAGlobalMember 2017-03-31 0001043961 tbio:UNMCMember 2016-02-25 2016-02-25 0001043961 tbio:SmithMember 2016-12-19 2016-12-19 0001043961 tbio:XIFINInc.Member 2017-03-31 0001043961 tbio:XIFINInc.Member 2016-12-31 0001043961 tbio:SmithMember 2017-03-31 0001043961 tbio:UNMCMember 2017-02-06 2017-02-06 0001043961 tbio:ScienceParkDevelopmentCorporationMember 2016-11-30 2016-11-30 0001043961 tbio:MountSinaiMember 2016-06-23 2016-06-23 0001043961 tbio:MountSinaiMember 2017-03-31 0001043961 tbio:CPAGlobalMember 2017-02-06 2017-02-06 0001043961 tbio:EdgeBioSystemsInc.Member 2016-09-13 2016-09-13 0001043961 tbio:SmithMember us-gaap:SubsequentEventMember 2017-04-07 2017-04-07 0001043961 tbio:XIFINInc.Member 2017-02-21 2017-02-21 0001043961 tbio:UNMCMember 2017-03-31 0001043961 tbio:EdgeBioSystemsInc.Member 2017-03-31 0001043961 tbio:ScienceParkDevelopmentCorporationMember 2017-03-06 2017-03-06 0001043961 tbio:EdgeBioSystemsInc.Member 2016-12-31 0001043961 tbio:MountSinaiMember 2016-12-31 0001043961 tbio:UNMCMember 2016-12-31 0001043961 tbio:CPAGlobalMember 2016-12-31 0001043961 tbio:VariousInstitutionalHoldersJanuary2021TwoMember 2016-12-31 0001043961 tbio:VariousInstitutionalHoldersDecember2020OneMember 2016-12-31 0001043961 tbio:VariousInstitutionalHoldersFebruary2020Member 2016-12-31 0001043961 tbio:AffiliatesofThirdSecurityLLCJanuary2021Member 2016-12-31 0001043961 tbio:VariousInstitutionalHoldersJanuary2018Member 2016-12-31 0001043961 tbio:VariousInstitutionalHoldersApril2020Member 2016-12-31 0001043961 tbio:AffiliatesofThirdSecurityLLCJanuary2018Member 2016-12-31 0001043961 tbio:VariousInstitutionalHoldersJanuary2021OneMember 2016-12-31 0001043961 tbio:AttheMarketOfferingAgreementMember tbio:CraigHallumCapitalGroupLLCMember 2016-01-01 2016-12-31 0001043961 tbio:SecurityPurchaseAgreementMember us-gaap:SeriesAPreferredStockMember 2016-01-08 2016-01-08 0001043961 us-gaap:SeriesAPreferredStockMember 2016-01-06 0001043961 tbio:SecurityPurchaseAgreementMember us-gaap:CommonStockMember 2016-01-08 0001043961 tbio:A2016WarrantMember us-gaap:CommonStockMember 2017-03-31 0001043961 tbio:SecurityPurchaseAgreementMember tbio:SeriesAWarrantsMember 2017-03-31 0001043961 tbio:SeriesA1WarrantMember 2016-01-06 2016-01-06 0001043961 tbio:SecurityPurchaseAgreementMember us-gaap:SeriesAPreferredStockMember 2016-01-08 0001043961 us-gaap:SeriesAPreferredStockMember 2010-12-29 0001043961 tbio:AttheMarketOfferingAgreementMember tbio:CraigHallumCapitalGroupLLCMember 2016-12-31 0001043961 us-gaap:CommonStockMember 2011-11-01 2011-11-30 0001043961 tbio:SecurityPurchaseAgreementMember tbio:SeriesAWarrantsMember us-gaap:CommonStockMember 2017-03-31 0001043961 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2010-12-29 0001043961 tbio:CraigHallumCapitalGroupLLCMember 2016-01-01 2016-01-31 0001043961 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2016-01-06 0001043961 us-gaap:SeriesAPreferredStockMember 2016-01-06 2016-01-06 0001043961 tbio:ThirdSecurityLlcAndAffiliatesMember us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2014-03-05 2014-03-05 0001043961 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2017-03-31 0001043961 tbio:AttheMarketOfferingAgreementMember tbio:CraigHallumCapitalGroupLLCMember 2016-06-07 0001043961 tbio:SecurityPurchaseAgreementMember us-gaap:SeriesAPreferredStockMember 2016-05-01 2016-05-31 0001043961 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2017-01-01 2017-03-31 0001043961 tbio:OfferingMember 2017-01-01 2017-03-31 0001043961 tbio:SecurityPurchaseAgreementMember 2016-01-08 2016-01-08 0001043961 tbio:A2016WarrantMember 2017-03-31 0001043961 tbio:VendorIIMember 2016-06-14 2016-06-14 0001043961 tbio:CraigHallumCapitalGroupLLCMember 2016-01-31 0001043961 tbio:ThirdSecurityLlcAndAffiliatesMember 2014-03-05 0001043961 tbio:SecurityPurchaseAgreementMember us-gaap:CommonStockMember 2016-05-01 2016-05-31 0001043961 tbio:A2016WarrantMember us-gaap:CommonStockMember 2016-01-01 2016-12-31 0001043961 tbio:ThirdSecurityLlcAndAffiliatesMember 2013-01-24 0001043961 us-gaap:SeriesAPreferredStockMember us-gaap:CommonStockMember 2016-01-06 2016-01-06 0001043961 tbio:AttheMarketOfferingAgreementMember tbio:CraigHallumCapitalGroupLLCMember 2016-10-01 2016-12-31 0001043961 tbio:ThirdSecurityLlcAndAffiliatesMember us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2014-03-05 0001043961 us-gaap:SeriesBPreferredStockMember us-gaap:CommonStockMember 2016-01-06 0001043961 2016-01-08 2016-01-08 0001043961 tbio:SecurityPurchaseAgreementMember tbio:SeriesAWarrantsMember us-gaap:CommonStockMember 2016-01-06 0001043961 us-gaap:SeriesAPreferredStockMember us-gaap:CommonStockMember 2016-01-06 0001043961 tbio:SecurityPurchaseAgreementMember tbio:SeriesAWarrantsMember 2017-01-01 2017-03-31 0001043961 2010-12-29 2010-12-29 0001043961 tbio:SecurityPurchaseAgreementMember tbio:SeriesAWarrantsMember us-gaap:MaximumMember 2017-03-31 0001043961 tbio:VendorMember 2016-05-31 2016-05-31 0001043961 tbio:A2016WarrantMember us-gaap:CommonStockMember 2017-01-01 2017-03-31 0001043961 us-gaap:PreferredStockMember 2017-03-31 0001043961 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2016-01-06 0001043961 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2016-01-06 2016-01-06 0001043961 us-gaap:SeriesBPreferredStockMember us-gaap:CommonStockMember 2016-01-06 2016-01-06 0001043961 tbio:CraigHallumCapitalGroupLLCMember us-gaap:ScenarioPreviouslyReportedMember 2016-01-01 2016-01-31 0001043961 us-gaap:MinimumMember 2017-03-31 0001043961 tbio:AttheMarketOfferingAgreementMember tbio:CraigHallumCapitalGroupLLCMember us-gaap:ScenarioPreviouslyReportedMember 2016-01-01 2016-12-31 0001043961 tbio:A2016WarrantMember 2016-01-01 2016-12-31 0001043961 tbio:SecurityPurchaseAgreementMember us-gaap:SeriesAPreferredStockMember 2017-03-31 0001043961 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2016-01-06 2016-01-06 0001043961 tbio:A2016WarrantMember 2017-01-01 2017-03-31 0001043961 tbio:SecurityPurchaseAgreementMember tbio:SeriesAWarrantsMember 2015-07-07 0001043961 us-gaap:SeriesAPreferredStockMember 2010-12-29 2010-12-29 0001043961 tbio:CraigHallumCapitalGroupLLCMember us-gaap:CommonStockMember 2016-01-31 0001043961 2016-01-01 2016-12-31 0001043961 2016-06-14 2016-06-14 0001043961 us-gaap:CommonStockMember 2016-01-06 2016-01-06 0001043961 us-gaap:PrivatePlacementMember 2017-01-01 2017-03-31 0001043961 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2010-12-29 2010-12-29 0001043961 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2014-01-01 2014-12-31 0001043961 us-gaap:SeriesBPreferredStockMember 2016-01-06 0001043961 tbio:SeriesA1ConvertiblePreferredStockandWarrantsMember 2016-01-06 2016-01-06 0001043961 us-gaap:SeriesBPreferredStockMember 2016-01-06 2016-01-06 0001043961 tbio:ThirdSecurityLlcAndAffiliatesMember us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2014-03-05 2014-03-05 0001043961 tbio:A2016WarrantLiabilityMember 2017-01-01 2017-03-31 0001043961 tbio:A2016WarrantLiabilityMember 2017-03-31 0001043961 tbio:A2012WarrantLiabilityMember 2012-02-01 2012-02-28 0001043961 tbio:A2016WarrantLiabilityMember 2016-01-01 2016-01-31 0001043961 tbio:A2012WarrantLiabilityMember 2016-01-01 2016-03-31 0001043961 tbio:A2012WarrantLiabilityMember 2015-12-31 0001043961 tbio:A2012WarrantLiabilityMember 2017-03-31 0001043961 tbio:A2012WarrantLiabilityMember 2017-01-01 2017-03-31 0001043961 tbio:A2012WarrantLiabilityMember 2016-12-31 0001043961 tbio:A2012WarrantLiabilityMember 2016-03-31 0001043961 tbio:A2016WarrantLiabilityMember 2016-01-01 2016-03-31 0001043961 tbio:A2016WarrantLiabilityMember 2016-12-31 0001043961 tbio:A2016WarrantLiabilityMember 2015-12-31 0001043961 tbio:A2016WarrantLiabilityMember 2016-03-31 0001043961 us-gaap:EmployeeStockOptionMember tbio:EquityIncentivePlan2006Member 2017-03-31 0001043961 us-gaap:EmployeeStockOptionMember tbio:EquityIncentivePlan2006Member 2017-01-01 2017-03-31 0001043961 us-gaap:EmployeeStockOptionMember tbio:EquityIncentivePlan2006Member 2016-12-31 0001043961 us-gaap:StockAppreciationRightsSARSMember 2017-03-31 0001043961 us-gaap:EmployeeStockOptionMember tbio:EquityIncentivePlan2006Member 2016-01-01 2016-03-31 0001043961 us-gaap:StockAppreciationRightsSARSMember 2017-01-01 2017-03-31 0001043961 us-gaap:BridgeLoanMember us-gaap:SubsequentEventMember 2017-04-13 0001043961 us-gaap:BridgeLoanMember us-gaap:SubsequentEventMember 2017-04-13 2017-04-13 0001043961 tbio:PrecipioMember us-gaap:SubsequentEventMember 2017-04-13 0001043961 tbio:AegisCorpMember us-gaap:SubsequentEventMember 2017-04-13 0001043961 us-gaap:SubsequentEventMember 2017-04-13 2017-04-13 0001043961 tbio:AegisCorpMember us-gaap:SubsequentEventMember 2017-04-13 2017-04-13 0001043961 us-gaap:SubsequentEventMember 2017-04-13 0001043961 tbio:PrecipioMember us-gaap:BridgeLoanMember us-gaap:SubsequentEventMember 2017-04-13 xbrli:pure iso4217:USD iso4217:USD xbrli:shares tbio:investor xbrli:shares tbio:Director tbio:operating_segments false --12-31 Q1 2017 2017-03-31 10-Q 0001043961 26863062 Smaller Reporting Company TRANSGENOMIC INC 100000 470599 718441 3400000 1800000 168000 1150000.00 2933106 1881456 1051650 83333 0.50 0.50 0.50 P90D P90D P5Y P5Y 3362276 1293102 800000 0.05 P10D 120000 7 0.2 0.01 600000 68000 0 1025000 -65000 0 321000 -33000 1800000 1827000 0 -169000 -247000 0.5 400000 2 152000 -280000 0.07 107527 0.05 84000 0.0325 0.3333 0.5 1031000 2000000 6000000 0.6667 83333 50000 941197 1436882 1400000 500000 500000 1 1 1 0.3333 1 1 4 0.1 0.0333 -20600000 6541000 8509000 225000 279000 3546000 3398000 205877000 206342000 100000 100000 12970881 4425218 1259000 1229000 495000 567000 31000 24000 100000 444000 222000 110000 59000 -222000 -51000 -612000 80000 9 1.21 4.00 1.66 2.24 9 1.21 1.21 4.23 0.25 1.21 0.25 2.32 2.32 12.96 11.73 4.39 0.93 1.00 0.50 0.50 0.93 1.075269 1161972 1882395 2873765 1097600 1212665 1161972 1773929 1882395 3334011 250000 161026 374618 122433 714780 441655 1161972 107527 800000 3681590 0.01 0.01 150000000 150000000 3500000 26446927 1177849 26863062 26446927 26863062 264000 268000 3000000 199000 200000 0 862057 2586205 1443297 1443297 2305354 2150538 2150538 160600000 24100000 1006419 1613353 505000 459000 7814000 3243000 4000000 571000 7368000 3243000 4000000 125000 0 400000 499000 7200000 281023 10400000 24100000 416135 502786 0.03 750000 4000000 925000 46250 750000 446250 561500 1150000.00 0.0675 0.06 0.06 0.0625 0.04 P90D 170000 200000 133000 100000 100000 100000 83000 48000 -1173000 73000 -1173000 118000 0 0 1183000 15000 -80000 53000 1103000 68000 400000 3700000 800000 -0.18 -0.12 -0.06 -0.07 -0.07 0.00 224000 192000 100000 -321000 33000 1.15 0.0166 330000 -9000 0 -33000 1437000 0 350000 0 20000 1446000 0 582000 0 615000 100000 100000 100000 100000 100000 0 -358000 0 -45000 -269000 199000 -2091000 -1835000 -2091000 -1835000 -1173000 -1173000 73000 73000 0 0 0 0 1230000 1967000 -73000 55000 17000 0 -6000 -9000 -481000 -587000 -41000 45000 562000 531000 0 0 100000 24000 15000 20609000 21872000 1259000 1229000 19824000 21129000 20000 4000000 0.005 600000 100000 7814000 7368000 0 0 0.091 200000 100000 700000 400000 200000 200000 100000 700000 600000 400000 300000 700000 400000 400000 600000 700000 700000 100000 2200000 400000 270000 200000 1728000 -1000 -26000 0 -1924000 -50000 -1312000 -130000 -3264000 -1762000 -3657000 -2484000 -1173000 -1762000 -1835000 73000 2 1 1974000 1754000 -2243000 -1555000 105000 200000 190000 58000 4000 1529000 1529000 203000 128000 100000 3239827 2188177 3362276 3262088 7000 0 200000 140000 219000 19000 0 0.1 393000 0 0.01 0.01 0.01 0.01 15000000 15000000 3879307 214705 214705 214705 214705 214705 0 0 2000 2000 100000 500000 4000000 1779000 0 500000 0 144000 127000 21000 1000 1000 1000 200000 550000 0 270000 134000 -225493000 -227255000 0.52 0.08 0.42 1.21 236000 658000 500000 1704000 1620000 110000 100000 -24000 0 P3Y P3Y 4.32 P1Y0M0D P6Y6M 547957 4.25 62739 14000 0 738026 675287 3.59 3.73 0 661914 2.12 0.00 0.56 4.85 50 1.00 0.50 0 P10Y P7Y2M 6780179 4474825 793235 64153 78000 2586205 1443297 2365243 89000 7000000 2200000 -19350000 -20643000 300000 582000 615000 20323333 26779835 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentrations of Cash.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, we may maintain a cash position with financial institutions in amounts that exceed federally insured limits.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Risks and Uncertainties.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain risks and uncertainties are inherent in our day-to-day operations and in the process of preparing our financial statements. The more significant of those risks are presented below and throughout the notes to the unaudited condensed consolidated financial statements.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements are presented in conformity with GAAP. Supplemental cash flows from discontinued operations are presented in Note 3 - &#8220;Discontinued Operations&#8221;. We have evaluated events occurring subsequent to March 31, 2017 for potential recognition or disclosure in the condensed consolidated financial statements and concluded there were no subsequent events that required recognition or disclosure.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated balance sheet as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> was derived from our audited balance sheet as of that date. There has been no change in the balance sheet from December 31, 2016. The accompanying condensed consolidated financial statements as of and for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;"> are unaudited and reflect all adjustments (consisting of only normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the interim periods. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> contained in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on April 13, 2017. The results of operations for the interim periods presented are not necessarily indicative of the results for fiscal year 2017.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;"></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">BUSINESS DESCRIPTION</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Business Description</font></div><div style="line-height:120%;text-align:justify;text-indent:41px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:41px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transgenomic, Inc., and Subsidiary, (&#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;, the &#8220;Company&#8221; or &#8220;Transgenomic&#8221;) is a biotechnology company advancing personalized medicine for the detection and treatment of cancer and integrated diseases through our proprietary molecular technologies and clinical and research services. A key goal is to bring our Multiplexed ICE COLD-PCR (&#8220;MX-ICP&#8221;) product to the clinical market through strategic partnerships and licensing agreements, enabling the use of blood and other bodily fluids for more effective and patient-friendly diagnosis, monitoring and treatment of cancer.</font></div><div style="line-height:120%;text-align:justify;text-indent:41px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:41px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MX-ICP is technology proprietary to Transgenomic. It is a reagent that improves the ability to detect genetic mutations. This technology has been validated internally on all currently available sequencing platforms, including Sanger, Next Gen Sequencing and Digital PCR. By enhancing the level of detection of genetic mutations and suppressing the normal or wild-type DNA, several benefits are provided.</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Historically, our operations were organized and reviewed by management along our major product lines and presented in </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> business segments: Laboratory Services and Genetic Assays and Platforms. Beginning with the quarter ended September 30, 2015, our operations are now organized as </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> business segment, our Laboratory Services segment, and during the fourth quarter of 2015, we began including a portion of our Laboratory Services segment as discontinued operations, this has continued through March 31, 2017.</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our current Laboratory Services business consists of our laboratory in Omaha, Nebraska, which is focused on providing genetic analytical services related to Oncology and pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical and biotechnology companies. Our laboratory employs a variety of genomic testing service technologies, including our proprietary MX-ICP technology. Our laboratory in Omaha is certified under the Clinical Laboratory Improvement Amendments (&#8220;CLIA&#8221;) as a high complexity laboratory and is accredited by the College of American Pathologists.</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our condensed consolidated balance sheets, statements of operations and statements of cash flows for all periods presented reflect our former Genetic Assays and Platforms activities and Patient Testing business as discontinued operations (See Note 3 - &#8220;Discontinued Operations&#8221;).</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Going Concern</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements have been prepared using accounting principles generally accepted in the United States of America applicable for a going concern, which assume that we will realize our assets and discharge our liabilities in the ordinary course of business. We have incurred substantial operating losses and have used cash in our operating activities for the past few years. As of March 31, 2017, we had negative working capital of </font><font style="font-family:inherit;font-size:10pt;">$20.6 million</font><font style="font-family:inherit;font-size:10pt;"> and we were also not in compliance with our loan agreement due to the fact that events of default existed, including our failure to make certain required monthly interest payments to the lenders. The Company&#8217;s ability to continue as a going concern is dependent upon a combination of completing its planned merger with Precipio Diagnostics, LLC (&#8220;Precipio&#8221;), generating additional revenue, improving cash collections, potentially selling underutilized assets and/or product lines related to discontinued operations and, if needed, raising necessary financing to meet its obligations and pay its liabilities arising from normal business operations when they come due. Following the planned merger, Transgenomic will change its name to Precipio, Inc. (&#8220;New Precipio&#8221;). On February 17, 2017, Transgenomic received written notification from the staff of Nasdaq that, as a result of Transgenomic&#8217;s inability to maintain certain Nasdaq continued listing requirements, Nasdaq had determined to delist Transgenomic&#8217;s shares from Nasdaq. Accordingly, trading in Transgenomic&#8217;s shares was suspended, and on February 22, 2017, Transgenomic&#8217;s shares began trading on the OTCQB exchange under the ticker &#8220;TBIO&#8221;. As discussed below upon completion of the merger, the New Precipio common stock will be required to meet the Nasdaq listing standards. As a result of the merger, New Precipio is expected to meet Nasdaq's initial listing requirements. In addition, at the time of the merger the Company intends to execute a reverse stock split. The outcome of these matters cannot be predicted with any certainty at this time and raises substantial doubt that the Company will be able to continue as a going concern for the next twelve months from the date of issuance of these condensed financial statements. These condensed consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern. There is no assurance that the Company will complete the merger in a timely manner or at all. The merger agreement is subject to many closing conditions and termination rights. The Company also cannot be certain that additional financing, if needed, will be available on acceptable terms, or at all, and its failure to raise capital when needed could limit its ability to continue its operations.</font></div><div style="line-height:174%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Merger Agreement</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 12, 2016, Transgenomic, New Haven Labs Inc., a wholly owned subsidiary of Transgenomic (&#8220;Merger Sub&#8221; and, together with Transgenomic, the &#8220;Transgenomic Parties&#8221;), and Precipio entered into an Agreement and Plan of Merger (as amended by the Merger Agreement Amendment (as defined below) the &#8220;Merger Agreement&#8221;) pursuant to which Precipio will become a wholly owned subsidiary of Transgenomic (the &#8220;Merger&#8221;), on the terms and subject to the conditions set forth in the Merger Agreement. On February 2, 2017, Transgenomic, Merger Sub and Precipio entered into a First Amendment to Agreement and Plan of Merger (the &#8220;Merger Agreement Amendment&#8221;), which provided for, among other things, the revision of the exchange ratio set forth in the Merger Agreement, the waiver and removal of certain closing conditions and the authorization of certain actions taken by each of Transgenomic and Precipio since the date the Merger Agreement. The parties expect the Merger to close in the second quarter of 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon the effectiveness of the Merger (the &#8220;Effective Time&#8221;), (i)&#160;the outstanding common units of Precipio will be converted into the right to receive approximately </font><font style="font-family:inherit;font-size:10pt;">160.6 million</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock of New Precipio (&#8220;New Precipio common stock&#8221;), together with cash in lieu of fractional units, which will result in Precipio common unit holders owning approximately </font><font style="font-family:inherit;font-size:10pt;">52%</font><font style="font-family:inherit;font-size:10pt;"> of the issued and outstanding shares of New Precipio common stock on a fully diluted basis, taking into account the issuance of shares of convertible preferred stock of New Precipio (&#8220;New Precipio preferred stock&#8221;) in the Merger and the private placement as discussed below (the &#8220;fully diluted New Precipio common stock&#8221;) and (ii)&#160;the outstanding preferred units of Precipio will be converted into the right to receive approximately </font><font style="font-family:inherit;font-size:10pt;">24.1 million</font><font style="font-family:inherit;font-size:10pt;"> shares of New Precipio preferred stock with an aggregate face amount equal to </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;"> (based upon the purchase price of the new preferred stock of New Precipio in the new preferred stock financing), which will result in the Precipio preferred unit holders owning approximately </font><font style="font-family:inherit;font-size:10pt;">8%</font><font style="font-family:inherit;font-size:10pt;"> of the fully diluted New Precipio common stock.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon completion of the merger, New Precipio will be required to meet the initial listing requirements to qualify its shares for listing and begin trading of its shares on Nasdaq. These initial listing requirements are more difficult to achieve than the continued listing requirements.&#160; Pursuant to the Merger Agreement, Transgenomic agreed to use its commercially reasonable efforts to cause the shares of Transgenomic common stock being issued in the merger to be approved for listing on Nasdaq at or prior to the effective time of the merger. Based on information currently available to Transgenomic, Transgenomic anticipates that its stock will be unable to meet the </font><font style="font-family:inherit;font-size:10pt;">$4.00</font><font style="font-family:inherit;font-size:10pt;"> (or, to the extent applicable, </font><font style="font-family:inherit;font-size:10pt;">$3.00</font><font style="font-family:inherit;font-size:10pt;">) minimum bid price initial listing requirement at the closing of the merger unless it effects a reverse stock split. On October 31, 2016, the stockholders of Transgenomic authorized the Transgenomic Board to effect a reverse stock split of the shares of Transgenomic common stock at a ratio of between one-for-ten to one-for-thirty, such ratio to be determined by our Board of Directors (the &#8220;Reverse Split Proposal&#8221;). The Reverse Split Proposal was described in detail in our definitive proxy statement filed with the Securities and Exchange Commission on September 22, 2016, as supplemented on October 13, 2016.&#160; In addition, often times a reverse stock split will not result in a trading price for the affected common stock that is proportional to the ratio of the split.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and Cash Equivalents and Other Current Assets.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents include cash and investments with original maturities at the date of acquisition of three months or less.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONTINGENCIES</font></div><div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are subject to a number of claims of various amounts that arise out of the normal course of our business. In addition to the claims described in this Note, we are delinquent on the payment of outstanding accounts payable amounting to approximately </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> with certain of our vendors and suppliers who have taken or have threatened to take legal action to collect such outstanding amounts. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 25, 2016, the Board of Regents of the University of Nebraska (&#8220;UNMC&#8221;) filed a lawsuit against us in the District Court of Douglas County, Nebraska, for breach of contract and seeking recovery of </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> owed by us to UNMC. A </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> liability has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016. We and UNMC entered into a settlement agreement dated February 6, 2017, which included, among other things, a mutual general release of claims, and our agreement to pay </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> to UNMC in installments over a period of time. As of March 15, 2017, the initial payment due to UNMC under the settlement agreement is delinquent. We and UNMC are currently in discussions to extend the date of the initial payment due to UNMC.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, on April 13, 2016, Fox Chase Cancer Center (&#8220;Fox Chase&#8221;) filed a lawsuit against us in the Court of Common Pleas of Philadelphia County, First Judicial District of Pennsylvania Civil Trial Division (the &#8220;Court of Common Pleas&#8221;), alleging, among other things, breach of contract, tortious interference with present and prospective contractual relations, unjust enrichment, fraudulent conversion and conspiracy and seeking punitive damages in addition to damages and other relief. This lawsuit relates to a license agreement we entered into with Fox Chase in August 2000, as amended (the &#8220;License Agreement&#8221;), as well as the assignment of certain of our rights under the License Agreement to Integrated DNA Technologies, Inc. (&#8220;IDT&#8221;) pursuant to the Surveyor Kit Patent, Technology and Inventory Purchase Agreement we entered into with IDT effective as of July 1, 2014 (the &#8220;IDT Agreement&#8221;). Pursuant to the terms of the IDT Agreement, we agreed to indemnify IDT with respect to certain of the claims asserted in the Fox Chase proceeding. On July 8, 2016, the Court of Common Pleas sustained our preliminary objections to several of Fox Chase&#8217;s claims and dismissed the claims for tortious interference, fraudulent conversion, conspiracy, punitive damages and attorney&#8217;s fees.&#160; Accordingly, the case has been narrowed so that only certain contract claims and an unjust enrichment claim remain pending against us. We believe that we have good and substantial defenses to the claims asserted by Fox Chase. We are unable to determine whether any loss will occur or to estimate the range of such potential loss; therefore, no amount of loss has been accrued by us as of the date of filing of this Quarterly Report on Form 10-Q. Furthermore, there is no guarantee that we will prevail in this suit or receive any damages or other relief if we do prevail.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> On June 23, 2016, the Icahn School of Medicine at Mount Sinai (&#8220;Mount Sinai&#8221;) filed a lawsuit against us in the Supreme Court of the State of New York, County of New York, alleging, among other things, breach of contract and, alternatively, unjust enrichment and quantum merit, and seeking recovery of </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> owed by us to Mount Sinai for services rendered. We and Mount Sinai entered into a settlement agreement dated October 27, 2016, which included, among other things, a mutual general release of claims, and our agreement to pay approximately </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> to Mount Sinai in installments over a period of time. A </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> liability has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016. Effective as of February 1, 2017, we and Mount Sinai agreed to amend the terms of our settlement agreement to extend the date of the initial payment due to Mount Sinai.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 19, 2016, Todd Smith (&#8220;Smith&#8221;) filed a lawsuit against us in the District Court of Douglas County Nebraska, alleging breach of contract and seeking recovery of </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;"> owed by us to Smith for costs and damages arising from a breach of our obligations pursuant to a lease agreement between the parties. On April 7, 2017, we entered into a settlement agreement with Smith related to the early termination of our lease for our Omaha, Nebraska facility. The agreement included, among other things, a mutual general release of claims, and our agreement to pay approximately </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> to Smith in installments over a period of time. A </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> liability has been recorded and is reflected in accrued expenses at March 31, 2017. The accrued liability includes </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> recorded as a net loss on the settlement and is included in other expense in our condensed consolidated statements of operations for the three months ended March 31, 2017. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 21, 2017, XIFIN, Inc. (&#8220;XIFIN&#8221;) filed a lawsuit against us in the District Court for the Southern District of California alleging breach of written contract and seeking recovery of approximately </font><font style="font-family:inherit;font-size:10pt;">$0.27 million</font><font style="font-family:inherit;font-size:10pt;"> owed by us to XIFIN for damages arising from a breach of our obligations pursuant to a Systems Services Agreement between us and XIFIN, dated as of February 22, 2013, as amended and restated on September 1, 2014. On April 5, 2017, the court clerk entered default against us. On May 5, 2017, XIFIN filed an application for entry of default judgment against us. A </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> liability has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We and Science Park Development Corporation (&#8220;SPDC&#8221;) entered into that certain Lease dated as of December 31, 2011, as modified by the First Amendment to Lease dated as of June 18, 2013, as further modified by a letter agreement dated as of February 2, 2015, as modified by the Second Amendment to Lease dated as of June 26, 2015 (the &#8220; SPDC Lease&#8221;). In November 2016, SPDC alleged that we defaulted on our obligations under the SPDC Lease. Specifically, SPDC alleges that we failed to pay approximately </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> in rental payments due under the SPDC Lease and that we vacated a portion of the leased premises in violation of the terms of the SPDC Lease. We and SPDC entered into a settlement agreement dated March 6, 2017, which included, among other things, a mutual general release of claims, and our agreement to pay approximately </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> to SPDC in installments over a period of time. This liability has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CPA Global provides us with certain patent management services. On February 6, 2017, CPA Global claimed that we owe approximately </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> for certain patent maintenance services rendered. CPA Global has not filed claims against us in connection with this allegation. A liability of approximately </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 9, 2016, counsel for Edge BioSystems, Inc. (&#8220;EdgeBio&#8221;) sent a demand letter on behalf of EdgeBio to us in connection with the terms of that certain Asset Purchase Agreement dated September 8, 2015 (the &#8220;EdgeBio Agreement&#8221;). EdgeBio alleges, among other things, that certain customers of EdgeBio erroneously remitted payments to us, that such payments should have been paid to EdgeBio and that we failed to remit these funds to EdgeBio in violation of the terms of the EdgeBio Agreement. On September 13, 2016, we received a demand for payment letter from EdgeBio&#8217;s counsel alleging that the balance due to EdgeBio is approximately </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">. A liability of approximately </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 17, 2017, Jesse Campbell (&#8220;Campbell&#8221;) filed a lawsuit individually and on behalf of others similarly situated against us in the District Court for the District of Nebraska alleging we have a materially incomplete and misleading proxy relating to a potential merger and that the merger agreement&#8217;s deal protection provisions deter superior offers.&#160; As a result, he alleges that we have violated Sections 14(a) and 20(a) of the Exchange Act and Rule 14a-9 promulgated thereafter.&#160; Although we intend to defend the lawsuit, there can be no assurance regarding the ultimate outcome of this case. Given the uncertainty of litigation, the legal standards that must be met for, among other things, class certification and success on the merits, we are unable to estimate the amount of loss, or range of possible loss, at this time that may result from this action. In the event that a settlement is reached related to these matters, the amount of such settlement may be material to our results of operations and financial condition and may have a material adverse impact on our liquidity.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Principles of Consolidation.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements include the accounts of Transgenomic, Inc. and our wholly owned subsidiary. All inter-company balances and transactions have been eliminated in consolidation.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DEBT</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:58%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dollars&#160;in&#160;Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revolving Line of Credit</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,243</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,243</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Term Loan</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible Promissory Notes </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">571</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,368</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,814</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of long-term debt</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,368</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,814</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt, net of current maturities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;"> </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revolving Line of Credit.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font><font style="font-family:inherit;font-size:10pt;">Amounts advanced under the Revolving Line accrue interest at an annual rate equal to the greater of (a) </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">6.25%</font><font style="font-family:inherit;font-size:10pt;"> or (b) the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Wall Street Journal</font><font style="font-family:inherit;font-size:10pt;"> prime rate plus </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">3%</font><font style="font-family:inherit;font-size:10pt;">. The current interest rate is </font><font style="font-family:inherit;font-size:10pt;">6.75%</font><font style="font-family:inherit;font-size:10pt;">. As discussed below under </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Additional Terms</font><font style="font-family:inherit;font-size:10pt;">, the interest rate is subject to increase if there is a default under the Loan Agreement. Interest is payable on a monthly basis, with the balance payable at the maturity of the Revolving Line. Under the Loan Agreement, we pay the Lenders a commitment fee of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$20,000</font><font style="font-family:inherit;font-size:10pt;"> on each one-year anniversary of March 13, 2013, the Effective Date, during the term of the Revolving Line. In addition, a fee of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">0.5%</font><font style="font-family:inherit;font-size:10pt;"> per annum is payable quarterly on the unused portion of the Revolving Line. The Revolving Line matures on November 1, 2017.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Term Loan.</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">We received </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> under the Term Loan on the Effective Date. Pursuant to the terms of the Loan Agreement, as amended, the maturity date of the Loan Agreement was extended until November 1, 2017 and no principal payments on the Term Loan are due until such date. The current interest rate is </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">9.1%</font><font style="font-family:inherit;font-size:10pt;">. As discussed below, the interest rate is subject to increase if there is a default under the Loan Agreement.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will pay the Lenders an additional final payment of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$120,000</font><font style="font-family:inherit;font-size:10pt;">, at maturity or prepayment of the Term Loan, which has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016. In addition, if we repay the Term Loan prior to maturity, we will pay the Lenders a prepayment penalty of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1%</font><font style="font-family:inherit;font-size:10pt;"> of the total outstanding balance under the Term Loan.</font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Additional Terms.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Loan Agreement contains affirmative and negative covenants. Under the Loan Agreement, we agreed not to (i) pledge or otherwise encumber our assets other than to the Lenders, (ii) enter into additional borrowings or guarantees, (iii) repurchase our capital stock, or (iv) enter into certain mergers or acquisitions without the Lenders&#8217; consent. Additionally, the Loan Agreement contains a subjective acceleration clause at the discretion of the Lenders. As of March 31, 2017, we were not in compliance with the Loan Agreement, as amended, due to the fact that events of default existed, including our failure to make certain required monthly interest payments.</font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To secure the repayment of any amounts borrowed under the Revolving Line and the Term Loan, we granted the Lenders a security interest in all of our assets. The occurrence of an event of default under the Loan Agreement could result in the acceleration of our obligations under the Loan Agreement, would increase the applicable interest rate under the Revolving Line or Term Loan (or both) by </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;"> and would permit the Lenders to exercise remedies with respect to the collateral under the Loan Agreement. At March 31, 2017, our applicable interest rates have been increased by </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> Convertible Promissory Notes. </font><font style="font-family:inherit;font-size:10pt;">The Notes accrue interest at a rate of </font><font style="font-family:inherit;font-size:10pt;">6%</font><font style="font-family:inherit;font-size:10pt;"> per year and matured on December 31, 2016. </font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revolving Line and Term Loan.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 13, 2013 (the &#8220;Effective Date&#8221;), we entered into a Loan and Security Agreement with affiliates of Third Security, LLC, a related party, (the &#8220;Lenders&#8221;) for (a) a revolving line of credit (the &#8220;Revolving Line&#8221;) with borrowing availability of up to </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;">, subject to reduction based on our eligible accounts receivable, and (b) a term loan (the &#8220;Term Loan&#8221; and, together with the Revolving Line, the &#8220;Loan Agreement&#8221;) of </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;">. From the Effective Date through 2015, there were a number of amendments to the Loan Agreement.</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 6, 2016, we entered into an eighth amendment to the Loan Agreement (the &#8220;Eighth Amendment&#8221;). The Eighth Amendment, among other things, (a) provided that the Lenders waived specified events of default under the terms of the Loan Agreement, (b) reduced our future minimum revenue covenants under the Loan Agreement, (c) extended the maturity date of the Loan Agreement until November 1, 2017, and (d) provided for the repayment of an overadvance of </font><font style="font-family:inherit;font-size:10pt;">$750,000</font><font style="font-family:inherit;font-size:10pt;"> previously provided by the Lenders to us pursuant to the Loan Agreement.</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the first quarter of 2016, the overadvance that existed at December 31, 2015 was repaid to the Lenders and </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> was received from certain of the Lenders and another lender affiliate in connection with the equity offering made on January 6, 2016.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 6, 2016, we entered into a ninth amendment to the Loan Agreement (the &#8220;Ninth Amendment&#8221;). The Ninth Amendment, among other things, (a) provided that the Lenders waived specified events of default under the terms of the Loan Agreement, (b) amended the prepayment terms of the Loan Agreement, (c) provided for the reduction of amounts available under the Revolving Line upon the prepayment or repayment of certain amounts by us, (d) removed the minimum liquidity ratio and minimum net revenue financial covenants applicable to us under the Loan Agreement, (e) amended the circumstances pursuant to which we may engage in certain sales or transfers of our business or property without the consent of the Lenders, and (f) capitalized certain amounts owed by us to the Lenders and added such overdue amounts to the outstanding principal amount of the Revolving Line. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 2, 2017, we entered into a termination and tenth amendment to the Loan Agreement (the &#8220;Tenth Amendment&#8221;). The Tenth Amendment, among other things, (i) provides that the Lenders will waive specified events of default under the terms of the Loan Agreement until the effective time of the Merger (or the termination of the Merger Agreement in accordance with its terms), (ii) provides for the conversion of all outstanding indebtedness owed to the Lenders under the Loan Agreement (the &#8220;Outstanding Indebtedness&#8221;) into shares of Transgenomic common stock and preferred stock (collectively, the &#8220;Conversion Shares&#8221;) effective as of the closing date of the Merger and (iii) the termination of the Loan Documents (as defined in the Loan Agreement) and the termination and release of all security interests and liens of the Lenders in the Collateral (as defined in the Loan Agreement) in each case immediately following the conversion of the Outstanding Indebtedness into Conversion Shares.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The effectiveness of certain provisions in the Tenth Amendment, including provisions relating to conversion of the Conversion Shares and termination of the Loan Documents, is conditioned on, among other things, the consummation of the Merger, and, in the event that the Merger is not consummated, these provisions in the Loan Agreement Amendment will terminate.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Tenth Amendment, the Lenders have agreed to convert the outstanding principal and accrued interest under the Loan Agreement into (i) approximately </font><font style="font-family:inherit;font-size:10pt;">10.4 million</font><font style="font-family:inherit;font-size:10pt;"> shares of New Precipio common stock immediately prior to the effectiveness of the Merger at a price equal to </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;"> per share and (ii) </font><font style="font-family:inherit;font-size:10pt;">24.1 million</font><font style="font-family:inherit;font-size:10pt;"> shares of New Precipio preferred stock. As of March 31, 2017, the outstanding amount owed under the Loan Agreement was approximately </font><font style="font-family:inherit;font-size:10pt;">$7.2 million</font><font style="font-family:inherit;font-size:10pt;"> of principal and </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> of accrued interest. The issuance of the Conversion Shares is subject to the approval of the Transgenomic stockholders in accordance with NASDAQ Capital Market listing rules.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Convertible Promissory Notes.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 31, 2014, we entered into an Unsecured Convertible Promissory Note Purchase Agreement (the &#8220;Note Purchase Agreement&#8221;) with an accredited investor (the &#8220;Investor&#8221;), pursuant to which we agreed to issue and sell to the Investor in a private placement an unsecured convertible promissory note (the &#8220;Initial Note&#8221;). We issued the Initial Note in the aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">$750,000</font><font style="font-family:inherit;font-size:10pt;"> to the Investor on December 31, 2014. Pursuant to the terms of the Initial Note, interest accrued at a rate of </font><font style="font-family:inherit;font-size:10pt;">6%</font><font style="font-family:inherit;font-size:10pt;"> per year and the Initial Note was set to mature on December 31, 2016. The Initial Note has been converted in full into </font><font style="font-family:inherit;font-size:10pt;">502,786</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock, in accordance with the terms of the Initial Note. </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 15, 2015, we entered into the Note Purchase Agreement with </font><font style="font-family:inherit;font-size:10pt;">seven</font><font style="font-family:inherit;font-size:10pt;"> accredited investors (the &#8220;Additional Investors&#8221;) and, on January 20, 2015, issued and sold to the Additional Investors, in a private placement, notes (the &#8220;Additional Notes&#8221;) in an aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">$925,000</font><font style="font-family:inherit;font-size:10pt;">. We also issued, to our placement agent for the Notes, a convertible promissory note in an aggregate principal amount equal to </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;"> of the proceeds received by us, or </font><font style="font-family:inherit;font-size:10pt;">$46,250</font><font style="font-family:inherit;font-size:10pt;"> (the &#8220;Agent Note&#8221;). The Additional Notes and Agent Note have the same terms and conditions as the Initial Note. As of December 31, 2016, </font><font style="font-family:inherit;font-size:10pt;">$400,000</font><font style="font-family:inherit;font-size:10pt;"> of the aggregate principal amount of the Additional Notes and Agent Note, and accrued interest thereon, had been converted into an aggregate of </font><font style="font-family:inherit;font-size:10pt;">281,023</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On the Maturity Date, the then outstanding aggregate amount owed on the Additional Notes and Agent Note of approximately </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">, including accrued interest, became due. Pursuant to the terms of the Initial Note, our failure to pay any principal or interest within </font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;"> days of the date such payment is due will constitute an event of default (the &#8220;Prospective Event of Default&#8221;).</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 10, 2017, the Additional Investors and our placement agent executed a waiver of the Prospective Event of Default, pursuant to which, they agreed to waive the Prospective Event of Default on the condition that the Company and the Additional Investors enter into definitive documentation evidencing the terms for an extended maturity date of the Additional Notes and the Agent Note on or before January 16, 2017 (the &#8220;Waiver Deadline&#8221;).</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 13, 2017, all but one Additional Investor exercised their conversion rights relating to their respective Additional Notes, including the Agent Note, and converted an aggregate principal amount of&#160;</font><font style="font-family:inherit;font-size:10pt;">$0.4</font><font style="font-family:inherit;font-size:10pt;"> million, and accrued interest of less than </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">, into </font><font style="font-family:inherit;font-size:10pt;">416,135</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock. The Waiver Deadline was extended with respect to the remaining Additional Investor who did not exercise conversion rights (the &#8220;Non-Converting Investor&#8221;) so that the parties could continue to discuss a resolution of the Prospective Event of Default relating to such Non-Converting Investor&#8217;s Additional Note with an outstanding principal amount due of </font><font style="font-family:inherit;font-size:10pt;">$0.1</font><font style="font-family:inherit;font-size:10pt;"> million.</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 17, 2017, the Non-Converting Investor agreed to extend the Maturity Date of its Additional Note pursuant to an amendment to the Additional Note (the &#8220;Amendment&#8221;). The Amendment provides that two-thirds of the outstanding principal amount of the Additional Note must be paid upon the earlier to occur of the close of the Company&#8217;s merger with Precipio Diagnostics, LLC or June 16, 2017 (such applicable date, the &#8220;Deferred Maturity Date&#8221;).&#160; The remaining one-third of the principal amount outstanding on the Additional Note must be paid on the six month anniversary of the Deferred Maturity Date (the &#8220;Extended Maturity Date&#8221;).</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">STOCK OPTIONS </font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Options.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes stock option activity under our 2006 Equity Incentive Plan (the "Plan") during the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at January&#160;1, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">738,026</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(62,739</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at March 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">675,287</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.73</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at March 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">547,957</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.25</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we did not grant any options to purchase shares of our common stock. Options to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">14,000</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock were granted during the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">661,914</font><font style="font-family:inherit;font-size:10pt;"> options that were vested or expected to vest with an aggregate intrinsic value of </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> with a remaining weighted average contractual life of </font><font style="font-family:inherit;font-size:10pt;">7.2</font><font style="font-family:inherit;font-size:10pt;"> years.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Appreciation Rights (</font><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">SARs</font><font style="font-family:inherit;font-size:10pt;">&#8221;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">83,333</font><font style="font-family:inherit;font-size:10pt;"> outstanding and exercisable SARs shares were vested or expected to vest. All outstanding SARs were issued solely to our chief executive officer. The weighted-average exercise price of these SARs was </font><font style="font-family:inherit;font-size:10pt;">$4.32</font><font style="font-family:inherit;font-size:10pt;"> per share and the aggregate intrinsic value was </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> with a remaining weighted average contractual life of </font><font style="font-family:inherit;font-size:10pt;">6.5</font><font style="font-family:inherit;font-size:10pt;"> years.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes stock option activity under our 2006 Equity Incentive Plan (the "Plan") during the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at January&#160;1, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">738,026</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(62,739</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at March 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">675,287</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.73</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at March 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">547,957</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.25</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DISCONTINUED OPERATIONS</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> In March 2016, we halted testing services in our Patient Testing laboratory in New Haven, Connecticut. As a result of this action, as of December 31, 2015, our Patient Testing business met the criteria to be reported as discontinued operations. The related assets, liabilities, results of operations and cash flows for the Patient Testing business are classified as assets held for sale, liabilities held for sale and discontinued operations for all periods presented.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Results of the discontinued operations consisted of the following:</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:62.5%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three months ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Dollars in thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,103</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of goods sold</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,183</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross profit (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(65</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,025</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating income (loss) from discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,173</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss on settlement of liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from discontinued operations before income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,173</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax expense </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from discontinued operations, net of taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,173</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At March 31, 2017 and December 31, 2016, the Company had assets of the discontinued operations of less than </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> which were classified as assets held for sale in the condensed consolidated balance sheets.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Loss Per Share.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic loss per share is calculated based on the weighted-average number of common shares outstanding during each period. Diluted loss per share includes shares issuable upon exercise of outstanding stock options, warrants or conversion rights that have exercise or conversion prices below the market value of our common stock.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and 2016, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning balance at January 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total (gains) or losses:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Recognized in earnings</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(330</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at March 31</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three months ended March 31, 2017 and 2016, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following: &#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:87.6953125%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three Months Ended</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning balance at January 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">582</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,437</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total (gains) or losses:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Recognized in earnings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at March 31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">615</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,446</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless otherwise specified, book value approximates fair value. The common stock warrant liability is recorded at fair value.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-left:30px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FAIR VALUE</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">FASB guidance on fair value measurements, which defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements for our financial assets and liabilities, as well as for other assets and liabilities that are carried at fair value on a recurring basis in our condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">FASB guidance establishes a three-level fair value hierarchy based upon the assumptions (inputs) used to price assets or liabilities. The three levels of inputs used to measure fair value are as follows:</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;1&#8212;Unadjusted quoted prices in active markets for identical assets or liabilities;</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;2&#8212;Observable inputs other than those included in Level&#160;1, such as quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets;&#160;and</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;3&#8212;Unobservable inputs reflecting our own assumptions and best estimate of what inputs market participants would use in pricing the asset or liability.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Debt.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our long term debt book value approximates fair market value due to the variable interest rate it bears. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock Warrant Liabilities.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain of our issued and outstanding warrants to purchase shares of common stock do not qualify to be treated as equity and, accordingly, are recorded as a liability.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2012 Warrant Liability</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2012 Warrant Liability represents the fair value of the </font><font style="font-family:inherit;font-size:10pt;">3.4 million</font><font style="font-family:inherit;font-size:10pt;"> warrants issued in February 2012 (as adjusted pursuant to the terms of the 2012 Warrants). We are required to record these instruments at fair value at each reporting date and changes are recorded as a non-cash adjustment to earnings. The gains or losses included in earnings are reported in other income (expense) in our condensed consolidated Statement of Operations. Management does not believe that this liability will be settled by a use of cash. The 2012 Warrants expired in February 2017 and, as such, the 2012 Warrant Liability no longer exists at March 31, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2012 Warrant Liability is considered a Level 3 financial instrument and is valued using a Monte Carlo simulation model. This method is well suited to valuing options with non-standard features, such as anti-dilution protection. A Monte Carlo simulation model uses repeated random sampling to simulate significant uncertainty in inputs. Assumptions and inputs used in the valuation of the common stock warrants are broken down into four sections: Static Business Inputs; Static Technical Inputs; Simulated Business Inputs; and Simulated Technical Inputs.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and 2016, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning balance at January 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total (gains) or losses:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Recognized in earnings</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(330</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at March 31</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2016 Warrant Liability</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2016 Warrant Liability represents the fair value of the </font><font style="font-family:inherit;font-size:10pt;">1.8 million</font><font style="font-family:inherit;font-size:10pt;"> warrants issued in January 2016, of which, </font><font style="font-family:inherit;font-size:10pt;">0.8 million</font><font style="font-family:inherit;font-size:10pt;"> warrants remain outstanding as of March 31, 2017. We are required to record these instruments at fair value at each reporting date and changes are recorded as a non-cash adjustment to earnings. The gains or losses included in earnings are reported in other income (expense) in our condensed consolidated Statement of Operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2016 Warrant Liability is considered a Level 3 financial instrument and is valued using a binomial lattice simulation model. This method is well suited to valuing options with non-standard features. Assumptions and inputs used in the valuation of the common stock warrants include; our equity value, which was estimated using our stock price of </font><font style="font-family:inherit;font-size:10pt;">$0.56</font><font style="font-family:inherit;font-size:10pt;"> as of March 31, 2017; volatility of </font><font style="font-family:inherit;font-size:10pt;">115%</font><font style="font-family:inherit;font-size:10pt;">; and a risk-free interest rate of </font><font style="font-family:inherit;font-size:10pt;">1.66%</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three months ended March 31, 2017 and 2016, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following: &#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:87.6953125%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three Months Ended</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning balance at January 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">582</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,437</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total (gains) or losses:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Recognized in earnings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at March 31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">615</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,446</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INCOME TAXES </font></div><div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Annually, we file U.S. Federal, state and foreign income tax returns.&#160; All U.S. Federal and most state loss carryforwards remain subject to adjustment in the event of an income tax examination.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax expense from continuing operations was </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> for both the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and 2016. We maintain a full valuation allowance on our net deferred tax assets,&#160;having concluded that we are not more likely than not going to realize the benefit of our deferred tax assets, including our net operating loss carryforwards.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, Revenue from Contracts with Customers. This guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to a customer. ASU No. 2014-09 will replace most existing revenue recognition guidance in generally accepted accounting principles in the U.S. when it becomes effective. In July 2015, the FASB decided to defer the effective date of this new accounting guidance by one year. As a result, ASU No. 2014-09 will be effective for us for all annual and interim reporting periods beginning after December 15, 2017 and early adoption would be permitted as of the original effective date. The new standard permits the use of either the retrospective or cumulative effect transition method. We do not expect to early adopt this guidance and we have not selected a transition method. We are currently evaluating the impact this guidance will have on our financial condition, results of operations and cash flows. </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard amends the recognition of lease assets and lease liabilities by lessees for those leases currently classified as operating leases and amends disclosure requirements associated with leasing arrangements. The new standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2018. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition, and provides for certain practical expedients. Transition will require application of the new guidance at the beginning of the earliest comparative period presented. We are currently assessing the impact that the adoption of this ASU will have on our consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The new standard simplifies several aspects related to the accounting for share-based payment transactions, including the accounting for income taxes, statutory tax withholding requirements, forfeitures and classification on the statement of cash flows. This guidance is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2016. The Company adopted ASU No. 2016-09 as of January&#160;1, 2017. The adoption of this guidance does not have a material effect on the Company&#8217;s financial position and results of operations.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August&#160;2016, FASB issued ASU No.&#160;2016-15</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">, </font><font style="font-family:inherit;font-size:10pt;">Classification of Certain Cash Receipts and Cash Payments.</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">ASU No.&#160;2016-15 eliminates the diversity in practice related to the classification of certain cash receipts and payments in the statement of cash flows by adding or clarifying guidance on eight specific cash flow issues. ASU No.&#160;2016-15 is effective for fiscal years beginning after December&#160;15, 2017, and for interim periods within that fiscal year. We do not believe ASU No.&#160;2016-15 will have a material effect on our financial position and results of operations.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, FASB issued ASU No.&#160;2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business. ASU No. 2017-01adds guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The new guidance is effective for fiscal years beginning after December&#160;15, 2017, and interim periods within those fiscal years. The Company does not believe ASU No. 2017-01 will have a material effect on its financial position and results of operations.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net Sales Recognition.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;padding-left:66px;text-indent:-36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue is realized and earned when all of the following criteria are met:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Persuasive evidence of an arrangement exists;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Delivery has occurred or services have been rendered;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The seller&#8217;s price to the buyer is fixed or determinable; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collectability is reasonably assured.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> In our Omaha, Nebraska laboratory, we perform services on a project by project basis. When we receive payment in advance, we initially defer the revenue and recognize it when we deliver the service. These projects typically do not extend beyond one year. At each of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and December 31, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, deferred net sales associated with pharmacogenomics research projects included in the balance sheet in deferred revenue were </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net sales from Patient Testing laboratories are reported as part of discontinued operations (See Note 3 - &#8220;Discontinued Operations&#8221;) and are recognized on an individual test basis and, since collectability is not reasonably assured, are recognized when cash is received. There are no deferred net sales associated with our Patient Testing services. </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Taxes collected from customers and remitted to government agencies for specific net sales producing transactions are recorded net with no effect on the income statement.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;"></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:58%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dollars&#160;in&#160;Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revolving Line of Credit</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,243</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,243</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Term Loan</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible Promissory Notes </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">571</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,368</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,814</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of long-term debt</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,368</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,814</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt, net of current maturities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;"> </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revolving Line of Credit.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font><font style="font-family:inherit;font-size:10pt;">Amounts advanced under the Revolving Line accrue interest at an annual rate equal to the greater of (a) </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">6.25%</font><font style="font-family:inherit;font-size:10pt;"> or (b) the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Wall Street Journal</font><font style="font-family:inherit;font-size:10pt;"> prime rate plus </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">3%</font><font style="font-family:inherit;font-size:10pt;">. The current interest rate is </font><font style="font-family:inherit;font-size:10pt;">6.75%</font><font style="font-family:inherit;font-size:10pt;">. As discussed below under </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Additional Terms</font><font style="font-family:inherit;font-size:10pt;">, the interest rate is subject to increase if there is a default under the Loan Agreement. Interest is payable on a monthly basis, with the balance payable at the maturity of the Revolving Line. Under the Loan Agreement, we pay the Lenders a commitment fee of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$20,000</font><font style="font-family:inherit;font-size:10pt;"> on each one-year anniversary of March 13, 2013, the Effective Date, during the term of the Revolving Line. In addition, a fee of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">0.5%</font><font style="font-family:inherit;font-size:10pt;"> per annum is payable quarterly on the unused portion of the Revolving Line. The Revolving Line matures on November 1, 2017.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Term Loan.</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">We received </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> under the Term Loan on the Effective Date. Pursuant to the terms of the Loan Agreement, as amended, the maturity date of the Loan Agreement was extended until November 1, 2017 and no principal payments on the Term Loan are due until such date. The current interest rate is </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">9.1%</font><font style="font-family:inherit;font-size:10pt;">. As discussed below, the interest rate is subject to increase if there is a default under the Loan Agreement.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will pay the Lenders an additional final payment of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$120,000</font><font style="font-family:inherit;font-size:10pt;">, at maturity or prepayment of the Term Loan, which has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016. In addition, if we repay the Term Loan prior to maturity, we will pay the Lenders a prepayment penalty of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1%</font><font style="font-family:inherit;font-size:10pt;"> of the total outstanding balance under the Term Loan.</font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Additional Terms.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Loan Agreement contains affirmative and negative covenants. Under the Loan Agreement, we agreed not to (i) pledge or otherwise encumber our assets other than to the Lenders, (ii) enter into additional borrowings or guarantees, (iii) repurchase our capital stock, or (iv) enter into certain mergers or acquisitions without the Lenders&#8217; consent. Additionally, the Loan Agreement contains a subjective acceleration clause at the discretion of the Lenders. As of March 31, 2017, we were not in compliance with the Loan Agreement, as amended, due to the fact that events of default existed, including our failure to make certain required monthly interest payments.</font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To secure the repayment of any amounts borrowed under the Revolving Line and the Term Loan, we granted the Lenders a security interest in all of our assets. The occurrence of an event of default under the Loan Agreement could result in the acceleration of our obligations under the Loan Agreement, would increase the applicable interest rate under the Revolving Line or Term Loan (or both) by </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;"> and would permit the Lenders to exercise remedies with respect to the collateral under the Loan Agreement. At March 31, 2017, our applicable interest rates have been increased by </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> Convertible Promissory Notes. </font><font style="font-family:inherit;font-size:10pt;">The Notes accrue interest at a rate of </font><font style="font-family:inherit;font-size:10pt;">6%</font><font style="font-family:inherit;font-size:10pt;"> per year and matured on December 31, 2016. </font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Results of the discontinued operations consisted of the following:</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:62.5%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three months ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Dollars in thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,103</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of goods sold</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,183</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross profit (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(65</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,025</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating income (loss) from discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,173</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss on settlement of liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from discontinued operations before income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,173</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax expense </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from discontinued operations, net of taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,173</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:39%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrant Holder</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Issue&#160;Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Expiration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Underlying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">441,655</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$9.00</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Affiliates of Third Security, LLC</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250,000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$9.00</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">April 2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">374,618</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.00</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">714,780</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2.24</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">122,433</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.66</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(5)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,161,972</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.21</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Affiliates of Third Security, LLC</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(6)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">161,026</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.21</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(6)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107,527</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.21</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,334,011</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:4px;padding-top:8px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with an offering which was completed in January 2013. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with a private placement which was completed in October 2014.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with an offering which was completed in February 2015.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with an offering which was completed in July 2015.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(5)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were originally issued in connection with the offering in July 2015, and were amended in connection with the January 2016 Offering, which was completed in January 2016.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(6)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with the January 2016 Offering, which was completed in January 2016.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock-Based Compensation.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All stock-based awards to date have exercise prices equal to the market price of our common stock on the date of grant and have </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;">-year contractual terms. Unvested awards as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> had vesting periods of up to </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> years from the date of grant. None of the awards outstanding at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> are subject to performance or market-based vesting conditions.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements are presented in conformity with GAAP. Supplemental cash flows from discontinued operations are presented in Note 3 - &#8220;Discontinued Operations&#8221;. We have evaluated events occurring subsequent to March 31, 2017 for potential recognition or disclosure in the condensed consolidated financial statements and concluded there were no subsequent events that required recognition or disclosure.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated balance sheet as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> was derived from our audited balance sheet as of that date. There has been no change in the balance sheet from December 31, 2016. The accompanying condensed consolidated financial statements as of and for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;"> are unaudited and reflect all adjustments (consisting of only normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the interim periods. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> contained in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on April 13, 2017. The results of operations for the interim periods presented are not necessarily indicative of the results for fiscal year 2017.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Principles of Consolidation.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements include the accounts of Transgenomic, Inc. and our wholly owned subsidiary. All inter-company balances and transactions have been eliminated in consolidation.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Risks and Uncertainties.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain risks and uncertainties are inherent in our day-to-day operations and in the process of preparing our financial statements. The more significant of those risks are presented below and throughout the notes to the unaudited condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless otherwise specified, book value approximates fair value. The common stock warrant liability is recorded at fair value. See Note 8 - &#8220;Fair Value&#8221; for additional information.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and Cash Equivalents and Other Current Assets.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents include cash and investments with original maturities at the date of acquisition of three months or less. Other current assets as of March 31, 2017 of </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> include prepaid assets of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> and other receivables of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentrations of Cash.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, we may maintain a cash position with financial institutions in amounts that exceed federally insured limits. We have not experienced any losses on such accounts as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Property and Equipment.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation expense in continuing operations related to property and equipment was less than </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> for each of the three month periods ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. Depreciation expense during each period includes depreciation related to equipment acquired under capital leases. </font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intangible Assets.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization expense for intangible assets was less than </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> during the three month periods ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. Amortization expense for intangible assets is expected to be </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> for each of the years ending December 31, 2017, 2018 and less than </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> for each of the years ending December 31, 2019, 2020 and 2021.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock-Based Compensation.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All stock-based awards to date have exercise prices equal to the market price of our common stock on the date of grant and have </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;">-year contractual terms. Unvested awards as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> had vesting periods of up to </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> years from the date of grant. None of the awards outstanding at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> are subject to performance or market-based vesting conditions.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and 2016, we recorded compensation expense for all stock awards of </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, within selling, general and administrative expense. As of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the unrecognized compensation expense related to unvested stock awards was less than </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">, which is expected to be recognized over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> year.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in our stock awards outstanding as of March 31, 2017 were fully vested stock appreciation rights (&#8220;SARs&#8221;)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">to purchase </font><font style="font-family:inherit;font-size:10pt;">83,333</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock. The SARs were issued solely to our executive officers and vested over </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> years from the date of grant. </font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net Sales Recognition.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;padding-left:66px;text-indent:-36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue is realized and earned when all of the following criteria are met:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Persuasive evidence of an arrangement exists;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Delivery has occurred or services have been rendered;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The seller&#8217;s price to the buyer is fixed or determinable; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collectability is reasonably assured.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> In our Omaha, Nebraska laboratory, we perform services on a project by project basis. When we receive payment in advance, we initially defer the revenue and recognize it when we deliver the service. These projects typically do not extend beyond one year. At each of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and December 31, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, deferred net sales associated with pharmacogenomics research projects included in the balance sheet in deferred revenue were </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net sales from Patient Testing laboratories are reported as part of discontinued operations (See Note 3 - &#8220;Discontinued Operations&#8221;) and are recognized on an individual test basis and, since collectability is not reasonably assured, are recognized when cash is received. There are no deferred net sales associated with our Patient Testing services. </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Taxes collected from customers and remitted to government agencies for specific net sales producing transactions are recorded net with no effect on the income statement.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Loss Per Share.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic loss per share is calculated based on the weighted-average number of common shares outstanding during each period. Diluted loss per share includes shares issuable upon exercise of outstanding stock options, warrants or conversion rights that have exercise or conversion prices below the market value of our common stock. Options, warrants and conversion rights pertaining to </font><font style="font-family:inherit;font-size:10pt;">4,425,218</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">12,970,881</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock have been excluded from the computation of diluted loss per share at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, respectively, because the effect is anti-dilutive due to the net loss.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, Revenue from Contracts with Customers. This guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to a customer. ASU No. 2014-09 will replace most existing revenue recognition guidance in generally accepted accounting principles in the U.S. when it becomes effective. In July 2015, the FASB decided to defer the effective date of this new accounting guidance by one year. As a result, ASU No. 2014-09 will be effective for us for all annual and interim reporting periods beginning after December 15, 2017 and early adoption would be permitted as of the original effective date. The new standard permits the use of either the retrospective or cumulative effect transition method. We do not expect to early adopt this guidance and we have not selected a transition method. We are currently evaluating the impact this guidance will have on our financial condition, results of operations and cash flows. </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard amends the recognition of lease assets and lease liabilities by lessees for those leases currently classified as operating leases and amends disclosure requirements associated with leasing arrangements. The new standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2018. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition, and provides for certain practical expedients. Transition will require application of the new guidance at the beginning of the earliest comparative period presented. We are currently assessing the impact that the adoption of this ASU will have on our consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The new standard simplifies several aspects related to the accounting for share-based payment transactions, including the accounting for income taxes, statutory tax withholding requirements, forfeitures and classification on the statement of cash flows. This guidance is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2016. The Company adopted ASU No. 2016-09 as of January&#160;1, 2017. The adoption of this guidance does not have a material effect on the Company&#8217;s financial position and results of operations.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August&#160;2016, FASB issued ASU No.&#160;2016-15</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">, </font><font style="font-family:inherit;font-size:10pt;">Classification of Certain Cash Receipts and Cash Payments.</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">ASU No.&#160;2016-15 eliminates the diversity in practice related to the classification of certain cash receipts and payments in the statement of cash flows by adding or clarifying guidance on eight specific cash flow issues. ASU No.&#160;2016-15 is effective for fiscal years beginning after December&#160;15, 2017, and for interim periods within that fiscal year. We do not believe ASU No.&#160;2016-15 will have a material effect on our financial position and results of operations.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, FASB issued ASU No.&#160;2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business. ASU No. 2017-01adds guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The new guidance is effective for fiscal years beginning after December&#160;15, 2017, and interim periods within those fiscal years. The Company does not believe ASU No. 2017-01 will have a material effect on its financial position and results of operations.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-left:36px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">STOCKHOLDERS&#8217; DEFICIT</font></div><div style="line-height:120%;padding-left:36px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:36px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock.</font></div><div style="line-height:120%;padding-left:36px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to our Third Amended and Restated Certificate of Incorporation, as amended, we currently have </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">150,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock authorized for issuance.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 6, 2016, we entered into a Securities Purchase Agreement (the &#8220;SPA&#8221;) with certain accredited investors (the &#8220;2016 Investors&#8221;), pursuant to which, on January 8, 2016, we sold to the 2016 Investors, and the 2016 Investors purchased from us (the &#8220;January 2016 Offering&#8221;), an aggregate of approximately </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;"> of units (the &#8220;Units&#8221;) consisting of (a) an aggregate of </font><font style="font-family:inherit;font-size:10pt;">2,365,243</font><font style="font-family:inherit;font-size:10pt;"> shares (the &#8220;A-1 Preferred Shares&#8221;) of our Series A-1 Convertible Preferred Stock (the &#8220;A-1 Preferred&#8221;), and (b) warrants (the &#8220;2016 Warrants&#8221;) to purchase up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">1,773,929</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock, with an initial value of </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;">. The gross amount of </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;"> included </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;"> of cash proceeds and </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> of debt settled with the issuance of preferred stock and warrants. Each Unit was sold to the 2016 Investors at a purchase price of </font><font style="font-family:inherit;font-size:10pt;">$0.93</font><font style="font-family:inherit;font-size:10pt;"> per Unit. The A-1 Preferred Shares are convertible into shares of our common stock at an initial rate of 1-for-1, which conversion rate is subject to further adjustment as set forth in our Certificate of Designation of Series A-1 Convertible Preferred Stock, which was filed with the Secretary of State of the State of Delaware on January 8, 2016 (the &#8220;Series A-1 Certificate of Designation&#8221;). We determined there was a beneficial conversion feature (&#8220;BCF&#8221;) in connection with this issuance and valued the BCF at </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">.&#160; The holders of the A-1 Preferred were able to convert at any time following the issuance.&#160; Accordingly, we recorded a dividend totaling </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> during 2016 related to this beneficial conversion, which was recorded against additional paid in capital. Pursuant to the terms of the Series A-1 Certificate of Designation, the holders of the A-1 Preferred Shares will generally be entitled to that number of votes as is equal to the product obtained by multiplying: (i) the number of whole shares of our common stock into which the A-1 Preferred may be converted as of the record date of such vote or consent, by (ii) </font><font style="font-family:inherit;font-size:10pt;">0.93</font><font style="font-family:inherit;font-size:10pt;">, rounded down to the nearest whole number. Therefore, every </font><font style="font-family:inherit;font-size:10pt;">1.075269</font><font style="font-family:inherit;font-size:10pt;"> shares of A-1 Preferred will generally initially be entitled to one vote. In May 2016, </font><font style="font-family:inherit;font-size:10pt;">2,150,538</font><font style="font-family:inherit;font-size:10pt;"> of the A-1 Preferred Shares were converted into </font><font style="font-family:inherit;font-size:10pt;">2,150,538</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock. At March 31, 2017, there were </font><font style="font-family:inherit;font-size:10pt;">214,705</font><font style="font-family:inherit;font-size:10pt;"> A-1 Preferred Shares outstanding.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2016 Warrants were immediately exercisable upon issuance, have a term of </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> years and have an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$1.21</font><font style="font-family:inherit;font-size:10pt;"> per share of our common stock. Each 2016 Warrant includes both cash and &#8220;cashless exercise&#8221; features and an exchange feature whereby the holder of the 2016 Warrant may exchange (the &#8220;Exchange Right&#8221;) all or any portion of the 2016 Warrant for a number of shares of our common stock equal to the quotient obtained by dividing the &#8220;Exchange Amount&#8221; by the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrant is exchanged (the &#8220;Exchange Price&#8221;). Under the 2016 Warrants, the &#8220;Exchange Amount&#8221; is based upon a Black Scholes option pricing model, and the aggregate Exchange Amount under all of the 2016 Warrants will be </font><font style="font-family:inherit;font-size:10pt;">$1.4</font><font style="font-family:inherit;font-size:10pt;"> million, subject to adjustment to the extent that the risk-free U.S. Treasury rate fluctuates between the date of issuance of the 2016 Warrants and the date the 2016 Warrants are exchanged. Each 2016 Warrant provides that the number of shares that may be issued upon exercise of the Exchange Right is limited to the number of shares that may be purchased pursuant to the terms of the 2016 Warrant, unless we have previously obtained stockholder approval or approval from The Nasdaq Stock Market LLC to issue any additional shares of our common stock (the &#8220;Additional Shares&#8221;) pursuant to the Exchange Right (the &#8220;Required Approvals&#8221;). For any Exchange Right exercised more than </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;"> days following the issuance of the 2016 Warrants, if we have not obtained either of the Required Approvals, we will be required to pay the 2016 Warrant holder an amount in cash for any Additional Shares that we cannot issue without the Required Approvals based on the Exchange Amount.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2016 Warrants further provide that, to the extent the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrant is exchanged is less than </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;">, the Exchange Price will be deemed to be equal to </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;">, and, in addition to issuing shares of our common stock based on this Exchange Price, we will be required to pay to the 2016 Warrant holder an amount in cash equal to the product obtained by multiplying (a) </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;"> minus the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrant is exchanged, by (b) the aggregate number of shares of our common stock issued to the 2016 Warrant holder by the Company in such exchange at an Exchange Price equal to </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;">. Therefore, if the Required Approvals are obtained, based on the Exchange Amount of </font><font style="font-family:inherit;font-size:10pt;">$1,436,882</font><font style="font-family:inherit;font-size:10pt;"> (which, as noted above, is subject to adjustment to the extent that the risk-free U.S. Treasury rate fluctuates between the date of the issuance of the 2016 Warrants and the date the 2016 Warrants are exchanged), the maximum number of shares of our common stock issuable pursuant to the Exchange Right in the 2016 Warrants will be </font><font style="font-family:inherit;font-size:10pt;">2,873,765</font><font style="font-family:inherit;font-size:10pt;">. In addition, if, for example, assuming an Exchange Amount of </font><font style="font-family:inherit;font-size:10pt;">$1,436,882</font><font style="font-family:inherit;font-size:10pt;">, the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrants are exchanged is </font><font style="font-family:inherit;font-size:10pt;">$0.25</font><font style="font-family:inherit;font-size:10pt;">, we would be required to pay to the 2016 Warrant holders cash in an aggregate amount of </font><font style="font-family:inherit;font-size:10pt;">$718,441</font><font style="font-family:inherit;font-size:10pt;"> in addition to issuing the 2016 Warrant holders </font><font style="font-family:inherit;font-size:10pt;">2,873,765</font><font style="font-family:inherit;font-size:10pt;"> shares. During the year ended December 31, 2016, </font><font style="font-family:inherit;font-size:10pt;">1,006,419</font><font style="font-family:inherit;font-size:10pt;"> of the 2016 Warrants were exchanged for </font><font style="font-family:inherit;font-size:10pt;">1,613,353</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock and cash due of </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">. As of March 31, 2017 and December 31, 2016, the </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> due to a 2016 Investor is included in other current liabilities on our condensed consolidated balance sheet.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with the terms of the SPA, we amended that certain Series A Warrant to purchase up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">1,161,972</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock previously issued by us to an affiliate of one of the 2016 Investors on July 7, 2015 (the &#8220;Original Warrant&#8221;), as previously reported by us on our Amendment No. 1 to Current Report on Form 8-K/A, filed with the SEC on July 7, 2015 (as so amended, the &#8220;Amended Warrant&#8221;). The Amended Warrant amends the Original Warrant to provide that the Amended Warrant is subject to the same terms and conditions as the 2016 Warrants and, therefore, includes both cash and &#8220;cashless exercise&#8221; features and an Exchange Right whereby the number of shares issuable pursuant to the Exchange Right is equal to the &#8220;Amended Warrant Exchange Amount&#8221;, which is based on a Black Scholes option pricing model, and will be </font><font style="font-family:inherit;font-size:10pt;">$941,197</font><font style="font-family:inherit;font-size:10pt;">, subject to adjustment to the extent that the risk-free U.S. treasury rate fluctuates between the date of issuance of the Amended Warrant and the date the Amended Warrant is exchanged. The Amended Warrant is exercisable for up to </font><font style="font-family:inherit;font-size:10pt;">1,161,972</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock in the event we have obtained either of the Required Approvals with respect to the Amended Warrant. In the event the Amended Warrant holder exercises the Amended Warrant more than </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;"> days following the issuance of the Amended Warrant, if we have not obtained either of the Required Approvals, we will be required to pay the Amended Warrant holder an amount in cash for the shares of our common stock that we cannot issue under the Amended Warrant pursuant to such exercise without the Required Approvals based on the Amended Warrant Exchange Amount.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Amended Warrant also provides that, to the extent the closing bid price of our common stock on the second trading day prior to the date the Amended Warrant is exchanged is less than </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;">, the Exchange Price will be deemed to be equal to </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;">, and, in addition to issuing shares of our common stock based on this Exchange Price (assuming receipt of the Required Approvals), we will be required to pay to the Amended Warrant holder an amount in cash equal to the product obtained by multiplying (a) </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;"> minus the closing bid price of our common stock on the second trading day prior to the date the Amended Warrant is exchanged, by (b) the aggregate number of shares of our common stock issued to the Amended Warrant holder by us in such exchange at an Exchange Price equal to </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;">. Therefore, if the Required Approvals are obtained, based on the Amended Warrant Exchange Amount of </font><font style="font-family:inherit;font-size:10pt;">$941,197</font><font style="font-family:inherit;font-size:10pt;"> (which, as noted above, is subject to adjustment to the extent that the risk-free U.S. Treasury rate fluctuates between the issuance of the Amended Warrant and the date the Amended Warrant is exchanged), the maximum number of shares of our common stock issuable pursuant to the Exchange Right in the Amended Warrant will be </font><font style="font-family:inherit;font-size:10pt;">1,882,395</font><font style="font-family:inherit;font-size:10pt;">. In addition, if, for example, assuming an Amended Warrant Exchange Amount of </font><font style="font-family:inherit;font-size:10pt;">$941,197</font><font style="font-family:inherit;font-size:10pt;">, the closing bid price of our common stock on the second trading day prior to the date the Amended Warrant is exchanged is </font><font style="font-family:inherit;font-size:10pt;">$0.25</font><font style="font-family:inherit;font-size:10pt;">, we would be required to pay to the Amended Warrant holder cash in an aggregate amount of </font><font style="font-family:inherit;font-size:10pt;">$470,599</font><font style="font-family:inherit;font-size:10pt;"> in addition to issuing the Amended Warrant holder </font><font style="font-family:inherit;font-size:10pt;">1,882,395</font><font style="font-family:inherit;font-size:10pt;"> shares.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with entering into the SPA, we also entered into a Registration Rights Agreement, dated January 8, 2016, with the 2016 Investors. Pursuant to the terms of the Registration Rights Agreement, we were required to file with the SEC a registration statement to register for resale the shares of our common stock issuable upon conversion of the A-1 Preferred Shares and the shares of our common stock issuable upon exercise of the 2016 Warrants and the Amended Warrant by January 25, 2016. We filed the required registration statement with the SEC on January 25, 2016.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Craig-Hallum (the &#8220;Placement Agent&#8221;) served as the sole placement agent for the January 2016 Offering. In consideration for services rendered as the Placement Agent in the January 2016 Offering, we (1) paid to the Placement Agent cash commissions equal to approximately </font><font style="font-family:inherit;font-size:10pt;">$140,000</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">7.0%</font><font style="font-family:inherit;font-size:10pt;"> of the gross proceeds received in the January 2016 Offering, excluding any proceeds received from Third Security, LLC or any of its affiliates; (2) issued to the Placement Agent, for a price of </font><font style="font-family:inherit;font-size:10pt;">$50</font><font style="font-family:inherit;font-size:10pt;">, a </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-year warrant to purchase up to </font><font style="font-family:inherit;font-size:10pt;">107,527</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$1.21</font><font style="font-family:inherit;font-size:10pt;"> per share (the &#8220;Agent Warrant&#8221;), which is subject to the same terms as the 2016 Warrants except that the Agent Warrant was not exercisable until July 8, 2016 and does not contain the Exchange Right; and (3) reimbursed the Placement Agent for reasonable out-of-pocket expenses, including fees paid to the Placement Agent&#8217;s legal counsel, incurred in connection with the January 2016 Offering, which reimbursable expenses did not exceed </font><font style="font-family:inherit;font-size:10pt;">$50,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The January 2016 Offering and the payment of all accrued and unpaid dividends on the Series A Preferred Stock and Series B Preferred Stock in the form of shares of our common stock at a rate of </font><font style="font-family:inherit;font-size:10pt;">$1.00</font><font style="font-family:inherit;font-size:10pt;"> per share of our common stock discussed under &#8220;-Conversion of Preferred Stock&#8221; below required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the February 2012 common stock and warrant sale (the &#8220;2012 Private Placement&#8221;). The exercise price of these warrants decreased to </font><font style="font-family:inherit;font-size:10pt;">$4.39</font><font style="font-family:inherit;font-size:10pt;"> per share and the number of shares issuable upon exercise of the warrants increased from </font><font style="font-family:inherit;font-size:10pt;">2,188,177</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">3,239,827</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 31, 2016, we issued to a vendor an aggregate of </font><font style="font-family:inherit;font-size:10pt;">78,000</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock and, on June 14, 2016, we issued to a second vendor an aggregate of </font><font style="font-family:inherit;font-size:10pt;">64,153</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock. Such shares of common stock were issued to the vendors in lieu of an aggregate cash amount of approximately </font><font style="font-family:inherit;font-size:10pt;">$89,000</font><font style="font-family:inherit;font-size:10pt;"> owed by us to such vendors for services previously performed by such vendors. We issued the shares to the vendors in transactions exempt from registration under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder and in reliance on similar exemptions under applicable state laws. The offering of the shares to the vendors did not involve a public offering, and no general solicitation or advertisement was made in connection with the offering of the shares to the vendors.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 7, 2016, we entered into an At the Market Offering Agreement (the &#8220;ATM Agreement&#8221;) with Craig-Hallum, as sales agent, pursuant to which we may offer and sell, from time to time, through Craig-Hallum, up to </font><font style="font-family:inherit;font-size:10pt;">$3,500,000</font><font style="font-family:inherit;font-size:10pt;"> of shares (the &#8220;Shares&#8221;) of our common stock. Any Shares offered and sold in the offering will be issued pursuant to our effective shelf registration statement on Form S-3 (File No. 333-201907) and the related prospectus previously declared effective by the SEC on February 13, 2015, as supplemented by a prospectus supplement, dated June 7, 2016, that we filed with the SEC pursuant to Rule 424(b)(5) under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The number of shares eligible for sale under the ATM Agreement will be subject to the limitations of General Instruction I.B.6 of Form S-3.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the ATM Agreement, we will pay Craig-Hallum a placement fee of </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> of the gross sales price of the Shares, unless Craig-Hallum acts as principal, in which case we may sell Shares to Craig-Hallum as principal at a price to be agreed upon by us and Craig-Hallum. We will also reimburse Craig-Hallum for certain expenses incurred in connection with the ATM Agreement, and agreed to provide indemnification and contribution to Craig-Hallum with respect to certain liabilities, including liabilities under the Securities Act and the Securities Exchange Act of 1934, as amended.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The ATM Agreement was terminated during the fourth quarter of 2016 and at the time of termination we had sold </font><font style="font-family:inherit;font-size:10pt;">1,177,849</font><font style="font-family:inherit;font-size:10pt;"> shares.&#160; The average sales price per common share was </font><font style="font-family:inherit;font-size:10pt;">$0.42</font><font style="font-family:inherit;font-size:10pt;"> and the aggregate net proceeds from the sales totaled </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">. We did not sell any shares under the ATM Agreement during the three month periods ended March 31, 2017 and 2016.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The sale of shares under the ATM Agreement required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the 2012 Private Placement. The exercise price of these warrants decreased to </font><font style="font-family:inherit;font-size:10pt;">$4.23</font><font style="font-family:inherit;font-size:10pt;"> per share and the number of shares issuable upon exercise of the warrants increased from </font><font style="font-family:inherit;font-size:10pt;">3,262,088</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">3,362,276</font><font style="font-family:inherit;font-size:10pt;">. The </font><font style="font-family:inherit;font-size:10pt;">3,362,276</font><font style="font-family:inherit;font-size:10pt;"> warrants issued in the 2012 Private Placement expired in February 2017.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock Warrants.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we did not issue any warrants, no warrants were exercised and </font><font style="font-family:inherit;font-size:10pt;">3,362,276</font><font style="font-family:inherit;font-size:10pt;"> warrants expired. During the three months ended March 31, 2016, we issued warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">2,933,106</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock and no warrants were exercised. The warrants issued in the three months ended March 31, 2016 included </font><font style="font-family:inherit;font-size:10pt;">1,051,650</font><font style="font-family:inherit;font-size:10pt;"> warrants issued due to repricing requirements of the Private Placement and </font><font style="font-family:inherit;font-size:10pt;">1,881,456</font><font style="font-family:inherit;font-size:10pt;"> warrants issued in connection with the January 2016 Offering. Warrants to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">3,334,011</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock were outstanding at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:39%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrant Holder</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Issue&#160;Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Expiration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Underlying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">441,655</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$9.00</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Affiliates of Third Security, LLC</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250,000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$9.00</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">April 2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">374,618</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.00</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">714,780</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2.24</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">122,433</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.66</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(5)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,161,972</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.21</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Affiliates of Third Security, LLC</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(6)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">161,026</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.21</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(6)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107,527</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.21</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,334,011</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:4px;padding-top:8px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with an offering which was completed in January 2013. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with a private placement which was completed in October 2014.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with an offering which was completed in February 2015.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with an offering which was completed in July 2015.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(5)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were originally issued in connection with the offering in July 2015, and were amended in connection with the January 2016 Offering, which was completed in January 2016.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(6)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with the January 2016 Offering, which was completed in January 2016.</font></div></td></tr></table><div style="line-height:174%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Preferred Stock Series A.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s Board of Directors is authorized to issue up to </font><font style="font-family:inherit;font-size:10pt;">15,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares of preferred stock in one or more series, from time to time, with such designations, powers, preferences and rights and such qualifications, limitations and restrictions as may be provided in a resolution or resolutions adopted by the Board of Directors. The authority of the Board of Directors includes, but is not limited to, the determination or fixing of the following with respect to shares of such class or any series thereof: (i)&#160;the number of shares; (ii)&#160;the dividend rate, whether dividends shall be cumulative and, if so, from which date; (iii)&#160;whether shares are to be redeemable and, if so, the terms and amount of any sinking fund providing for the purchase or redemption of such shares; (iv)&#160;whether shares shall be convertible and, if so, the terms and provisions thereof; (v)&#160;what restrictions are to apply, if any, on the issue or reissue of any additional preferred stock; and (vi)&#160;whether shares have voting rights. The preferred stock may be issued with a preference over the common stock as to the payment of dividends. We have no current plans to issue any additional preferred stock. Classes of stock such as the preferred stock may be used, in certain circumstances, to create voting impediments on extraordinary corporate transactions or to frustrate persons seeking to effect a merger or otherwise to gain control of the Company. For the foregoing reasons, any additional preferred stock issued by the Company could have an adverse effect on the rights of the holders of the common stock.</font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December&#160;29, 2010, we entered into a transaction with the Third Security Investors, pursuant to the terms of a Series A Convertible Preferred Stock Purchase Agreement (the &#8220;Series A Purchase Agreement&#8221;), in which we: (i)&#160;sold an aggregate of </font><font style="font-family:inherit;font-size:10pt;">2,586,205</font><font style="font-family:inherit;font-size:10pt;"> shares of Series A Preferred Stock at a price of </font><font style="font-family:inherit;font-size:10pt;">$2.32</font><font style="font-family:inherit;font-size:10pt;"> per share; and (ii)&#160;issued Series A Warrants to purchase up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">1,293,102</font><font style="font-family:inherit;font-size:10pt;"> shares of Series A Preferred Stock having an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$2.32</font><font style="font-family:inherit;font-size:10pt;"> per share (the sale of Series A Preferred Stock and issuance of the Series A Warrants hereafter referred to together as the &#8220;Financing&#8221;). The Series A Warrants may be exercised at any time from December&#160;29, 2010 until December&#160;28, 2015 and contain a &#8220;cashless exercise&#8221; feature. The gross proceeds from the Series A financing were </font><font style="font-family:inherit;font-size:10pt;">$6.0 million</font><font style="font-family:inherit;font-size:10pt;">. The </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> of costs incurred to complete the Series A financing were recorded as a reduction in the value of the Series A Preferred Stock. We used the net proceeds from the financing to acquire the FAMILION family of genetic tests from PGxHealth, a subsidiary of Clinical Data, Inc. Until the November 2011 modifications, the Series A Preferred Stock met the definition of mandatorily redeemable stock as it was preferred capital stock that was redeemable at the option of the holder through December 2015 and was reported outside of equity. The Series A Preferred Stock was to be accreted to its redemption value of </font><font style="font-family:inherit;font-size:10pt;">$6.0 million</font><font style="font-family:inherit;font-size:10pt;">. Until the November 2011 modifications, the Series A Warrants did not qualify to be treated as equity and, accordingly, were recorded as a liability. A preferred stock anti-dilution feature is embedded within the Series A Preferred Stock that met the definition of a derivative.</font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Series A financing, we filed a Certificate of Designation of Series A Convertible Preferred Stock (the &#8220;Series A Certificate of Designation&#8221;) with the Secretary of State of the State of Delaware, designating </font><font style="font-family:inherit;font-size:10pt;">3,879,307</font><font style="font-family:inherit;font-size:10pt;"> shares of our preferred stock as Series A Preferred Stock. As of December 31, 2013, the Series A Preferred Stock, including the Series A Preferred Stock issuable upon exercise of the Series A Warrants, was convertible into shares of our common stock at a rate of 4-for-1, which conversion rate is subject to further adjustment as set forth in the Series A Certificate of Designation. Giving effect to the reverse split of our stock in January 2014, the conversion rate was adjusted to 1-for-3. Certain rights of the holders of the Series A Preferred Stock are senior to the rights of the holders of our common stock. The Series A Preferred Stock has a liquidation preference equal to its original price per share, plus any accrued and unpaid dividends thereon. The holders of the Series A Preferred Stock are entitled to receive quarterly dividends, which accrue at the rate of </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> of the original price per share per annum, whether or not declared, and which shall compound annually and shall be cumulative. In any calendar quarter in which we have positive distributable cash flow as defined in the Series A Purchase Agreement, we are required to pay from funds legally available a cash dividend in the amount equal to the lesser of </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> of such distributable cash flow or the aggregate amount of dividends accrued on the Series A Preferred Stock.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Generally, the holders of the Series A Preferred Stock are entitled to vote together with the holders of common stock, as a single group, on an as-converted basis. However, the Series A Certificate of Designation provides that we shall not perform some activities, subject to certain exceptions, without the affirmative vote of a majority of the holders of the outstanding shares of Series A Preferred Stock. The holders of the Series A Preferred Stock, along with the holders of the Series B Preferred Stock, also are entitled to elect or appoint, as a single group, </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#160;directors of the Company.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Series A financing, we also entered into a registration rights agreement with the Third Security Investors (the &#8220;Registration Rights Agreement&#8221;). Pursuant to the terms of the Registration Rights Agreement, the Company has granted certain demand, &#8220;piggyback&#8221; and S-3 registration rights covering the resale of the shares of common stock underlying the Series A Preferred Stock issued pursuant to the Series A Purchase Agreement and issuable upon exercise of the Series A Warrants and all shares of common stock issuable upon any dividend or other distribution with respect thereto.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2011, we entered into a transaction with the Third Security Investors, pursuant to an Agreement Regarding Preferred Stock (the &#8220;Amendment Agreement&#8221;), in which the Third Security Investors agreed to (i) waive their rights to enforce the anti-dilution and redemption features of the Series A Preferred Stock and (ii) at the next annual stockholders&#8217; meeting, vote to amend the Series A Certificate of Designation to remove the anti-dilution and redemption features of the Series A Preferred Stock. In exchange, the Company issued shares of common stock to the Third Security Investors having an aggregate market value of </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the Amendment Agreement, the values of the Series A Preferred Stock and Series A Warrants, including the Series A Preferred Stock conversion feature and Series A Warrant liability, were reclassified into stockholders&#8217; equity as of the date of the Amendment Agreement.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Preferred Stock Series B.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 5, 2014, we entered into a Series B Convertible Preferred Stock Purchase Agreement (the &#8220;Series B Purchase Agreement&#8221;) with affiliates of Third Security, LLC (the &#8220;2014 Third Security Investors&#8221;), pursuant to which we, in a private placement, sold and issued an aggregate of </font><font style="font-family:inherit;font-size:10pt;">1,443,297</font><font style="font-family:inherit;font-size:10pt;"> shares of our Series B Preferred Stock, par value </font><font style="font-family:inherit;font-size:10pt;">$0.01</font><font style="font-family:inherit;font-size:10pt;"> per share (the &#8220;Series B Preferred Stock&#8221;), at a price per share of </font><font style="font-family:inherit;font-size:10pt;">$4.85</font><font style="font-family:inherit;font-size:10pt;"> for an aggregate purchase price of approximately </font><font style="font-family:inherit;font-size:10pt;">$7.0 million</font><font style="font-family:inherit;font-size:10pt;">. Each share of Series B Preferred Stock issued pursuant to the Series B Purchase Agreement was initially convertible into shares of our common stock at a rate of </font><font style="font-family:inherit;font-size:10pt;">1</font><font style="font-family:inherit;font-size:10pt;">-for-1, which conversion rate was subject to further adjustment as set forth in the Certificate of Designation of Series B Convertible Preferred Stock.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Series B financing, we also entered into a Registration Rights Agreement, dated March 5, 2014, with the 2014 Third Security Investors, pursuant to which we granted certain demand, &#8220;piggy-back&#8221; and S-3 registrations rights covering the resale of the shares of common stock underlying the Series B Preferred Stock issued pursuant to the Series B Purchase Agreement and all shares of common stock issuable upon any dividend or other distribution with respect thereto.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Series B financing required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement. The exercise price of the warrants decreased from </font><font style="font-family:inherit;font-size:10pt;">$12.96</font><font style="font-family:inherit;font-size:10pt;"> per share to </font><font style="font-family:inherit;font-size:10pt;">$11.73</font><font style="font-family:inherit;font-size:10pt;"> per share and the number of shares issuable upon exercise of the warrants increased from </font><font style="font-family:inherit;font-size:10pt;">1,097,600</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">1,212,665</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Conversion of Preferred Stock - Series A and Series B.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 6, 2016, the Company entered into a Conversion Agreement (the &#8220;Conversion Agreement&#8221;) with the holders (the &#8220;Preferred Holders&#8221;) of all of the Company&#8217;s outstanding shares of Series A Convertible Preferred Stock, par value </font><font style="font-family:inherit;font-size:10pt;">$0.01</font><font style="font-family:inherit;font-size:10pt;"> per share (the &#8220;Series A Preferred Stock&#8221;), and Series B Preferred Stock, pursuant to which, among other things, the Preferred Holders: (a) elected to convert all of the outstanding shares of Series A Preferred Stock and Series B Preferred Stock into shares of our common stock, in each case in accordance with the terms thereof, and (b) agreed that all accrued and unpaid dividends on the Series A Preferred Stock and Series B Preferred Stock would be paid by the Company in shares of our common stock at a rate of </font><font style="font-family:inherit;font-size:10pt;">$1.00</font><font style="font-family:inherit;font-size:10pt;"> per share of our common stock (collectively, the &#8220;Conversion&#8221;).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The outstanding shares of Series A Preferred Stock were convertible into shares of our common stock at a rate of </font><font style="font-family:inherit;font-size:10pt;">1</font><font style="font-family:inherit;font-size:10pt;">-for-3, and the outstanding shares of Series B Preferred Stock were convertible into shares of our common stock at a rate of 1-for-1. Prior to the entry into the Conversion Agreement, there were </font><font style="font-family:inherit;font-size:10pt;">2,586,205</font><font style="font-family:inherit;font-size:10pt;"> shares of Series A Preferred Stock outstanding, which were converted into </font><font style="font-family:inherit;font-size:10pt;">862,057</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock, and </font><font style="font-family:inherit;font-size:10pt;">1,443,297</font><font style="font-family:inherit;font-size:10pt;"> shares of Series B Preferred Stock outstanding, which were converted into </font><font style="font-family:inherit;font-size:10pt;">1,443,297</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock, for an aggregate of </font><font style="font-family:inherit;font-size:10pt;">2,305,354</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock issued upon conversion of the Series A Preferred Stock and Series B Preferred Stock (the &#8220;Conversion Shares&#8221;). At the time of the entry into the Conversion Agreement, there were </font><font style="font-family:inherit;font-size:10pt;">$3.7</font><font style="font-family:inherit;font-size:10pt;"> million in accrued and unpaid dividends on the outstanding shares of Series A Preferred Stock, which were converted, in accordance with the Conversion Agreement, into </font><font style="font-family:inherit;font-size:10pt;">3,681,590</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock, and </font><font style="font-family:inherit;font-size:10pt;">$0.8</font><font style="font-family:inherit;font-size:10pt;"> million in accrued and unpaid dividends on the outstanding shares of Series B Preferred Stock, which were converted, in accordance with the terms of the Conversion Agreement, into </font><font style="font-family:inherit;font-size:10pt;">793,235</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock, for an aggregate of </font><font style="font-family:inherit;font-size:10pt;">4,474,825</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock issued pursuant to the accrued and unpaid dividends on the Series A Preferred Stock and Series B Preferred Stock. Therefore, in connection with the full conversion of the Series A Preferred Stock and Series B Preferred Stock, plus the conversion of all accrued and unpaid dividends thereon, we issued an aggregate of </font><font style="font-family:inherit;font-size:10pt;">6,780,179</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock to the Preferred Holders on January 6, 2016.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following the conversion of the shares of Series A Preferred Stock and Series B Preferred Stock into common stock, </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> shares of Series A Preferred Stock or Series B Preferred Stock remain outstanding.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Preferred Stock Dividends.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We had </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> undeclared dividends for the three months ended March 31, 2017. For the three months ended March 31, 2016, we had undeclared dividends. In accordance with the FASB&#8217;s Accounting Standards Codification Topic 260-10-45-11, &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Earnings per Share</font><font style="font-family:inherit;font-size:10pt;">&#8221;, these dividends were added to the net loss per share calculation.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SUBSEQUENT EVENTS</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 13, 2017, Transgenomic completed the sale of an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$1.15 million</font><font style="font-family:inherit;font-size:10pt;"> of promissory notes (the &#8220;Bridge Notes&#8221;) in a bridge financing pursuant to a securities purchase agreement (the &#8220;Purchase Agreement&#8221;). Transgenomic may receive additional investments of up to </font><font style="font-family:inherit;font-size:10pt;">$100,000</font><font style="font-family:inherit;font-size:10pt;"> in connection with the bridge financing. The financing is intended to help facilitate the completion of Transgenomic&#8217;s merger with Precipio, which is expected to close during the second quarter of 2017. Transgenomic received net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$1,031,000</font><font style="font-family:inherit;font-size:10pt;"> from the sale of the Bridge Notes.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Bridge Notes have an annual interest rate of </font><font style="font-family:inherit;font-size:10pt;">4%</font><font style="font-family:inherit;font-size:10pt;"> and a </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;">-day maturity. Transgenomic may repay the Bridge Notes at any time in cash upon payment of a </font><font style="font-family:inherit;font-size:10pt;">20%</font><font style="font-family:inherit;font-size:10pt;"> premium. In connection with the issuance of the Bridge Notes, Transgenomic issued warrants (the &#8220;Bridge Warrants&#8221;) to acquire </font><font style="font-family:inherit;font-size:10pt;">1.15 million</font><font style="font-family:inherit;font-size:10pt;"> shares of Transgenomic common stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;"> per share, subject to anti-dilution protection. The Purchase Agreement provides certain piggyback registration rights for the holders of the Bridge Warrants for a period of six months after the closing of the bridge financing.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of the bridge financing, Transgenomic agreed to loan </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> of the net proceeds from the sale of the Bridge Notes to Precipio pursuant to a promissory note (the &#8220;Precipio Note&#8221;) with an original principal amount of up to </font><font style="font-family:inherit;font-size:10pt;">$561,500</font><font style="font-family:inherit;font-size:10pt;"> upon substantially the same terms and conditions as the Bridge Notes. The payment of the Precipio Note is subordinated to the payment by Precipio of its secured </font><font style="font-family:inherit;font-size:10pt;">$500,000</font><font style="font-family:inherit;font-size:10pt;"> bank debt pursuant to a subordination agreement.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aegis Capital Corp. acted as placement agent for the bridge financing and received a placement agent fee of </font><font style="font-family:inherit;font-size:10pt;">$84,000</font><font style="font-family:inherit;font-size:10pt;"> and warrants (the &#8220;Aegis Warrants&#8221;) to acquire </font><font style="font-family:inherit;font-size:10pt;">168,000</font><font style="font-family:inherit;font-size:10pt;"> shares of Transgenomic common stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;"> per share. The Aegis Warrants are identical to the Bridge Warrants except that the Aegis Warrants do not have anti-dilution protection.</font></div></div> EX-101.SCH 5 tbio-20170331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2101100 - Disclosure - BUSINESS DESCRIPTION link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - BUSINESS DESCRIPTION (Details) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1001001 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICALS) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 2408401 - Disclosure - CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - DEBT (Convertible Promissory Notes) (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - DEBT (Revolving Line and Term Loan) (Details) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - DEBT (Schedule of Debt) (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - DISCONTINUED OPERATIONS link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - DISCONTINUED OPERATIONS (Revenues and Net Income (Loss)) (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - DISCONTINUED OPERATIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - DOCUMENT AND ENTITY INFORMATION link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - FAIR VALUE link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - FAIR VALUE (Details) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - FAIR VALUE (Tables) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 2409401 - Disclosure - INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - STOCK OPTIONS link:presentationLink link:calculationLink link:definitionLink 2412403 - Disclosure - STOCK OPTIONS (Stock Appreciation Rights) (Details) link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - STOCK OPTIONS (Stock Options) (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - STOCK OPTIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - STOCKHOLDERS' EQUITY (Common Stock) (Details) link:presentationLink link:calculationLink link:definitionLink 2410403 - Disclosure - STOCKHOLDERS' EQUITY (Common Stock Warrants) (Details) link:presentationLink link:calculationLink link:definitionLink 2410406 - Disclosure - STOCKHOLDERS' EQUITY (Conversion of Preferred Stock) (Details) link:presentationLink link:calculationLink link:definitionLink 2410407 - Disclosure - STOCKHOLDERS' EQUITY (Preferred Stock Dividends) (Details) link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - STOCKHOLDERS' EQUITY (Preferred Stock Series A) (Details) link:presentationLink link:calculationLink link:definitionLink 2410405 - Disclosure - STOCKHOLDERS' EQUITY (Preferred Stock Series B) (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 2414401 - Disclosure - SUBSEQUENT EVENTS (Details) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 2402404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Intangible Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narratives) (Details) link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Property, Plant and Equipment) (Details) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 1005001 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (PARENTHETICALS) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 tbio-20170331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 tbio-20170331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 tbio-20170331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Debt Disclosure [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Revolving credit facility Revolving Credit Facility [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Line of credit Line of Credit [Member] Term loan Term Loan [Member] Term Loan [Member] Convertible notes payable Convertible Notes Payable [Member] Lender Name [Axis] Lender Name [Axis] Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] Third Security LLC and affiliates Third Security LLC And Affiliates [Member] Third Security LLC And Affiliates [Member] Legal Entity [Axis] Legal Entity [Axis] Entity [Domain] Entity [Domain] Precipio Precipio [Member] Precipio [Member] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Convertible Common Stock Convertible Common Stock [Member] Convertible Preferred Stock Convertible Preferred Stock [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Current borrowing capacity Line of Credit Facility, Current Borrowing Capacity Face amount Debt Instrument, Face Amount Payment to lenders to support the amount advanced Repayments of Long-term Lines of Credit Number of shares converted (shares) Debt Conversion, Converted Instrument, Shares Issued Share price (in dollars per share) Share Price Conversion of convertible promissory notes Debt Conversion, Converted Instrument, Amount Debt conversion, converted Instrument, interest Debt Conversion, Converted Instrument, Interest Debt Conversion, Converted Instrument, Interest Discontinued Operations and Disposal Groups [Abstract] DISCONTINUED OPERATIONS Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] DEBT Debt Disclosure [Text Block] Accounting Policies [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Maximum Maximum [Member] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Selling, General and Administrative Expenses Selling, General and Administrative Expenses [Member] Title of Individual [Axis] Title of Individual [Axis] Relationship to Entity [Domain] Relationship to Entity [Domain] Executive Officers Executive Officer [Member] Business segments Segments [Axis] Segments Segments [Domain] Pharmacogenomic Services Pharmacogenomic services [Member] Pharmacogenomic services [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Other current assets Other Assets, Current Current prepaid expense Prepaid Expense, Current Other current receivables Other Receivables, Net, Current Share-based compensation arrangement by share-based payment award, expiration period Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Stock options, unvested options, vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Stock-based compensation expense Share-based Compensation Unrecognized compensation expense related to unvested stock awards, not yet recognized Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Unvested stock options, unrecognized compensation expense weighted average recognition period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Common stock rights issued (in shares) Class of Warrant or Right, Number of Issued Warrants or Rights Class of Warrant or Right, Number of Issued Warrants or Rights Deferred revenue Deferred Revenue, Current Options, warrants and conversion rights, common stock callable and antidilutive (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Fair Value Disclosures [Abstract] Schedule of changes in fair value of liability Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Precipio Common Stock Common Stock [Member] Preferred Stock Preferred Stock [Member] Minimum Minimum [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Number of operating segments Number of Operating Segments Working capital Working Capital (Deficiency) Working Capital (Deficiency) Number of shares converted, shares Conversion of Stock, Shares Converted Percentage of shares owned after transaction Sale of Stock, Percentage of Ownership after Transaction Debt settled with issuance of preferred stock and warrants Conversion of Stock, Amount Converted Reverse stock split ratio Stockholders' Equity Note, Reverse Stock Split, Conversion Ratio Stockholders' Equity Note, Reverse Stock Split, Conversion Ratio Disclosure of Compensation Related Costs, Share-based Payments [Abstract] STOCK OPTIONS Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stockholders' Equity Note [Abstract] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Class of Stock [Line Items] Class of Stock [Line Items] Cumulative undeclared dividends, preferred stock Dividends, Preferred Stock, Cash, Not Declared Dividends, Preferred Stock, Cash, Not Declared FAIR VALUE Financial Instruments Disclosure [Text Block] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Preferred stock Series A Preferred Stock Series A Preferred Stock [Member] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Private placement, net (in shares) Stock Issued During Period, Shares, New Issues Common stock warrant, exercise price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Convertible notes, number of securities called by note Convertible notes, Number of Securities Called by Note Convertible notes, Number of Securities Called by Note Proceeds from issuance of common stock and convertible notes Proceeds from issuance of common stock and convertible notes Proceeds from issuance of common stock and convertible notes Payments of stock issuance costs Payments of Stock Issuance Costs Preferred stock, dividend rate (percentage) Preferred Stock, Dividend Rate, Percentage Preferred Stock, compound dividend rate maximum (percentage) Preferred Stock, Dividend Rate, Compound Percentage Maximum Preferred Stock, Dividend Rate, Compound Percentage Maximum Number of directors Number of Directors Number of Directors Redemption value adjustment Temporary Equity, Accretion to Redemption Value, Adjustment Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Principles of Consolidation Consolidation, Policy [Policy Text Block] Risks and Uncertainties Risks and Uncertainties [Policy Text Block] Risks and Uncertainties [Policy Text Block] Fair Value Fair Value Measurement, Policy [Policy Text Block] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Concentrations of Cash Concentration of Cash Policy [Policy Text Block] Concentration of Cash Policy [Policy Text Block] Stock-Based Compensation Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Net Sales Recognition Revenue Recognition, Policy [Policy Text Block] Loss Per Share Earnings Per Share, Policy [Policy Text Block] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] Award Type [Axis] Award Type [Axis] Equity Award [Domain] Equity Award [Domain] Employee Stock Option Employee Stock Option [Member] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Equity Incentive Plan 2006 Equity Incentive Plan 2006 [Member] Equity Incentive Plan 2006 [Member] Number of Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Outstanding at beginning of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Outstanding at end of period (in shares) Exercisable at end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Weighted-Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Outstanding at beginning of period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Forfeited (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Outstanding at end of period (in dollars per share) Exercisable at end of period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Stock options, expected to vest, outstanding (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Stock options, expected to vest, outstanding, aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Stock options, expected to vest remaining contractual term Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Statement of Cash Flows [Abstract] Warranty Holders and Issuance [Axis] Warranty Holders and Issuance [Axis] Warranty Holders and Issuance [Axis] Warranty Holders and Issuance [Domain] Warranty Holders and Issuance [Domain] Warranty Holders and Issuance [Domain] Various Institutional Holders; January 2018 Various Institutional Holders; January 2018 [Member] Various Institutional Holders; January 2018 [Member] Affiliates of Third Security, LLC; January 2018 Affiliates of Third Security, LLC; January 2018 [Member] Affiliates of Third Security, LLC; January 2018 [Member] Various Institutional Holders; April 2020 Various Institutional Holders; April 2020 [Member] Various Institutional Holders; April 2020 [Member] Various Institutional Holders; February 2020 Various Institutional Holders; February 2020 [Member] Various Institutional Holders; February 2020 [Member] Various Institutional Holders; December 2020 Various Institutional Holders; December 2020 One [Member] Various Institutional Holders; December 2020 One [Member] Various Institutional Holders; January 2021 Various Institutional Holders; January 2021 One [Member] Various Institutional Holders; January 2021 One [Member] Affiliates of Third Security, LLC; January 2021 Affiliates of Third Security, LLC; January 2021 [Member] Affiliates of Third Security, LLC; January 2021 [Member] Various Institutional Holders; January 2021 Various Institutional Holders; January 2021 Two [Member] Various Institutional Holders; January 2021 Two [Member] Sale of Stock [Axis] Sale of Stock [Axis] Sale of Stock [Domain] Sale of Stock [Domain] Private Placement Private Placement [Member] Offering Offering [Member] Offering [Member] Class of stock warrants expired (shares) Class of Warrant or Right, Number of Issued Warrants Expired Class of Warrant or Right, Number of Issued Warrants Expired Common stock warrants issued (in shares) Underlying Shares Class of Warrant or Right, Outstanding Exercise Price (in dollars per share) Conversion of Stock [Table] Conversion of Stock [Table] Series B preferred stock Series B Preferred Stock [Member] Conversion of Stock [Line Items] Conversion of Stock [Line Items] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Conversion ratio Stockholders' Equity Note, Conversion Ratio Stockholders' Equity Note, Conversion Ratio Dividends payable Dividends Payable Common stock dividend (shares) Common Stock Dividends, Shares Stock dividends (shares) Stock Dividends, Shares Shares, issued (shares) Shares, Issued Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Schedule of debt Schedule of Debt [Table Text Block] BUSINESS DESCRIPTION Business Description and Basis of Presentation [Text Block] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Private placement, net Stock Issued During Period, Value, New Issues Common stock warrant, common stock called (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Schedule of discontinued operations impact on income statement and balance sheets Disposal Groups, Including Discontinued Operations [Table Text Block] Amortization expense for intangible assets Amortization of Intangible Assets Remaining amortization expense, 2017 Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year Amortization expense, 2018 Finite-Lived Intangible Assets, Amortization Expense, Year Two Amortization expense, 2019 (less than) Finite-Lived Intangible Assets, Amortization Expense, Year Three Amortization expense, 2020 (less than) Finite-Lived Intangible Assets, Amortization Expense, Year Four Amortization expense, 2021 (less than) Finite-Lived Intangible Assets, Amortization Expense, Year Five SARs Stock Appreciation Rights (SARs) [Member] Number of SARs Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercisable, Number Weighted-Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Outstanding (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Stock appreciation rights, aggregate intrinsic value, outstanding Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding Convertible promissory notes Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] Wall Street Journal prime rate Wall Street Journal Prime Rate [Member] Wall Street Journal Prime Rate [Member] Total debt Debt and Capital Lease Obligations Current portion of long-term debt Long-term Debt, Current Maturities Long-term debt, net of current maturities Long-term Debt, Excluding Current Maturities Annual interest rate (as a percent) Debt Instrument, Interest Rate, Stated Percentage Basis spread on variable rate (as a percent) Debt Instrument, Basis Spread on Variable Rate Effective interest rate (as a percent) Debt Instrument, Interest Rate, Effective Percentage Commitment fee amount Line of Credit Facility, Commitment Fee Amount Commitment fee (as a percent) Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Proceeds from issuance of long-term debt Proceeds from Issuance of Long-term Debt Current interest rate (as a percent) Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate Future debt extinguishment costs Debt Instrument, Future Debt Extinguishment Costs Debt Instrument, Future Debt Extinguishment Costs Prepayment penalty percentage of outstanding balance (as a percent) Debt Instrument, Prepayment Penalty Percent Debt Instrument, Prepayment Penalty Percent Increase in interest rate in case of debt default (as a percent) Debt Instrument, Debt Default, Interest Rate, Stated Percentage Increase Debt Instrument, Debt Default, Interest Rate, Stated Percentage Increase Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Additional Notes Additional Notes [Member] Additional Notes [Member] Agent Note Agent Note [Member] Agent Note [Member] Additional notes Additional Note Private Placement [Member] Additional Note Private Placement [Member] Interest rate (as a percent) Number of additional accredited investors Debt Instrument, Number of Additional Accredited Investors Debt Instrument, Number of Additional Accredited Investors Percentage of initial note Percentage of Initial Note Percentage of Initial Note Long-term debt Long-term Debt Debt instrument, default period Debt Instrument, Debt Default, Period Debt Instrument, Debt Default, Period Accrued interest Interest Payable Required cumulative principal payment, percent Required Cumulative Payment on Principal Per Amendment, Percent Required Cumulative Payment on Principal Per Amendment, Percent Portion of principal required by deferred maturity date, percent Portion of Principal Required to Be Paid Prior to Deferred Maturity Date, Percent Portion of Principal Required to Be Paid Prior to Deferred Maturity Date, Percent Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Liability Class [Axis] Liability Class [Axis] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] 2012 Warrant Liability 2012 Warrant Liability [Member] 2012 Warrant Liability [Member] 2016 Warrant Liability 2016 Warrant Liability [Member] 2016 Warrant Liability [Member] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Warrants outstanding (shares) Volatility (as a percent) Fair Value Assumptions, Expected Volatility Rate Risk-free interest rate (as a percent) Fair Value Assumptions, Risk Free Interest Rate Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Beginning balance Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value Additions Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases Total (gains) or losses: Total gains or losses [Abstract] Total gains or losses [Abstract] Recognized in earnings Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Balance at end of period Summary of stock option activity Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Statement of Financial Position [Abstract] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized (in shares) Common Stock, Shares Authorized Common stock, shares issued (in shares) Common Stock, Shares, Issued Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Commitments and Contingencies Disclosure [Abstract] CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Income Tax Disclosure [Abstract] INCOME TAXES Income Tax Disclosure [Text Block] Schedule of stockholders' equity, including warrants and rights Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Document and Entity Information [Abstract] Document and Entity Information [Abstract] Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Document Type Document Type Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Discontinued operations Discontinued Operations [Member] Disposal Group Name [Axis] Disposal Group Name [Axis] Disposal Group Name [Domain] Disposal Group Name [Domain] Genetic Assays and Platforms and Patient Testing Genetic Assays and Platforms and Patient Testing [Member] Genetic Assays and Platforms and Patient Testing [Member] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Net sales Disposal Group, Including Discontinued Operation, Revenue Cost of goods sold Disposal Group, Including Discontinued Operation, Costs of Goods Sold Gross profit (loss) Disposal Group, Including Discontinued Operation, Gross Profit (Loss) Selling, general and administrative expense Disposal Group, Including Discontinued Operation, Selling, General And Administrative Expense Disposal Group, Including Discontinued Operation, Selling, General And Administrative Expense Research and development expense Disposal Group, Including Discontinued Operation, Research and Development Expense Disposal Group, Including Discontinued Operation, Research and Development Expense Operating income (loss) from discontinued operations Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, before Income Tax Loss on settlement of liability Gain (Loss) on Extinguishment of Debt Income (loss) from discontinued operations before income taxes Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax Income tax expense Discontinued Operation, Tax Effect of Discontinued Operation Income (loss) from discontinued operations, net of taxes Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent Assets held for sale Disposal Group, Including Discontinued Operation, Assets, Current Loss Contingencies [Table] Loss Contingencies [Table] Litigation Case [Axis] Litigation Case [Axis] Litigation Case [Domain] Litigation Case [Domain] UNMC UNMC [Member] UNMC [Member] Mount Sinai Mount Sinai [Member] Mount Sinai [Member] Smith Smith [Member] Smith [Member] XIFIN, Inc. XIFIN, Inc. [Member] XIFIN, Inc. [Member] Science Park Development Corporation Science Park Development Corporation [Member] Science Park Development Corporation [Member] CPA Global CPA Global [Member] CPA Global [Member] Edge BioSystems, Inc. Edge BioSystems, Inc. [Member] Edge BioSystems, Inc. [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Delinquent accounts payable Delinquent Accounts Payable Delinquent Accounts Payable Damages sought in a lawsuit Loss Contingency, Damages Sought, Value Contingency accrual Loss Contingency Accrual Accrual of possible loss in a lawsuit Loss Contingency, Damages Awarded, Value Deferred loss payment Loss Contingency, Deferred Payment Loss Contingency, Deferred Payment ASSETS Assets [Abstract] CURRENT ASSETS: Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Accounts receivable, net Accounts Receivable, Net, Current Inventories Inventory, Net Total current assets Assets, Current Property and equipment, net Property, Plant and Equipment, Net OTHER ASSETS: Assets, Noncurrent [Abstract] Intangibles, net Intangible Assets, Net (Excluding Goodwill) Other assets Other Assets, Noncurrent Assets Assets LIABILITIES AND STOCKHOLDERS’ DEFICIT Liabilities and Equity [Abstract] CURRENT LIABILITIES: Liabilities, Current [Abstract] Current maturities of long-term debt Accounts payable Accounts Payable, Current Accrued compensation Employee-related Liabilities, Current Accrued expenses Accrued Liabilities, Current Deferred revenue Other current liabilities Other Liabilities, Current Total current liabilities Liabilities, Current LONG TERM LIABILITIES: Liabilities, Noncurrent [Abstract] Common stock warrant liability Warrants and Rights Outstanding Other long-term liabilities Other Liabilities, Noncurrent Total liabilities Liabilities STOCKHOLDERS’ DEFICIT: Stockholders' Equity Attributable to Parent [Abstract] Preferred stock, $0.01 par value, 15,000,000 shares authorized, 214,705 shares issued and outstanding Preferred Stock, Value, Issued Common stock, $0.01 par value, 150,000,000 shares authorized, 26,863,062 shares at March 31, 2017 and 26,446,927 shares at December 31, 2016 issued and outstanding Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Accumulated deficit Retained Earnings (Accumulated Deficit) Total stockholders’ deficit Stockholders' Equity Attributable to Parent Liabilities and stockholders' equity Liabilities and Equity Subsequent Events [Abstract] Subsequent Event [Table] Subsequent Event [Table] Short-term Debt, Type [Axis] Short-term Debt, Type [Axis] Short-term Debt, Type [Domain] Short-term Debt, Type [Domain] Bridge Loan [Member] Bridge Loan [Member] Aegis Corp Aegis Corp [Member] Aegis Corp [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Maximum additional bridge loan amount Additional Short-term Loan, Maximum Amount Authorized Additional Short-term Loan, Maximum Amount Authorized Proceeds from the sales of debt instrument Proceeds From the Sales of Debt Instrument Proceeds From the Sales of Debt Instrument Debt instrument, term Debt Instrument, Term Debt instrument, premium rate (percentage) Debt Instrument, Premium Fee, Percentage Debt Instrument, Premium Fee, Percentage Percentage of loan to related party Loan to Related Party Percentage Loan to Related Party Percentage Secured debt Secured Debt Placement fees Placement Fees Placement Fees Subsequent Events Subsequent Events [Text Block] Income tax expense (benefit) Income Tax Expense (Benefit) CASH FLOWS USED IN OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] NET LOSS Net Income (Loss) Attributable to Parent Less income (loss) from discontinued operations, net of tax Loss from continuing operations Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Adjustments to reconcile net loss to net cash flows used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization Stock-based compensation and change in liability of stock appreciation rights Provision for losses on doubtful accounts Provision for Doubtful Accounts Warrant revaluation Fair Value Adjustment of Warrants Loss on settlement of lease termination Gain (Loss) on Contract Termination Deferred interest Increase (Decrease) in Interest Payable, Net Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Inventories Increase (Decrease) in Inventories Other assets Increase (Decrease) in Other Operating Assets Accounts payable Increase (Decrease) in Accounts Payable Accrued expenses and other liabilities Increase (Decrease) in Other Accounts Payable and Accrued Liabilities Net cash used in operating activities, continuing operations Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash provided by (used in) operating activities, discontinued operations Cash Provided by (Used in) Operating Activities, Discontinued Operations Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities CASH FLOWS USED IN INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Change in other assets Payments for (Proceeds from) Other Investing Activities Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities CASH FLOWS (USED IN) PROVIDED BY FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Principal payments on capital lease obligations Repayments of Long-term Capital Lease Obligations Issuance of preferred stock and warrants, net of costs of $219 Proceeds from Issuance of Preferred Stock and Preference Stock Proceeds from debt Proceeds from Notes Payable Principal payments on debt Repayments of Notes Payable Net cash flows (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities NET CHANGE IN CASH AND CASH EQUIVALENTS Cash and Cash Equivalents, Period Increase (Decrease) CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD CASH AND CASH EQUIVALENTS AT END OF PERIOD SUPPLEMENTAL CASH FLOW INFORMATION Supplemental Cash Flow Information [Abstract] Cash paid during the period for interest Interest Paid SUPPLEMENTAL DISCLOSURE OF NON-CASH INFORMATION Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Initial valuation of warrant issued in conjunction with Private Placement Initial Fair Value of Warrants Issued Initial Fair Value of Warrants Issued STOCKHOLDERS' EQUITY Stockholders' Equity Note Disclosure [Text Block] Security Purchase Agreement Security Purchase Agreement [Member] Security Purchase Agreement [Member] Series A-1 Convertible Preferred Stock and Warrants Series A-1 Convertible Preferred Stock and Warrants [Member] Series A-1 Convertible Preferred Stock and Warrants [Member] 2016 Warrant 2016 Warrant [Member] 2016 Warrant [Member] Series A-1 Warrant Series A-1 Warrant [Member] Series A-1 Warrant [Member] Series A Warrants Series A Warrants [Member] Series A Warrants [Member] At the Market Offering Agreement At the Market Offering Agreement [Member] At the Market Offering Agreement [Member] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Craig-Hallum Capital Group LLC Craig-Hallum Capital Group LLC [Member] Craig-Hallum Capital Group LLC [Member] Vendor I Vendor [Member] Vendor [Member] Vendor II Vendor II [Member] Vendor II [Member] Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Previously Reported Scenario, Previously Reported [Member] Net proceeds from the issuance of stock warrants Proceeds from Issuance of Common Stock and Warrants, Net Proceeds from Issuance of Common Stock and Warrants, Net Dividends Dividends Class of warrant or right, number of securities called by each warrant or right (per right) Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Class of warrant or right, exercise term Class of Warrant or Right, Exercise Term1 Class of Warrant or Right, Exercise Term1 Stock warrant exchange amount Stock Warrant Exchange Amount Stock Warrant Exchange Amount Exercise period not subject to cash payment Class of Warrant or Right, Exercise Period Not Subject to Cash Payment Class of Warrant or Right, Exercise Period Not Subject to Cash Payment Price per share of stock warrants exchanged (usd per unit) Class of Warrant or Right, Exchange Price of Warrants or Rights Class of Warrant or Right, Exchange Price of Warrants or Rights Cash payment for portion of stock warrants exercised Cash Payment Portion of Stock Warrants Exercised Cash Payment Portion of Stock Warrants Exercised Stock warrants settled with cash Stock Warrants Settled with Cash Stock Warrants Settled with Cash Payments of stock issuance costs, percentage of gross offering proceeds Payments of Stock Issuance Costs, Percentage of Gross Offering Proceeds Payments of Stock Issuance Costs, Percentage of Gross Offering Proceeds Payments of stock Issuance costs, warrant right to purchase common stock (shares) Payments of Stock Issuance Costs, Warrant Right To Purchase Common Stock Shares Payments of Stock Issuance Costs, Warrant Right To Purchase Common Stock Shares Sale of stock, price per share Sale of Stock, Price Per Share Reimbursable expenses Stock Issuance Costs, Reimbursable Expenses Stock Issuance Costs, Reimbursable Expenses Partners' capital account, units, sold in private placement (units) Partners' Capital Account, Units, Sold in Private Placement Stock issued for services (shares) Stock Issued During Period, Shares, Issued for Services Stock issued for services Stock Issued During Period, Value, Issued for Services Placement fees, percentage of gross sales price Placement Fees, Percentage of Gross Sales Price Placement Fees, Percentage of Gross Sales Price Proceeds from the issuance of stock Proceeds from Issuance of Common Stock Depreciation expense Depreciation Income Statement [Abstract] Statement [Table] Statement [Table] Operating Activities [Axis] Operating Activities [Axis] Operating Activities [Domain] Operating Activities [Domain] Continuing operations Continuing Operations [Member] Statement [Line Items] Statement [Line Items] NET SALES Revenue, Net COST OF GOODS SOLD Cost of Goods and Services Sold Gross profit (loss) Gross Profit OPERATING EXPENSES: Operating Expenses [Abstract] Selling, general and administrative Selling, General and Administrative Expense Research and development Research and Development Expense Operating Expenses Operating Expenses OPERATING LOSS FROM CONTINUING OPERATIONS Operating Income (Loss) OTHER INCOME (EXPENSE): Nonoperating Income (Expense) [Abstract] Interest expense, net Interest income and (expense), net Interest income and (expense), net Warrant revaluation Gain (Loss) On Stock Warrants Revaluation Other Income (Expense) Other Income (Expense) Other Income (Expense) LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest INCOME TAX EXPENSE (BENEFIT) LOSS FROM CONTINUING OPERATIONS INCOME (LOSS) FROM DISCONTINUED OPERATIONS, NET OF TAXES PREFERRED STOCK DIVIDENDS Preferred Stock Dividends, Income Statement Impact NET LOSS AVAILABLE TO COMMON STOCKHOLDERS Net Income (Loss) Available to Common Stockholders, Basic BASIC AND DILUTED LOSS PER COMMON SHARE (IN DOLLARS PER SHARE) Earnings Per Share, Basic and Diluted BASIC AND DILUTED WEIGHTED-AVERAGE SHARES OF COMMON STOCK OUTSTANDING (IN SHARES) Weighted Average Number of Shares Outstanding, Basic and Diluted EX-101.PRE 9 tbio-20170331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 10 R1.htm IDEA: XBRL DOCUMENT v3.7.0.1
DOCUMENT AND ENTITY INFORMATION - shares
 3 Months Ended
Mar. 31, 2017
Apr. 30, 2017
Document and Entity Information [Abstract]    
Entity Registrant Name TRANSGENOMIC INC  
Entity Central Index Key 0001043961  
Current Fiscal Year End Date --12-31  
Entity Filer Category Smaller Reporting Company  
Document Type 10-Q  
Document Period End Date Mar. 31, 2017  
Document Fiscal Year Focus 2017  
Document Fiscal Period Focus Q1  
Amendment Flag false  
Entity Common Stock, Shares Outstanding   26,863,062
XML 11 R2.htm IDEA: XBRL DOCUMENT v3.7.0.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2017
Dec. 31, 2016
CURRENT ASSETS:    
Cash and cash equivalents $ 59 $ 110
Accounts receivable, net 279 225
Inventories 15 24
Other current assets 190 105
Assets held for sale 24 31
Total current assets 567 495
Property and equipment, net 127 144
OTHER ASSETS:    
Intangibles, net 531 562
Other assets 4 58
Assets 1,229 1,259
CURRENT LIABILITIES:    
Current maturities of long-term debt 7,368 7,814
Accounts payable 8,509 6,541
Accrued compensation 192 224
Accrued expenses 3,398 3,546
Deferred revenue 133 170
Other current liabilities 1,529 1,529
Total current liabilities 21,129 19,824
LONG TERM LIABILITIES:    
Common stock warrant liability 615 582
Other long-term liabilities 128 203
Total liabilities 21,872 20,609
STOCKHOLDERS’ DEFICIT:    
Preferred stock, $0.01 par value, 15,000,000 shares authorized, 214,705 shares issued and outstanding 2 2
Common stock, $0.01 par value, 150,000,000 shares authorized, 26,863,062 shares at March 31, 2017 and 26,446,927 shares at December 31, 2016 issued and outstanding 268 264
Additional paid-in capital 206,342 205,877
Accumulated deficit (227,255) (225,493)
Total stockholders’ deficit (20,643) (19,350)
Liabilities and stockholders' equity $ 1,229 $ 1,259
XML 12 R3.htm IDEA: XBRL DOCUMENT v3.7.0.1
CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICALS) - $ / shares
Mar. 31, 2017
Dec. 31, 2016
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 15,000,000 15,000,000
Preferred stock, shares issued (in shares) 214,705 214,705
Preferred stock, shares outstanding (in shares) 214,705 214,705
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 150,000,000 150,000,000
Common stock, shares issued (in shares) 26,863,062 26,446,927
Common stock, shares outstanding (in shares) 26,863,062 26,446,927
XML 13 R4.htm IDEA: XBRL DOCUMENT v3.7.0.1
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
 3 Months Ended
Mar. 31, 2017
Mar. 31, 2016
NET SALES $ 658,000 $ 236,000
COST OF GOODS SOLD 459,000 505,000
Gross profit (loss) 199,000 (269,000)
OPERATING EXPENSES:    
Selling, general and administrative 1,620,000 1,704,000
Research and development 134,000 270,000
Operating Expenses 1,754,000 1,974,000
OPERATING LOSS FROM CONTINUING OPERATIONS (1,555,000) (2,243,000)
OTHER INCOME (EXPENSE):    
Interest expense, net (247,000) (169,000)
Warrant revaluation (33,000) 321,000
Other Income (Expense) (280,000) 152,000
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES (1,835,000) (2,091,000)
INCOME TAX EXPENSE (BENEFIT) 0 0
LOSS FROM CONTINUING OPERATIONS (1,835,000) (2,091,000)
INCOME (LOSS) FROM DISCONTINUED OPERATIONS, NET OF TAXES 73,000 (1,173,000)
NET LOSS (1,762,000) (3,264,000)
PREFERRED STOCK DIVIDENDS 0 (393,000)
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS $ (1,762,000) $ (3,657,000)
BASIC AND DILUTED LOSS PER COMMON SHARE (IN DOLLARS PER SHARE) $ (0.07) $ (0.18)
BASIC AND DILUTED WEIGHTED-AVERAGE SHARES OF COMMON STOCK OUTSTANDING (IN SHARES) 26,779,835 20,323,333
Continuing operations    
OTHER INCOME (EXPENSE):    
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS $ (1,835,000) $ (2,484,000)
BASIC AND DILUTED LOSS PER COMMON SHARE (IN DOLLARS PER SHARE) $ (0.07) $ (0.12)
Discontinued operations    
OTHER INCOME (EXPENSE):    
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS $ 73,000 $ (1,173,000)
BASIC AND DILUTED LOSS PER COMMON SHARE (IN DOLLARS PER SHARE) $ 0.00 $ (0.06)
XML 14 R5.htm IDEA: XBRL DOCUMENT v3.7.0.1
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2017
Mar. 31, 2016
CASH FLOWS USED IN OPERATING ACTIVITIES:    
NET LOSS $ (1,762) $ (3,264)
Less income (loss) from discontinued operations, net of tax 73 (1,173)
Loss from continuing operations (1,835) (2,091)
Adjustments to reconcile net loss to net cash flows used in operating activities:    
Depreciation and amortization 48 83
Stock-based compensation and change in liability of stock appreciation rights (24) 110
Provision for losses on doubtful accounts 1 21
Warrant revaluation 33 (321)
Loss on settlement of lease termination 358 0
Deferred interest 0 17
Changes in operating assets and liabilities:    
Accounts receivable (55) 73
Inventories 9 6
Other assets (45) 41
Accounts payable 1,967 1,230
Accrued expenses and other liabilities (587) (481)
Net cash used in operating activities, continuing operations (130) (1,312)
Net cash provided by (used in) operating activities, discontinued operations 80 (612)
Net cash used in operating activities (50) (1,924)
CASH FLOWS USED IN INVESTING ACTIVITIES:    
Purchases of property and equipment 0 (19)
Change in other assets 0 (7)
Net cash used in investing activities 0 (26)
CASH FLOWS (USED IN) PROVIDED BY FINANCING ACTIVITIES:    
Principal payments on capital lease obligations (1) (1)
Issuance of preferred stock and warrants, net of costs of $219 0 1,779
Proceeds from debt 0 500
Principal payments on debt 0 (550)
Net cash flows (used in) provided by financing activities (1) 1,728
NET CHANGE IN CASH AND CASH EQUIVALENTS (51) (222)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD 110 444
CASH AND CASH EQUIVALENTS AT END OF PERIOD 59 222
SUPPLEMENTAL CASH FLOW INFORMATION    
Cash paid during the period for interest 0 0
SUPPLEMENTAL DISCLOSURE OF NON-CASH INFORMATION    
Initial valuation of warrant issued in conjunction with Private Placement 0 1,827
Conversion of convertible promissory notes 499 0
Debt settled with issuance of preferred stock and warrants $ 0 $ 199
XML 15 R6.htm IDEA: XBRL DOCUMENT v3.7.0.1
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (PARENTHETICALS)
$ in Thousands
 3 Months Ended
Mar. 31, 2016
USD ($)
Statement of Cash Flows [Abstract]  
Payments of stock issuance costs $ 219
XML 16 R7.htm IDEA: XBRL DOCUMENT v3.7.0.1
BUSINESS DESCRIPTION
 3 Months Ended
Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
BUSINESS DESCRIPTION
BUSINESS DESCRIPTION
Business Description

Transgenomic, Inc., and Subsidiary, (“we”, “us”, “our”, the “Company” or “Transgenomic”) is a biotechnology company advancing personalized medicine for the detection and treatment of cancer and integrated diseases through our proprietary molecular technologies and clinical and research services. A key goal is to bring our Multiplexed ICE COLD-PCR (“MX-ICP”) product to the clinical market through strategic partnerships and licensing agreements, enabling the use of blood and other bodily fluids for more effective and patient-friendly diagnosis, monitoring and treatment of cancer.

MX-ICP is technology proprietary to Transgenomic. It is a reagent that improves the ability to detect genetic mutations. This technology has been validated internally on all currently available sequencing platforms, including Sanger, Next Gen Sequencing and Digital PCR. By enhancing the level of detection of genetic mutations and suppressing the normal or wild-type DNA, several benefits are provided.

Historically, our operations were organized and reviewed by management along our major product lines and presented in two business segments: Laboratory Services and Genetic Assays and Platforms. Beginning with the quarter ended September 30, 2015, our operations are now organized as one business segment, our Laboratory Services segment, and during the fourth quarter of 2015, we began including a portion of our Laboratory Services segment as discontinued operations, this has continued through March 31, 2017.

Our current Laboratory Services business consists of our laboratory in Omaha, Nebraska, which is focused on providing genetic analytical services related to Oncology and pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical and biotechnology companies. Our laboratory employs a variety of genomic testing service technologies, including our proprietary MX-ICP technology. Our laboratory in Omaha is certified under the Clinical Laboratory Improvement Amendments (“CLIA”) as a high complexity laboratory and is accredited by the College of American Pathologists.

Our condensed consolidated balance sheets, statements of operations and statements of cash flows for all periods presented reflect our former Genetic Assays and Platforms activities and Patient Testing business as discontinued operations (See Note 3 - “Discontinued Operations”).

Going Concern

The condensed consolidated financial statements have been prepared using accounting principles generally accepted in the United States of America applicable for a going concern, which assume that we will realize our assets and discharge our liabilities in the ordinary course of business. We have incurred substantial operating losses and have used cash in our operating activities for the past few years. As of March 31, 2017, we had negative working capital of $20.6 million and we were also not in compliance with our loan agreement due to the fact that events of default existed, including our failure to make certain required monthly interest payments to the lenders. The Company’s ability to continue as a going concern is dependent upon a combination of completing its planned merger with Precipio Diagnostics, LLC (“Precipio”), generating additional revenue, improving cash collections, potentially selling underutilized assets and/or product lines related to discontinued operations and, if needed, raising necessary financing to meet its obligations and pay its liabilities arising from normal business operations when they come due. Following the planned merger, Transgenomic will change its name to Precipio, Inc. (“New Precipio”). On February 17, 2017, Transgenomic received written notification from the staff of Nasdaq that, as a result of Transgenomic’s inability to maintain certain Nasdaq continued listing requirements, Nasdaq had determined to delist Transgenomic’s shares from Nasdaq. Accordingly, trading in Transgenomic’s shares was suspended, and on February 22, 2017, Transgenomic’s shares began trading on the OTCQB exchange under the ticker “TBIO”. As discussed below upon completion of the merger, the New Precipio common stock will be required to meet the Nasdaq listing standards. As a result of the merger, New Precipio is expected to meet Nasdaq's initial listing requirements. In addition, at the time of the merger the Company intends to execute a reverse stock split. The outcome of these matters cannot be predicted with any certainty at this time and raises substantial doubt that the Company will be able to continue as a going concern for the next twelve months from the date of issuance of these condensed financial statements. These condensed consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern. There is no assurance that the Company will complete the merger in a timely manner or at all. The merger agreement is subject to many closing conditions and termination rights. The Company also cannot be certain that additional financing, if needed, will be available on acceptable terms, or at all, and its failure to raise capital when needed could limit its ability to continue its operations.
Merger Agreement
On October 12, 2016, Transgenomic, New Haven Labs Inc., a wholly owned subsidiary of Transgenomic (“Merger Sub” and, together with Transgenomic, the “Transgenomic Parties”), and Precipio entered into an Agreement and Plan of Merger (as amended by the Merger Agreement Amendment (as defined below) the “Merger Agreement”) pursuant to which Precipio will become a wholly owned subsidiary of Transgenomic (the “Merger”), on the terms and subject to the conditions set forth in the Merger Agreement. On February 2, 2017, Transgenomic, Merger Sub and Precipio entered into a First Amendment to Agreement and Plan of Merger (the “Merger Agreement Amendment”), which provided for, among other things, the revision of the exchange ratio set forth in the Merger Agreement, the waiver and removal of certain closing conditions and the authorization of certain actions taken by each of Transgenomic and Precipio since the date the Merger Agreement. The parties expect the Merger to close in the second quarter of 2017.
Upon the effectiveness of the Merger (the “Effective Time”), (i) the outstanding common units of Precipio will be converted into the right to receive approximately 160.6 million shares of common stock of New Precipio (“New Precipio common stock”), together with cash in lieu of fractional units, which will result in Precipio common unit holders owning approximately 52% of the issued and outstanding shares of New Precipio common stock on a fully diluted basis, taking into account the issuance of shares of convertible preferred stock of New Precipio (“New Precipio preferred stock”) in the Merger and the private placement as discussed below (the “fully diluted New Precipio common stock”) and (ii) the outstanding preferred units of Precipio will be converted into the right to receive approximately 24.1 million shares of New Precipio preferred stock with an aggregate face amount equal to $3.0 million (based upon the purchase price of the new preferred stock of New Precipio in the new preferred stock financing), which will result in the Precipio preferred unit holders owning approximately 8% of the fully diluted New Precipio common stock.
Upon completion of the merger, New Precipio will be required to meet the initial listing requirements to qualify its shares for listing and begin trading of its shares on Nasdaq. These initial listing requirements are more difficult to achieve than the continued listing requirements.  Pursuant to the Merger Agreement, Transgenomic agreed to use its commercially reasonable efforts to cause the shares of Transgenomic common stock being issued in the merger to be approved for listing on Nasdaq at or prior to the effective time of the merger. Based on information currently available to Transgenomic, Transgenomic anticipates that its stock will be unable to meet the $4.00 (or, to the extent applicable, $3.00) minimum bid price initial listing requirement at the closing of the merger unless it effects a reverse stock split. On October 31, 2016, the stockholders of Transgenomic authorized the Transgenomic Board to effect a reverse stock split of the shares of Transgenomic common stock at a ratio of between one-for-ten to one-for-thirty, such ratio to be determined by our Board of Directors (the “Reverse Split Proposal”). The Reverse Split Proposal was described in detail in our definitive proxy statement filed with the Securities and Exchange Commission on September 22, 2016, as supplemented on October 13, 2016.  In addition, often times a reverse stock split will not result in a trading price for the affected common stock that is proportional to the ratio of the split.
XML 17 R8.htm IDEA: XBRL DOCUMENT v3.7.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 3 Months Ended
Mar. 31, 2017
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation.
The accompanying condensed consolidated financial statements are presented in conformity with GAAP. Supplemental cash flows from discontinued operations are presented in Note 3 - “Discontinued Operations”. We have evaluated events occurring subsequent to March 31, 2017 for potential recognition or disclosure in the condensed consolidated financial statements and concluded there were no subsequent events that required recognition or disclosure.
The condensed consolidated balance sheet as of December 31, 2016 was derived from our audited balance sheet as of that date. There has been no change in the balance sheet from December 31, 2016. The accompanying condensed consolidated financial statements as of and for the three months ended March 31, 2017 and 2016 are unaudited and reflect all adjustments (consisting of only normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the interim periods. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2016 contained in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the “SEC”) on April 13, 2017. The results of operations for the interim periods presented are not necessarily indicative of the results for fiscal year 2017.
Principles of Consolidation.
The condensed consolidated financial statements include the accounts of Transgenomic, Inc. and our wholly owned subsidiary. All inter-company balances and transactions have been eliminated in consolidation.
Risks and Uncertainties.
Certain risks and uncertainties are inherent in our day-to-day operations and in the process of preparing our financial statements. The more significant of those risks are presented below and throughout the notes to the unaudited condensed consolidated financial statements.
Fair Value.
Unless otherwise specified, book value approximates fair value. The common stock warrant liability is recorded at fair value. See Note 8 - “Fair Value” for additional information.
Cash and Cash Equivalents and Other Current Assets.
Cash and cash equivalents include cash and investments with original maturities at the date of acquisition of three months or less. Other current assets as of March 31, 2017 of $0.2 million include prepaid assets of $0.1 million and other receivables of $0.1 million.
Concentrations of Cash.
From time to time, we may maintain a cash position with financial institutions in amounts that exceed federally insured limits. We have not experienced any losses on such accounts as of March 31, 2017.
 
Property and Equipment.
Depreciation expense in continuing operations related to property and equipment was less than $0.1 million for each of the three month periods ended March 31, 2017 and 2016. Depreciation expense during each period includes depreciation related to equipment acquired under capital leases.
Intangible Assets.
Amortization expense for intangible assets was less than $0.1 million during the three month periods ended March 31, 2017 and 2016. Amortization expense for intangible assets is expected to be $0.1 million for each of the years ending December 31, 2017, 2018 and less than $0.1 million for each of the years ending December 31, 2019, 2020 and 2021.
Stock-Based Compensation.
All stock-based awards to date have exercise prices equal to the market price of our common stock on the date of grant and have ten-year contractual terms. Unvested awards as of March 31, 2017 had vesting periods of up to three years from the date of grant. None of the awards outstanding at March 31, 2017 are subject to performance or market-based vesting conditions.
During the three months ended March 31, 2017 and 2016, we recorded compensation expense for all stock awards of zero and $0.1 million, respectively, within selling, general and administrative expense. As of March 31, 2017, the unrecognized compensation expense related to unvested stock awards was less than $0.1 million, which is expected to be recognized over a weighted-average period of one year.
Included in our stock awards outstanding as of March 31, 2017 were fully vested stock appreciation rights (“SARs”) to purchase 83,333 shares of our common stock. The SARs were issued solely to our executive officers and vested over three years from the date of grant.
Net Sales Recognition.
Revenue is realized and earned when all of the following criteria are met:
•
Persuasive evidence of an arrangement exists;
•
Delivery has occurred or services have been rendered;
•
The seller’s price to the buyer is fixed or determinable; and
•
Collectability is reasonably assured.

In our Omaha, Nebraska laboratory, we perform services on a project by project basis. When we receive payment in advance, we initially defer the revenue and recognize it when we deliver the service. These projects typically do not extend beyond one year. At each of March 31, 2017 and December 31, 2016, deferred net sales associated with pharmacogenomics research projects included in the balance sheet in deferred revenue were $0.1 million and $0.2 million, respectively.

Net sales from Patient Testing laboratories are reported as part of discontinued operations (See Note 3 - “Discontinued Operations”) and are recognized on an individual test basis and, since collectability is not reasonably assured, are recognized when cash is received. There are no deferred net sales associated with our Patient Testing services.

Taxes collected from customers and remitted to government agencies for specific net sales producing transactions are recorded net with no effect on the income statement.
Loss Per Share.
Basic loss per share is calculated based on the weighted-average number of common shares outstanding during each period. Diluted loss per share includes shares issuable upon exercise of outstanding stock options, warrants or conversion rights that have exercise or conversion prices below the market value of our common stock. Options, warrants and conversion rights pertaining to 4,425,218 and 12,970,881 shares of our common stock have been excluded from the computation of diluted loss per share at March 31, 2017 and 2016, respectively, because the effect is anti-dilutive due to the net loss.
Recent Accounting Pronouncements.
In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers. This guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to a customer. ASU No. 2014-09 will replace most existing revenue recognition guidance in generally accepted accounting principles in the U.S. when it becomes effective. In July 2015, the FASB decided to defer the effective date of this new accounting guidance by one year. As a result, ASU No. 2014-09 will be effective for us for all annual and interim reporting periods beginning after December 15, 2017 and early adoption would be permitted as of the original effective date. The new standard permits the use of either the retrospective or cumulative effect transition method. We do not expect to early adopt this guidance and we have not selected a transition method. We are currently evaluating the impact this guidance will have on our financial condition, results of operations and cash flows.

In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard amends the recognition of lease assets and lease liabilities by lessees for those leases currently classified as operating leases and amends disclosure requirements associated with leasing arrangements. The new standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2018. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition, and provides for certain practical expedients. Transition will require application of the new guidance at the beginning of the earliest comparative period presented. We are currently assessing the impact that the adoption of this ASU will have on our consolidated financial statements.
In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The new standard simplifies several aspects related to the accounting for share-based payment transactions, including the accounting for income taxes, statutory tax withholding requirements, forfeitures and classification on the statement of cash flows. This guidance is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2016. The Company adopted ASU No. 2016-09 as of January 1, 2017. The adoption of this guidance does not have a material effect on the Company’s financial position and results of operations.

In August 2016, FASB issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments. ASU No. 2016-15 eliminates the diversity in practice related to the classification of certain cash receipts and payments in the statement of cash flows by adding or clarifying guidance on eight specific cash flow issues. ASU No. 2016-15 is effective for fiscal years beginning after December 15, 2017, and for interim periods within that fiscal year. We do not believe ASU No. 2016-15 will have a material effect on our financial position and results of operations.

In January 2017, FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business. ASU No. 2017-01adds guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The new guidance is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company does not believe ASU No. 2017-01 will have a material effect on its financial position and results of operations.
XML 18 R9.htm IDEA: XBRL DOCUMENT v3.7.0.1
DISCONTINUED OPERATIONS
 3 Months Ended
Mar. 31, 2017
Discontinued Operations and Disposal Groups [Abstract]  
DISCONTINUED OPERATIONS
DISCONTINUED OPERATIONS

In March 2016, we halted testing services in our Patient Testing laboratory in New Haven, Connecticut. As a result of this action, as of December 31, 2015, our Patient Testing business met the criteria to be reported as discontinued operations. The related assets, liabilities, results of operations and cash flows for the Patient Testing business are classified as assets held for sale, liabilities held for sale and discontinued operations for all periods presented.
Results of the discontinued operations consisted of the following:
 
Three months ended March 31,
(Dollars in thousands)
2017
 
2016
Net sales
$
68

 
$
1,103

Cost of goods sold
15

 
1,183

Gross profit (loss)
53

 
(80
)
Selling, general and administrative expense
(65
)
 
1,025

Research and development expense
—

 
68

Operating income (loss) from discontinued operations
118

 
(1,173
)
Loss on settlement of liability
(45
)
 
—

Income (loss) from discontinued operations before income taxes
73

 
(1,173
)
Income tax expense
—

 
—

Income (loss) from discontinued operations, net of taxes
$
73

 
$
(1,173
)


At March 31, 2017 and December 31, 2016, the Company had assets of the discontinued operations of less than $0.1 million which were classified as assets held for sale in the condensed consolidated balance sheets.
XML 19 R10.htm IDEA: XBRL DOCUMENT v3.7.0.1
DEBT
 3 Months Ended
Mar. 31, 2017
Debt Disclosure [Abstract]  
DEBT
DEBT
 
 
Dollars in Thousands
 
 
March 31, 2017
 
December 31, 2016
Revolving Line of Credit(1)
 
$
3,243

 
$
3,243

Term Loan(2)
 
4,000

 
4,000

Convertible Promissory Notes (3)
 
125

 
571

Total debt
 
7,368

 
7,814

Current portion of long-term debt
 
(7,368
)
 
(7,814
)
Long-term debt, net of current maturities
 
$
—

 
$
—

 
(1)
Revolving Line of Credit. Amounts advanced under the Revolving Line accrue interest at an annual rate equal to the greater of (a) 6.25% or (b) the Wall Street Journal prime rate plus 3%. The current interest rate is 6.75%. As discussed below under Additional Terms, the interest rate is subject to increase if there is a default under the Loan Agreement. Interest is payable on a monthly basis, with the balance payable at the maturity of the Revolving Line. Under the Loan Agreement, we pay the Lenders a commitment fee of $20,000 on each one-year anniversary of March 13, 2013, the Effective Date, during the term of the Revolving Line. In addition, a fee of 0.5% per annum is payable quarterly on the unused portion of the Revolving Line. The Revolving Line matures on November 1, 2017.

(2)
Term Loan. We received $4.0 million under the Term Loan on the Effective Date. Pursuant to the terms of the Loan Agreement, as amended, the maturity date of the Loan Agreement was extended until November 1, 2017 and no principal payments on the Term Loan are due until such date. The current interest rate is 9.1%. As discussed below, the interest rate is subject to increase if there is a default under the Loan Agreement.

We will pay the Lenders an additional final payment of $120,000, at maturity or prepayment of the Term Loan, which has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016. In addition, if we repay the Term Loan prior to maturity, we will pay the Lenders a prepayment penalty of 1% of the total outstanding balance under the Term Loan.

Additional Terms.
The Loan Agreement contains affirmative and negative covenants. Under the Loan Agreement, we agreed not to (i) pledge or otherwise encumber our assets other than to the Lenders, (ii) enter into additional borrowings or guarantees, (iii) repurchase our capital stock, or (iv) enter into certain mergers or acquisitions without the Lenders’ consent. Additionally, the Loan Agreement contains a subjective acceleration clause at the discretion of the Lenders. As of March 31, 2017, we were not in compliance with the Loan Agreement, as amended, due to the fact that events of default existed, including our failure to make certain required monthly interest payments.

To secure the repayment of any amounts borrowed under the Revolving Line and the Term Loan, we granted the Lenders a security interest in all of our assets. The occurrence of an event of default under the Loan Agreement could result in the acceleration of our obligations under the Loan Agreement, would increase the applicable interest rate under the Revolving Line or Term Loan (or both) by 5% and would permit the Lenders to exercise remedies with respect to the collateral under the Loan Agreement. At March 31, 2017, our applicable interest rates have been increased by 5%.

(3) Convertible Promissory Notes. The Notes accrue interest at a rate of 6% per year and matured on December 31, 2016.

Revolving Line and Term Loan.

On March 13, 2013 (the “Effective Date”), we entered into a Loan and Security Agreement with affiliates of Third Security, LLC, a related party, (the “Lenders”) for (a) a revolving line of credit (the “Revolving Line”) with borrowing availability of up to $4.0 million, subject to reduction based on our eligible accounts receivable, and (b) a term loan (the “Term Loan” and, together with the Revolving Line, the “Loan Agreement”) of $4.0 million. From the Effective Date through 2015, there were a number of amendments to the Loan Agreement.
On January 6, 2016, we entered into an eighth amendment to the Loan Agreement (the “Eighth Amendment”). The Eighth Amendment, among other things, (a) provided that the Lenders waived specified events of default under the terms of the Loan Agreement, (b) reduced our future minimum revenue covenants under the Loan Agreement, (c) extended the maturity date of the Loan Agreement until November 1, 2017, and (d) provided for the repayment of an overadvance of $750,000 previously provided by the Lenders to us pursuant to the Loan Agreement.

During the first quarter of 2016, the overadvance that existed at December 31, 2015 was repaid to the Lenders and $0.2 million was received from certain of the Lenders and another lender affiliate in connection with the equity offering made on January 6, 2016.

On June 6, 2016, we entered into a ninth amendment to the Loan Agreement (the “Ninth Amendment”). The Ninth Amendment, among other things, (a) provided that the Lenders waived specified events of default under the terms of the Loan Agreement, (b) amended the prepayment terms of the Loan Agreement, (c) provided for the reduction of amounts available under the Revolving Line upon the prepayment or repayment of certain amounts by us, (d) removed the minimum liquidity ratio and minimum net revenue financial covenants applicable to us under the Loan Agreement, (e) amended the circumstances pursuant to which we may engage in certain sales or transfers of our business or property without the consent of the Lenders, and (f) capitalized certain amounts owed by us to the Lenders and added such overdue amounts to the outstanding principal amount of the Revolving Line.
 
On February 2, 2017, we entered into a termination and tenth amendment to the Loan Agreement (the “Tenth Amendment”). The Tenth Amendment, among other things, (i) provides that the Lenders will waive specified events of default under the terms of the Loan Agreement until the effective time of the Merger (or the termination of the Merger Agreement in accordance with its terms), (ii) provides for the conversion of all outstanding indebtedness owed to the Lenders under the Loan Agreement (the “Outstanding Indebtedness”) into shares of Transgenomic common stock and preferred stock (collectively, the “Conversion Shares”) effective as of the closing date of the Merger and (iii) the termination of the Loan Documents (as defined in the Loan Agreement) and the termination and release of all security interests and liens of the Lenders in the Collateral (as defined in the Loan Agreement) in each case immediately following the conversion of the Outstanding Indebtedness into Conversion Shares.

The effectiveness of certain provisions in the Tenth Amendment, including provisions relating to conversion of the Conversion Shares and termination of the Loan Documents, is conditioned on, among other things, the consummation of the Merger, and, in the event that the Merger is not consummated, these provisions in the Loan Agreement Amendment will terminate.

In connection with the Tenth Amendment, the Lenders have agreed to convert the outstanding principal and accrued interest under the Loan Agreement into (i) approximately 10.4 million shares of New Precipio common stock immediately prior to the effectiveness of the Merger at a price equal to $0.50 per share and (ii) 24.1 million shares of New Precipio preferred stock. As of March 31, 2017, the outstanding amount owed under the Loan Agreement was approximately $7.2 million of principal and $0.8 million of accrued interest. The issuance of the Conversion Shares is subject to the approval of the Transgenomic stockholders in accordance with NASDAQ Capital Market listing rules.

Convertible Promissory Notes.

On December 31, 2014, we entered into an Unsecured Convertible Promissory Note Purchase Agreement (the “Note Purchase Agreement”) with an accredited investor (the “Investor”), pursuant to which we agreed to issue and sell to the Investor in a private placement an unsecured convertible promissory note (the “Initial Note”). We issued the Initial Note in the aggregate principal amount of $750,000 to the Investor on December 31, 2014. Pursuant to the terms of the Initial Note, interest accrued at a rate of 6% per year and the Initial Note was set to mature on December 31, 2016. The Initial Note has been converted in full into 502,786 shares of our common stock, in accordance with the terms of the Initial Note.

On January 15, 2015, we entered into the Note Purchase Agreement with seven accredited investors (the “Additional Investors”) and, on January 20, 2015, issued and sold to the Additional Investors, in a private placement, notes (the “Additional Notes”) in an aggregate principal amount of $925,000. We also issued, to our placement agent for the Notes, a convertible promissory note in an aggregate principal amount equal to 5% of the proceeds received by us, or $46,250 (the “Agent Note”). The Additional Notes and Agent Note have the same terms and conditions as the Initial Note. As of December 31, 2016, $400,000 of the aggregate principal amount of the Additional Notes and Agent Note, and accrued interest thereon, had been converted into an aggregate of 281,023 shares of our common stock.

On the Maturity Date, the then outstanding aggregate amount owed on the Additional Notes and Agent Note of approximately $0.6 million, including accrued interest, became due. Pursuant to the terms of the Initial Note, our failure to pay any principal or interest within 10 days of the date such payment is due will constitute an event of default (the “Prospective Event of Default”).

On January 10, 2017, the Additional Investors and our placement agent executed a waiver of the Prospective Event of Default, pursuant to which, they agreed to waive the Prospective Event of Default on the condition that the Company and the Additional Investors enter into definitive documentation evidencing the terms for an extended maturity date of the Additional Notes and the Agent Note on or before January 16, 2017 (the “Waiver Deadline”).

On January 13, 2017, all but one Additional Investor exercised their conversion rights relating to their respective Additional Notes, including the Agent Note, and converted an aggregate principal amount of $0.4 million, and accrued interest of less than $0.1 million, into 416,135 shares of our common stock. The Waiver Deadline was extended with respect to the remaining Additional Investor who did not exercise conversion rights (the “Non-Converting Investor”) so that the parties could continue to discuss a resolution of the Prospective Event of Default relating to such Non-Converting Investor’s Additional Note with an outstanding principal amount due of $0.1 million.

On January 17, 2017, the Non-Converting Investor agreed to extend the Maturity Date of its Additional Note pursuant to an amendment to the Additional Note (the “Amendment”). The Amendment provides that two-thirds of the outstanding principal amount of the Additional Note must be paid upon the earlier to occur of the close of the Company’s merger with Precipio Diagnostics, LLC or June 16, 2017 (such applicable date, the “Deferred Maturity Date”).  The remaining one-third of the principal amount outstanding on the Additional Note must be paid on the six month anniversary of the Deferred Maturity Date (the “Extended Maturity Date”).
XML 20 R11.htm IDEA: XBRL DOCUMENT v3.7.0.1
CONTINGENCIES
 3 Months Ended
Mar. 31, 2017
Commitments and Contingencies Disclosure [Abstract]  
CONTINGENCIES
CONTINGENCIES

We are subject to a number of claims of various amounts that arise out of the normal course of our business. In addition to the claims described in this Note, we are delinquent on the payment of outstanding accounts payable amounting to approximately $0.6 million with certain of our vendors and suppliers who have taken or have threatened to take legal action to collect such outstanding amounts.
On February 25, 2016, the Board of Regents of the University of Nebraska (“UNMC”) filed a lawsuit against us in the District Court of Douglas County, Nebraska, for breach of contract and seeking recovery of $0.7 million owed by us to UNMC. A $0.4 million liability has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016. We and UNMC entered into a settlement agreement dated February 6, 2017, which included, among other things, a mutual general release of claims, and our agreement to pay $0.4 million to UNMC in installments over a period of time. As of March 15, 2017, the initial payment due to UNMC under the settlement agreement is delinquent. We and UNMC are currently in discussions to extend the date of the initial payment due to UNMC.
In addition, on April 13, 2016, Fox Chase Cancer Center (“Fox Chase”) filed a lawsuit against us in the Court of Common Pleas of Philadelphia County, First Judicial District of Pennsylvania Civil Trial Division (the “Court of Common Pleas”), alleging, among other things, breach of contract, tortious interference with present and prospective contractual relations, unjust enrichment, fraudulent conversion and conspiracy and seeking punitive damages in addition to damages and other relief. This lawsuit relates to a license agreement we entered into with Fox Chase in August 2000, as amended (the “License Agreement”), as well as the assignment of certain of our rights under the License Agreement to Integrated DNA Technologies, Inc. (“IDT”) pursuant to the Surveyor Kit Patent, Technology and Inventory Purchase Agreement we entered into with IDT effective as of July 1, 2014 (the “IDT Agreement”). Pursuant to the terms of the IDT Agreement, we agreed to indemnify IDT with respect to certain of the claims asserted in the Fox Chase proceeding. On July 8, 2016, the Court of Common Pleas sustained our preliminary objections to several of Fox Chase’s claims and dismissed the claims for tortious interference, fraudulent conversion, conspiracy, punitive damages and attorney’s fees.  Accordingly, the case has been narrowed so that only certain contract claims and an unjust enrichment claim remain pending against us. We believe that we have good and substantial defenses to the claims asserted by Fox Chase. We are unable to determine whether any loss will occur or to estimate the range of such potential loss; therefore, no amount of loss has been accrued by us as of the date of filing of this Quarterly Report on Form 10-Q. Furthermore, there is no guarantee that we will prevail in this suit or receive any damages or other relief if we do prevail.
On June 23, 2016, the Icahn School of Medicine at Mount Sinai (“Mount Sinai”) filed a lawsuit against us in the Supreme Court of the State of New York, County of New York, alleging, among other things, breach of contract and, alternatively, unjust enrichment and quantum merit, and seeking recovery of $0.7 million owed by us to Mount Sinai for services rendered. We and Mount Sinai entered into a settlement agreement dated October 27, 2016, which included, among other things, a mutual general release of claims, and our agreement to pay approximately $0.7 million to Mount Sinai in installments over a period of time. A $0.7 million liability has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016. Effective as of February 1, 2017, we and Mount Sinai agreed to amend the terms of our settlement agreement to extend the date of the initial payment due to Mount Sinai.
On December 19, 2016, Todd Smith (“Smith”) filed a lawsuit against us in the District Court of Douglas County Nebraska, alleging breach of contract and seeking recovery of $2.2 million owed by us to Smith for costs and damages arising from a breach of our obligations pursuant to a lease agreement between the parties. On April 7, 2017, we entered into a settlement agreement with Smith related to the early termination of our lease for our Omaha, Nebraska facility. The agreement included, among other things, a mutual general release of claims, and our agreement to pay approximately $0.6 million to Smith in installments over a period of time. A $0.6 million liability has been recorded and is reflected in accrued expenses at March 31, 2017. The accrued liability includes $0.4 million recorded as a net loss on the settlement and is included in other expense in our condensed consolidated statements of operations for the three months ended March 31, 2017.
On February 21, 2017, XIFIN, Inc. (“XIFIN”) filed a lawsuit against us in the District Court for the Southern District of California alleging breach of written contract and seeking recovery of approximately $0.27 million owed by us to XIFIN for damages arising from a breach of our obligations pursuant to a Systems Services Agreement between us and XIFIN, dated as of February 22, 2013, as amended and restated on September 1, 2014. On April 5, 2017, the court clerk entered default against us. On May 5, 2017, XIFIN filed an application for entry of default judgment against us. A $0.3 million and $0.2 million liability has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016, respectively.
We and Science Park Development Corporation (“SPDC”) entered into that certain Lease dated as of December 31, 2011, as modified by the First Amendment to Lease dated as of June 18, 2013, as further modified by a letter agreement dated as of February 2, 2015, as modified by the Second Amendment to Lease dated as of June 26, 2015 (the “ SPDC Lease”). In November 2016, SPDC alleged that we defaulted on our obligations under the SPDC Lease. Specifically, SPDC alleges that we failed to pay approximately $0.4 million in rental payments due under the SPDC Lease and that we vacated a portion of the leased premises in violation of the terms of the SPDC Lease. We and SPDC entered into a settlement agreement dated March 6, 2017, which included, among other things, a mutual general release of claims, and our agreement to pay approximately $0.4 million to SPDC in installments over a period of time. This liability has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016.
CPA Global provides us with certain patent management services. On February 6, 2017, CPA Global claimed that we owe approximately $0.2 million for certain patent maintenance services rendered. CPA Global has not filed claims against us in connection with this allegation. A liability of approximately $0.2 million has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016.
On March 9, 2016, counsel for Edge BioSystems, Inc. (“EdgeBio”) sent a demand letter on behalf of EdgeBio to us in connection with the terms of that certain Asset Purchase Agreement dated September 8, 2015 (the “EdgeBio Agreement”). EdgeBio alleges, among other things, that certain customers of EdgeBio erroneously remitted payments to us, that such payments should have been paid to EdgeBio and that we failed to remit these funds to EdgeBio in violation of the terms of the EdgeBio Agreement. On September 13, 2016, we received a demand for payment letter from EdgeBio’s counsel alleging that the balance due to EdgeBio is approximately $0.1 million. A liability of approximately $0.1 million has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016.
On February 17, 2017, Jesse Campbell (“Campbell”) filed a lawsuit individually and on behalf of others similarly situated against us in the District Court for the District of Nebraska alleging we have a materially incomplete and misleading proxy relating to a potential merger and that the merger agreement’s deal protection provisions deter superior offers.  As a result, he alleges that we have violated Sections 14(a) and 20(a) of the Exchange Act and Rule 14a-9 promulgated thereafter.  Although we intend to defend the lawsuit, there can be no assurance regarding the ultimate outcome of this case. Given the uncertainty of litigation, the legal standards that must be met for, among other things, class certification and success on the merits, we are unable to estimate the amount of loss, or range of possible loss, at this time that may result from this action. In the event that a settlement is reached related to these matters, the amount of such settlement may be material to our results of operations and financial condition and may have a material adverse impact on our liquidity.
XML 21 R12.htm IDEA: XBRL DOCUMENT v3.7.0.1
INCOME TAXES
 3 Months Ended
Mar. 31, 2017
Income Tax Disclosure [Abstract]  
INCOME TAXES
INCOME TAXES

Annually, we file U.S. Federal, state and foreign income tax returns.  All U.S. Federal and most state loss carryforwards remain subject to adjustment in the event of an income tax examination.
Income tax expense from continuing operations was zero for both the three months ended March 31, 2017 and 2016. We maintain a full valuation allowance on our net deferred tax assets, having concluded that we are not more likely than not going to realize the benefit of our deferred tax assets, including our net operating loss carryforwards.
XML 22 R13.htm IDEA: XBRL DOCUMENT v3.7.0.1
STOCKHOLDERS' EQUITY
 3 Months Ended
Mar. 31, 2017
Stockholders' Equity Note [Abstract]  
STOCKHOLDERS' EQUITY
STOCKHOLDERS’ DEFICIT

Common Stock.

Pursuant to our Third Amended and Restated Certificate of Incorporation, as amended, we currently have 150,000,000 shares of common stock authorized for issuance.

On January 6, 2016, we entered into a Securities Purchase Agreement (the “SPA”) with certain accredited investors (the “2016 Investors”), pursuant to which, on January 8, 2016, we sold to the 2016 Investors, and the 2016 Investors purchased from us (the “January 2016 Offering”), an aggregate of approximately $2.2 million of units (the “Units”) consisting of (a) an aggregate of 2,365,243 shares (the “A-1 Preferred Shares”) of our Series A-1 Convertible Preferred Stock (the “A-1 Preferred”), and (b) warrants (the “2016 Warrants”) to purchase up to an aggregate of 1,773,929 shares of our common stock, with an initial value of $1.8 million. The gross amount of $2.2 million included $2.0 million of cash proceeds and $0.2 million of debt settled with the issuance of preferred stock and warrants. Each Unit was sold to the 2016 Investors at a purchase price of $0.93 per Unit. The A-1 Preferred Shares are convertible into shares of our common stock at an initial rate of 1-for-1, which conversion rate is subject to further adjustment as set forth in our Certificate of Designation of Series A-1 Convertible Preferred Stock, which was filed with the Secretary of State of the State of Delaware on January 8, 2016 (the “Series A-1 Certificate of Designation”). We determined there was a beneficial conversion feature (“BCF”) in connection with this issuance and valued the BCF at $0.4 million.  The holders of the A-1 Preferred were able to convert at any time following the issuance.  Accordingly, we recorded a dividend totaling $0.4 million during 2016 related to this beneficial conversion, which was recorded against additional paid in capital. Pursuant to the terms of the Series A-1 Certificate of Designation, the holders of the A-1 Preferred Shares will generally be entitled to that number of votes as is equal to the product obtained by multiplying: (i) the number of whole shares of our common stock into which the A-1 Preferred may be converted as of the record date of such vote or consent, by (ii) 0.93, rounded down to the nearest whole number. Therefore, every 1.075269 shares of A-1 Preferred will generally initially be entitled to one vote. In May 2016, 2,150,538 of the A-1 Preferred Shares were converted into 2,150,538 shares of our common stock. At March 31, 2017, there were 214,705 A-1 Preferred Shares outstanding.

The 2016 Warrants were immediately exercisable upon issuance, have a term of five years and have an exercise price of $1.21 per share of our common stock. Each 2016 Warrant includes both cash and “cashless exercise” features and an exchange feature whereby the holder of the 2016 Warrant may exchange (the “Exchange Right”) all or any portion of the 2016 Warrant for a number of shares of our common stock equal to the quotient obtained by dividing the “Exchange Amount” by the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrant is exchanged (the “Exchange Price”). Under the 2016 Warrants, the “Exchange Amount” is based upon a Black Scholes option pricing model, and the aggregate Exchange Amount under all of the 2016 Warrants will be $1.4 million, subject to adjustment to the extent that the risk-free U.S. Treasury rate fluctuates between the date of issuance of the 2016 Warrants and the date the 2016 Warrants are exchanged. Each 2016 Warrant provides that the number of shares that may be issued upon exercise of the Exchange Right is limited to the number of shares that may be purchased pursuant to the terms of the 2016 Warrant, unless we have previously obtained stockholder approval or approval from The Nasdaq Stock Market LLC to issue any additional shares of our common stock (the “Additional Shares”) pursuant to the Exchange Right (the “Required Approvals”). For any Exchange Right exercised more than 90 days following the issuance of the 2016 Warrants, if we have not obtained either of the Required Approvals, we will be required to pay the 2016 Warrant holder an amount in cash for any Additional Shares that we cannot issue without the Required Approvals based on the Exchange Amount.

The 2016 Warrants further provide that, to the extent the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrant is exchanged is less than $0.50, the Exchange Price will be deemed to be equal to $0.50, and, in addition to issuing shares of our common stock based on this Exchange Price, we will be required to pay to the 2016 Warrant holder an amount in cash equal to the product obtained by multiplying (a) $0.50 minus the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrant is exchanged, by (b) the aggregate number of shares of our common stock issued to the 2016 Warrant holder by the Company in such exchange at an Exchange Price equal to $0.50. Therefore, if the Required Approvals are obtained, based on the Exchange Amount of $1,436,882 (which, as noted above, is subject to adjustment to the extent that the risk-free U.S. Treasury rate fluctuates between the date of the issuance of the 2016 Warrants and the date the 2016 Warrants are exchanged), the maximum number of shares of our common stock issuable pursuant to the Exchange Right in the 2016 Warrants will be 2,873,765. In addition, if, for example, assuming an Exchange Amount of $1,436,882, the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrants are exchanged is $0.25, we would be required to pay to the 2016 Warrant holders cash in an aggregate amount of $718,441 in addition to issuing the 2016 Warrant holders 2,873,765 shares. During the year ended December 31, 2016, 1,006,419 of the 2016 Warrants were exchanged for 1,613,353 shares of our common stock and cash due of $0.5 million. As of March 31, 2017 and December 31, 2016, the $0.5 million due to a 2016 Investor is included in other current liabilities on our condensed consolidated balance sheet.

In accordance with the terms of the SPA, we amended that certain Series A Warrant to purchase up to an aggregate of 1,161,972 shares of our common stock previously issued by us to an affiliate of one of the 2016 Investors on July 7, 2015 (the “Original Warrant”), as previously reported by us on our Amendment No. 1 to Current Report on Form 8-K/A, filed with the SEC on July 7, 2015 (as so amended, the “Amended Warrant”). The Amended Warrant amends the Original Warrant to provide that the Amended Warrant is subject to the same terms and conditions as the 2016 Warrants and, therefore, includes both cash and “cashless exercise” features and an Exchange Right whereby the number of shares issuable pursuant to the Exchange Right is equal to the “Amended Warrant Exchange Amount”, which is based on a Black Scholes option pricing model, and will be $941,197, subject to adjustment to the extent that the risk-free U.S. treasury rate fluctuates between the date of issuance of the Amended Warrant and the date the Amended Warrant is exchanged. The Amended Warrant is exercisable for up to 1,161,972 shares of our common stock in the event we have obtained either of the Required Approvals with respect to the Amended Warrant. In the event the Amended Warrant holder exercises the Amended Warrant more than 90 days following the issuance of the Amended Warrant, if we have not obtained either of the Required Approvals, we will be required to pay the Amended Warrant holder an amount in cash for the shares of our common stock that we cannot issue under the Amended Warrant pursuant to such exercise without the Required Approvals based on the Amended Warrant Exchange Amount.

The Amended Warrant also provides that, to the extent the closing bid price of our common stock on the second trading day prior to the date the Amended Warrant is exchanged is less than $0.50, the Exchange Price will be deemed to be equal to $0.50, and, in addition to issuing shares of our common stock based on this Exchange Price (assuming receipt of the Required Approvals), we will be required to pay to the Amended Warrant holder an amount in cash equal to the product obtained by multiplying (a) $0.50 minus the closing bid price of our common stock on the second trading day prior to the date the Amended Warrant is exchanged, by (b) the aggregate number of shares of our common stock issued to the Amended Warrant holder by us in such exchange at an Exchange Price equal to $0.50. Therefore, if the Required Approvals are obtained, based on the Amended Warrant Exchange Amount of $941,197 (which, as noted above, is subject to adjustment to the extent that the risk-free U.S. Treasury rate fluctuates between the issuance of the Amended Warrant and the date the Amended Warrant is exchanged), the maximum number of shares of our common stock issuable pursuant to the Exchange Right in the Amended Warrant will be 1,882,395. In addition, if, for example, assuming an Amended Warrant Exchange Amount of $941,197, the closing bid price of our common stock on the second trading day prior to the date the Amended Warrant is exchanged is $0.25, we would be required to pay to the Amended Warrant holder cash in an aggregate amount of $470,599 in addition to issuing the Amended Warrant holder 1,882,395 shares.

In connection with entering into the SPA, we also entered into a Registration Rights Agreement, dated January 8, 2016, with the 2016 Investors. Pursuant to the terms of the Registration Rights Agreement, we were required to file with the SEC a registration statement to register for resale the shares of our common stock issuable upon conversion of the A-1 Preferred Shares and the shares of our common stock issuable upon exercise of the 2016 Warrants and the Amended Warrant by January 25, 2016. We filed the required registration statement with the SEC on January 25, 2016.

Craig-Hallum (the “Placement Agent”) served as the sole placement agent for the January 2016 Offering. In consideration for services rendered as the Placement Agent in the January 2016 Offering, we (1) paid to the Placement Agent cash commissions equal to approximately $140,000, or 7.0% of the gross proceeds received in the January 2016 Offering, excluding any proceeds received from Third Security, LLC or any of its affiliates; (2) issued to the Placement Agent, for a price of $50, a five-year warrant to purchase up to 107,527 shares of our common stock at an exercise price of $1.21 per share (the “Agent Warrant”), which is subject to the same terms as the 2016 Warrants except that the Agent Warrant was not exercisable until July 8, 2016 and does not contain the Exchange Right; and (3) reimbursed the Placement Agent for reasonable out-of-pocket expenses, including fees paid to the Placement Agent’s legal counsel, incurred in connection with the January 2016 Offering, which reimbursable expenses did not exceed $50,000.

The January 2016 Offering and the payment of all accrued and unpaid dividends on the Series A Preferred Stock and Series B Preferred Stock in the form of shares of our common stock at a rate of $1.00 per share of our common stock discussed under “-Conversion of Preferred Stock” below required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the February 2012 common stock and warrant sale (the “2012 Private Placement”). The exercise price of these warrants decreased to $4.39 per share and the number of shares issuable upon exercise of the warrants increased from 2,188,177 to 3,239,827.

On May 31, 2016, we issued to a vendor an aggregate of 78,000 shares of our common stock and, on June 14, 2016, we issued to a second vendor an aggregate of 64,153 shares of our common stock. Such shares of common stock were issued to the vendors in lieu of an aggregate cash amount of approximately $89,000 owed by us to such vendors for services previously performed by such vendors. We issued the shares to the vendors in transactions exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder and in reliance on similar exemptions under applicable state laws. The offering of the shares to the vendors did not involve a public offering, and no general solicitation or advertisement was made in connection with the offering of the shares to the vendors.

On June 7, 2016, we entered into an At the Market Offering Agreement (the “ATM Agreement”) with Craig-Hallum, as sales agent, pursuant to which we may offer and sell, from time to time, through Craig-Hallum, up to $3,500,000 of shares (the “Shares”) of our common stock. Any Shares offered and sold in the offering will be issued pursuant to our effective shelf registration statement on Form S-3 (File No. 333-201907) and the related prospectus previously declared effective by the SEC on February 13, 2015, as supplemented by a prospectus supplement, dated June 7, 2016, that we filed with the SEC pursuant to Rule 424(b)(5) under the Securities Act of 1933, as amended (the “Securities Act”). The number of shares eligible for sale under the ATM Agreement will be subject to the limitations of General Instruction I.B.6 of Form S-3.

Under the terms of the ATM Agreement, we will pay Craig-Hallum a placement fee of 3.25% of the gross sales price of the Shares, unless Craig-Hallum acts as principal, in which case we may sell Shares to Craig-Hallum as principal at a price to be agreed upon by us and Craig-Hallum. We will also reimburse Craig-Hallum for certain expenses incurred in connection with the ATM Agreement, and agreed to provide indemnification and contribution to Craig-Hallum with respect to certain liabilities, including liabilities under the Securities Act and the Securities Exchange Act of 1934, as amended.
 
The ATM Agreement was terminated during the fourth quarter of 2016 and at the time of termination we had sold 1,177,849 shares.  The average sales price per common share was $0.42 and the aggregate net proceeds from the sales totaled $0.5 million. We did not sell any shares under the ATM Agreement during the three month periods ended March 31, 2017 and 2016.

The sale of shares under the ATM Agreement required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the 2012 Private Placement. The exercise price of these warrants decreased to $4.23 per share and the number of shares issuable upon exercise of the warrants increased from 3,262,088 to 3,362,276. The 3,362,276 warrants issued in the 2012 Private Placement expired in February 2017.
Common Stock Warrants.
During the three months ended March 31, 2017, we did not issue any warrants, no warrants were exercised and 3,362,276 warrants expired. During the three months ended March 31, 2016, we issued warrants to purchase 2,933,106 shares of common stock and no warrants were exercised. The warrants issued in the three months ended March 31, 2016 included 1,051,650 warrants issued due to repricing requirements of the Private Placement and 1,881,456 warrants issued in connection with the January 2016 Offering. Warrants to purchase an aggregate of 3,334,011 shares of common stock were outstanding at March 31, 2017.
 
Warrant Holder
 
Issue Year
 
Expiration
 
Underlying
Shares
 
Exercise
Price
Various Institutional Holders(1)
 
2013
 
January 2018
 
441,655
 
$9.00
Affiliates of Third Security, LLC(1)
 
2013
 
January 2018
 
250,000
 
$9.00
Various Institutional Holders(2)
 
2014
 
April 2020
 
374,618
 
$4.00
Various Institutional Holders(3)
 
2015
 
February 2020
 
714,780
 
$2.24
Various Institutional Holders(4)
 
2015
 
December 2020
 
122,433
 
$1.66
Various Institutional Holders(5)
 
2015
 
January 2021
 
1,161,972
 
$1.21
Affiliates of Third Security, LLC(6)
 
2016
 
January 2021
 
161,026
 
$1.21
Various Institutional Holders(6)
 
2016
 
January 2021
 
107,527
 
$1.21
 
 
 
 
 
 
3,334,011
 
 


(1)
These warrants were issued in connection with an offering which was completed in January 2013.
(2)
These warrants were issued in connection with a private placement which was completed in October 2014.
(3)
These warrants were issued in connection with an offering which was completed in February 2015.
(4)
These warrants were issued in connection with an offering which was completed in July 2015.
(5)
These warrants were originally issued in connection with the offering in July 2015, and were amended in connection with the January 2016 Offering, which was completed in January 2016.
(6)
These warrants were issued in connection with the January 2016 Offering, which was completed in January 2016.
Preferred Stock Series A.
The Company’s Board of Directors is authorized to issue up to 15,000,000 shares of preferred stock in one or more series, from time to time, with such designations, powers, preferences and rights and such qualifications, limitations and restrictions as may be provided in a resolution or resolutions adopted by the Board of Directors. The authority of the Board of Directors includes, but is not limited to, the determination or fixing of the following with respect to shares of such class or any series thereof: (i) the number of shares; (ii) the dividend rate, whether dividends shall be cumulative and, if so, from which date; (iii) whether shares are to be redeemable and, if so, the terms and amount of any sinking fund providing for the purchase or redemption of such shares; (iv) whether shares shall be convertible and, if so, the terms and provisions thereof; (v) what restrictions are to apply, if any, on the issue or reissue of any additional preferred stock; and (vi) whether shares have voting rights. The preferred stock may be issued with a preference over the common stock as to the payment of dividends. We have no current plans to issue any additional preferred stock. Classes of stock such as the preferred stock may be used, in certain circumstances, to create voting impediments on extraordinary corporate transactions or to frustrate persons seeking to effect a merger or otherwise to gain control of the Company. For the foregoing reasons, any additional preferred stock issued by the Company could have an adverse effect on the rights of the holders of the common stock.

On December 29, 2010, we entered into a transaction with the Third Security Investors, pursuant to the terms of a Series A Convertible Preferred Stock Purchase Agreement (the “Series A Purchase Agreement”), in which we: (i) sold an aggregate of 2,586,205 shares of Series A Preferred Stock at a price of $2.32 per share; and (ii) issued Series A Warrants to purchase up to an aggregate of 1,293,102 shares of Series A Preferred Stock having an exercise price of $2.32 per share (the sale of Series A Preferred Stock and issuance of the Series A Warrants hereafter referred to together as the “Financing”). The Series A Warrants may be exercised at any time from December 29, 2010 until December 28, 2015 and contain a “cashless exercise” feature. The gross proceeds from the Series A financing were $6.0 million. The $0.2 million of costs incurred to complete the Series A financing were recorded as a reduction in the value of the Series A Preferred Stock. We used the net proceeds from the financing to acquire the FAMILION family of genetic tests from PGxHealth, a subsidiary of Clinical Data, Inc. Until the November 2011 modifications, the Series A Preferred Stock met the definition of mandatorily redeemable stock as it was preferred capital stock that was redeemable at the option of the holder through December 2015 and was reported outside of equity. The Series A Preferred Stock was to be accreted to its redemption value of $6.0 million. Until the November 2011 modifications, the Series A Warrants did not qualify to be treated as equity and, accordingly, were recorded as a liability. A preferred stock anti-dilution feature is embedded within the Series A Preferred Stock that met the definition of a derivative.

In connection with the Series A financing, we filed a Certificate of Designation of Series A Convertible Preferred Stock (the “Series A Certificate of Designation”) with the Secretary of State of the State of Delaware, designating 3,879,307 shares of our preferred stock as Series A Preferred Stock. As of December 31, 2013, the Series A Preferred Stock, including the Series A Preferred Stock issuable upon exercise of the Series A Warrants, was convertible into shares of our common stock at a rate of 4-for-1, which conversion rate is subject to further adjustment as set forth in the Series A Certificate of Designation. Giving effect to the reverse split of our stock in January 2014, the conversion rate was adjusted to 1-for-3. Certain rights of the holders of the Series A Preferred Stock are senior to the rights of the holders of our common stock. The Series A Preferred Stock has a liquidation preference equal to its original price per share, plus any accrued and unpaid dividends thereon. The holders of the Series A Preferred Stock are entitled to receive quarterly dividends, which accrue at the rate of 10% of the original price per share per annum, whether or not declared, and which shall compound annually and shall be cumulative. In any calendar quarter in which we have positive distributable cash flow as defined in the Series A Purchase Agreement, we are required to pay from funds legally available a cash dividend in the amount equal to the lesser of 50% of such distributable cash flow or the aggregate amount of dividends accrued on the Series A Preferred Stock.
Generally, the holders of the Series A Preferred Stock are entitled to vote together with the holders of common stock, as a single group, on an as-converted basis. However, the Series A Certificate of Designation provides that we shall not perform some activities, subject to certain exceptions, without the affirmative vote of a majority of the holders of the outstanding shares of Series A Preferred Stock. The holders of the Series A Preferred Stock, along with the holders of the Series B Preferred Stock, also are entitled to elect or appoint, as a single group, two directors of the Company.
In connection with the Series A financing, we also entered into a registration rights agreement with the Third Security Investors (the “Registration Rights Agreement”). Pursuant to the terms of the Registration Rights Agreement, the Company has granted certain demand, “piggyback” and S-3 registration rights covering the resale of the shares of common stock underlying the Series A Preferred Stock issued pursuant to the Series A Purchase Agreement and issuable upon exercise of the Series A Warrants and all shares of common stock issuable upon any dividend or other distribution with respect thereto.
In November 2011, we entered into a transaction with the Third Security Investors, pursuant to an Agreement Regarding Preferred Stock (the “Amendment Agreement”), in which the Third Security Investors agreed to (i) waive their rights to enforce the anti-dilution and redemption features of the Series A Preferred Stock and (ii) at the next annual stockholders’ meeting, vote to amend the Series A Certificate of Designation to remove the anti-dilution and redemption features of the Series A Preferred Stock. In exchange, the Company issued shares of common stock to the Third Security Investors having an aggregate market value of $0.3 million.
As a result of the Amendment Agreement, the values of the Series A Preferred Stock and Series A Warrants, including the Series A Preferred Stock conversion feature and Series A Warrant liability, were reclassified into stockholders’ equity as of the date of the Amendment Agreement.
Preferred Stock Series B.

On March 5, 2014, we entered into a Series B Convertible Preferred Stock Purchase Agreement (the “Series B Purchase Agreement”) with affiliates of Third Security, LLC (the “2014 Third Security Investors”), pursuant to which we, in a private placement, sold and issued an aggregate of 1,443,297 shares of our Series B Preferred Stock, par value $0.01 per share (the “Series B Preferred Stock”), at a price per share of $4.85 for an aggregate purchase price of approximately $7.0 million. Each share of Series B Preferred Stock issued pursuant to the Series B Purchase Agreement was initially convertible into shares of our common stock at a rate of 1-for-1, which conversion rate was subject to further adjustment as set forth in the Certificate of Designation of Series B Convertible Preferred Stock.

In connection with the Series B financing, we also entered into a Registration Rights Agreement, dated March 5, 2014, with the 2014 Third Security Investors, pursuant to which we granted certain demand, “piggy-back” and S-3 registrations rights covering the resale of the shares of common stock underlying the Series B Preferred Stock issued pursuant to the Series B Purchase Agreement and all shares of common stock issuable upon any dividend or other distribution with respect thereto.

The Series B financing required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement. The exercise price of the warrants decreased from $12.96 per share to $11.73 per share and the number of shares issuable upon exercise of the warrants increased from 1,097,600 to 1,212,665.

Conversion of Preferred Stock - Series A and Series B.

On January 6, 2016, the Company entered into a Conversion Agreement (the “Conversion Agreement”) with the holders (the “Preferred Holders”) of all of the Company’s outstanding shares of Series A Convertible Preferred Stock, par value $0.01 per share (the “Series A Preferred Stock”), and Series B Preferred Stock, pursuant to which, among other things, the Preferred Holders: (a) elected to convert all of the outstanding shares of Series A Preferred Stock and Series B Preferred Stock into shares of our common stock, in each case in accordance with the terms thereof, and (b) agreed that all accrued and unpaid dividends on the Series A Preferred Stock and Series B Preferred Stock would be paid by the Company in shares of our common stock at a rate of $1.00 per share of our common stock (collectively, the “Conversion”).

The outstanding shares of Series A Preferred Stock were convertible into shares of our common stock at a rate of 1-for-3, and the outstanding shares of Series B Preferred Stock were convertible into shares of our common stock at a rate of 1-for-1. Prior to the entry into the Conversion Agreement, there were 2,586,205 shares of Series A Preferred Stock outstanding, which were converted into 862,057 shares of our common stock, and 1,443,297 shares of Series B Preferred Stock outstanding, which were converted into 1,443,297 shares of our common stock, for an aggregate of 2,305,354 shares of our common stock issued upon conversion of the Series A Preferred Stock and Series B Preferred Stock (the “Conversion Shares”). At the time of the entry into the Conversion Agreement, there were $3.7 million in accrued and unpaid dividends on the outstanding shares of Series A Preferred Stock, which were converted, in accordance with the Conversion Agreement, into 3,681,590 shares of our common stock, and $0.8 million in accrued and unpaid dividends on the outstanding shares of Series B Preferred Stock, which were converted, in accordance with the terms of the Conversion Agreement, into 793,235 shares of our common stock, for an aggregate of 4,474,825 shares of our common stock issued pursuant to the accrued and unpaid dividends on the Series A Preferred Stock and Series B Preferred Stock. Therefore, in connection with the full conversion of the Series A Preferred Stock and Series B Preferred Stock, plus the conversion of all accrued and unpaid dividends thereon, we issued an aggregate of 6,780,179 shares of our common stock to the Preferred Holders on January 6, 2016.

Following the conversion of the shares of Series A Preferred Stock and Series B Preferred Stock into common stock, no shares of Series A Preferred Stock or Series B Preferred Stock remain outstanding.
Preferred Stock Dividends.
We had no undeclared dividends for the three months ended March 31, 2017. For the three months ended March 31, 2016, we had undeclared dividends. In accordance with the FASB’s Accounting Standards Codification Topic 260-10-45-11, “Earnings per Share”, these dividends were added to the net loss per share calculation.
XML 23 R14.htm IDEA: XBRL DOCUMENT v3.7.0.1
FAIR VALUE
 3 Months Ended
Mar. 31, 2017
Fair Value Disclosures [Abstract]  
FAIR VALUE
FAIR VALUE

FASB guidance on fair value measurements, which defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements for our financial assets and liabilities, as well as for other assets and liabilities that are carried at fair value on a recurring basis in our condensed consolidated financial statements.
FASB guidance establishes a three-level fair value hierarchy based upon the assumptions (inputs) used to price assets or liabilities. The three levels of inputs used to measure fair value are as follows:
Level 1—Unadjusted quoted prices in active markets for identical assets or liabilities;
Level 2—Observable inputs other than those included in Level 1, such as quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets; and
Level 3—Unobservable inputs reflecting our own assumptions and best estimate of what inputs market participants would use in pricing the asset or liability.

Debt.
Our long term debt book value approximates fair market value due to the variable interest rate it bears.

Common Stock Warrant Liabilities.

Certain of our issued and outstanding warrants to purchase shares of common stock do not qualify to be treated as equity and, accordingly, are recorded as a liability.

2012 Warrant Liability
The 2012 Warrant Liability represents the fair value of the 3.4 million warrants issued in February 2012 (as adjusted pursuant to the terms of the 2012 Warrants). We are required to record these instruments at fair value at each reporting date and changes are recorded as a non-cash adjustment to earnings. The gains or losses included in earnings are reported in other income (expense) in our condensed consolidated Statement of Operations. Management does not believe that this liability will be settled by a use of cash. The 2012 Warrants expired in February 2017 and, as such, the 2012 Warrant Liability no longer exists at March 31, 2017.
The 2012 Warrant Liability is considered a Level 3 financial instrument and is valued using a Monte Carlo simulation model. This method is well suited to valuing options with non-standard features, such as anti-dilution protection. A Monte Carlo simulation model uses repeated random sampling to simulate significant uncertainty in inputs. Assumptions and inputs used in the valuation of the common stock warrants are broken down into four sections: Static Business Inputs; Static Technical Inputs; Simulated Business Inputs; and Simulated Technical Inputs.

During the three months ended March 31, 2017 and 2016, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following:
 
 
Dollars in Thousands
 
 
For the Three Months Ended
 
 
March 31, 2017
 
March 31, 2016
Beginning balance at January 1
 
$
—

 
$
350

Total (gains) or losses:
 

 
 
Recognized in earnings
 
—

 
(330
)
Balance at March 31
 
$
—

 
$
20




2016 Warrant Liability
The 2016 Warrant Liability represents the fair value of the 1.8 million warrants issued in January 2016, of which, 0.8 million warrants remain outstanding as of March 31, 2017. We are required to record these instruments at fair value at each reporting date and changes are recorded as a non-cash adjustment to earnings. The gains or losses included in earnings are reported in other income (expense) in our condensed consolidated Statement of Operations.
The 2016 Warrant Liability is considered a Level 3 financial instrument and is valued using a binomial lattice simulation model. This method is well suited to valuing options with non-standard features. Assumptions and inputs used in the valuation of the common stock warrants include; our equity value, which was estimated using our stock price of $0.56 as of March 31, 2017; volatility of 115%; and a risk-free interest rate of 1.66%.
During the three months ended March 31, 2017 and 2016, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following:     
 
 
Dollars in Thousands
 
 
 
For the Three Months Ended
 
 
 
March 31, 2017
 
March 31, 2016
 
Beginning balance at January 1
 
$
582

 
$
—

 
Additions
 
—

 
1,437

 
Total (gains) or losses:
 
 
 
 
 
Recognized in earnings
 
33

 
9

 
Balance at March 31
 
$
615

 
$
1,446

 
XML 24 R15.htm IDEA: XBRL DOCUMENT v3.7.0.1
STOCK OPTIONS
 3 Months Ended
Mar. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
STOCK OPTIONS
STOCK OPTIONS
 
Stock Options.

The following table summarizes stock option activity under our 2006 Equity Incentive Plan (the "Plan") during the three months ended March 31, 2017:
 
 
Number of
Options
 
Weighted-Average
Exercise Price
Outstanding at January 1, 2017
738,026

 
$
3.59

Granted
—

 
—

Forfeited
(62,739
)
 
2.12

Outstanding at March 31, 2017
675,287

 
$
3.73

Exercisable at March 31, 2017
547,957

 
$
4.25


    
During the three months ended March 31, 2017, we did not grant any options to purchase shares of our common stock. Options to purchase an aggregate of 14,000 shares of our common stock were granted during the three months ended March 31, 2016.

As of March 31, 2017, there were 661,914 options that were vested or expected to vest with an aggregate intrinsic value of zero with a remaining weighted average contractual life of 7.2 years.

Stock Appreciation Rights (“SARs”)

As of March 31, 2017, 83,333 outstanding and exercisable SARs shares were vested or expected to vest. All outstanding SARs were issued solely to our chief executive officer. The weighted-average exercise price of these SARs was $4.32 per share and the aggregate intrinsic value was zero with a remaining weighted average contractual life of 6.5 years.
XML 25 R16.htm IDEA: XBRL DOCUMENT v3.7.0.1
SUBSEQUENT EVENTS
 3 Months Ended
Mar. 31, 2017
Subsequent Events [Abstract]  
Subsequent Events
SUBSEQUENT EVENTS

On April 13, 2017, Transgenomic completed the sale of an aggregate of $1.15 million of promissory notes (the “Bridge Notes”) in a bridge financing pursuant to a securities purchase agreement (the “Purchase Agreement”). Transgenomic may receive additional investments of up to $100,000 in connection with the bridge financing. The financing is intended to help facilitate the completion of Transgenomic’s merger with Precipio, which is expected to close during the second quarter of 2017. Transgenomic received net proceeds of $1,031,000 from the sale of the Bridge Notes.
 
The Bridge Notes have an annual interest rate of 4% and a 90-day maturity. Transgenomic may repay the Bridge Notes at any time in cash upon payment of a 20% premium. In connection with the issuance of the Bridge Notes, Transgenomic issued warrants (the “Bridge Warrants”) to acquire 1.15 million shares of Transgenomic common stock at an exercise price of $0.50 per share, subject to anti-dilution protection. The Purchase Agreement provides certain piggyback registration rights for the holders of the Bridge Warrants for a period of six months after the closing of the bridge financing.
 
As part of the bridge financing, Transgenomic agreed to loan 50% of the net proceeds from the sale of the Bridge Notes to Precipio pursuant to a promissory note (the “Precipio Note”) with an original principal amount of up to $561,500 upon substantially the same terms and conditions as the Bridge Notes. The payment of the Precipio Note is subordinated to the payment by Precipio of its secured $500,000 bank debt pursuant to a subordination agreement.
 
Aegis Capital Corp. acted as placement agent for the bridge financing and received a placement agent fee of $84,000 and warrants (the “Aegis Warrants”) to acquire 168,000 shares of Transgenomic common stock at an exercise price of $0.50 per share. The Aegis Warrants are identical to the Bridge Warrants except that the Aegis Warrants do not have anti-dilution protection.
XML 26 R17.htm IDEA: XBRL DOCUMENT v3.7.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 3 Months Ended
Mar. 31, 2017
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation.
The accompanying condensed consolidated financial statements are presented in conformity with GAAP. Supplemental cash flows from discontinued operations are presented in Note 3 - “Discontinued Operations”. We have evaluated events occurring subsequent to March 31, 2017 for potential recognition or disclosure in the condensed consolidated financial statements and concluded there were no subsequent events that required recognition or disclosure.
The condensed consolidated balance sheet as of December 31, 2016 was derived from our audited balance sheet as of that date. There has been no change in the balance sheet from December 31, 2016. The accompanying condensed consolidated financial statements as of and for the three months ended March 31, 2017 and 2016 are unaudited and reflect all adjustments (consisting of only normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the interim periods. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2016 contained in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the “SEC”) on April 13, 2017. The results of operations for the interim periods presented are not necessarily indicative of the results for fiscal year 2017.
Principles of Consolidation
Principles of Consolidation.
The condensed consolidated financial statements include the accounts of Transgenomic, Inc. and our wholly owned subsidiary. All inter-company balances and transactions have been eliminated in consolidation.
Risks and Uncertainties
Risks and Uncertainties.
Certain risks and uncertainties are inherent in our day-to-day operations and in the process of preparing our financial statements. The more significant of those risks are presented below and throughout the notes to the unaudited condensed consolidated financial statements.
Fair Value
Fair Value.
Unless otherwise specified, book value approximates fair value. The common stock warrant liability is recorded at fair value.
Cash and Cash Equivalents
Cash and Cash Equivalents and Other Current Assets.
Cash and cash equivalents include cash and investments with original maturities at the date of acquisition of three months or less.
Concentrations of Cash
Concentrations of Cash.
From time to time, we may maintain a cash position with financial institutions in amounts that exceed federally insured limits.
Stock-Based Compensation
Stock-Based Compensation.
All stock-based awards to date have exercise prices equal to the market price of our common stock on the date of grant and have ten-year contractual terms. Unvested awards as of March 31, 2017 had vesting periods of up to three years from the date of grant. None of the awards outstanding at March 31, 2017 are subject to performance or market-based vesting conditions.
Net Sales Recognition
Net Sales Recognition.
Revenue is realized and earned when all of the following criteria are met:
•
Persuasive evidence of an arrangement exists;
•
Delivery has occurred or services have been rendered;
•
The seller’s price to the buyer is fixed or determinable; and
•
Collectability is reasonably assured.

In our Omaha, Nebraska laboratory, we perform services on a project by project basis. When we receive payment in advance, we initially defer the revenue and recognize it when we deliver the service. These projects typically do not extend beyond one year. At each of March 31, 2017 and December 31, 2016, deferred net sales associated with pharmacogenomics research projects included in the balance sheet in deferred revenue were $0.1 million and $0.2 million, respectively.

Net sales from Patient Testing laboratories are reported as part of discontinued operations (See Note 3 - “Discontinued Operations”) and are recognized on an individual test basis and, since collectability is not reasonably assured, are recognized when cash is received. There are no deferred net sales associated with our Patient Testing services.

Taxes collected from customers and remitted to government agencies for specific net sales producing transactions are recorded net with no effect on the income statement.
Loss Per Share
Loss Per Share.
Basic loss per share is calculated based on the weighted-average number of common shares outstanding during each period. Diluted loss per share includes shares issuable upon exercise of outstanding stock options, warrants or conversion rights that have exercise or conversion prices below the market value of our common stock.
Recent Accounting Pronouncements
Recent Accounting Pronouncements.
In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers. This guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to a customer. ASU No. 2014-09 will replace most existing revenue recognition guidance in generally accepted accounting principles in the U.S. when it becomes effective. In July 2015, the FASB decided to defer the effective date of this new accounting guidance by one year. As a result, ASU No. 2014-09 will be effective for us for all annual and interim reporting periods beginning after December 15, 2017 and early adoption would be permitted as of the original effective date. The new standard permits the use of either the retrospective or cumulative effect transition method. We do not expect to early adopt this guidance and we have not selected a transition method. We are currently evaluating the impact this guidance will have on our financial condition, results of operations and cash flows.

In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard amends the recognition of lease assets and lease liabilities by lessees for those leases currently classified as operating leases and amends disclosure requirements associated with leasing arrangements. The new standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2018. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition, and provides for certain practical expedients. Transition will require application of the new guidance at the beginning of the earliest comparative period presented. We are currently assessing the impact that the adoption of this ASU will have on our consolidated financial statements.
In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The new standard simplifies several aspects related to the accounting for share-based payment transactions, including the accounting for income taxes, statutory tax withholding requirements, forfeitures and classification on the statement of cash flows. This guidance is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2016. The Company adopted ASU No. 2016-09 as of January 1, 2017. The adoption of this guidance does not have a material effect on the Company’s financial position and results of operations.

In August 2016, FASB issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments. ASU No. 2016-15 eliminates the diversity in practice related to the classification of certain cash receipts and payments in the statement of cash flows by adding or clarifying guidance on eight specific cash flow issues. ASU No. 2016-15 is effective for fiscal years beginning after December 15, 2017, and for interim periods within that fiscal year. We do not believe ASU No. 2016-15 will have a material effect on our financial position and results of operations.

In January 2017, FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business. ASU No. 2017-01adds guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The new guidance is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company does not believe ASU No. 2017-01 will have a material effect on its financial position and results of operations.
XML 27 R18.htm IDEA: XBRL DOCUMENT v3.7.0.1
DISCONTINUED OPERATIONS (Tables)
 3 Months Ended
Mar. 31, 2017
Discontinued Operations and Disposal Groups [Abstract]  
Schedule of discontinued operations impact on income statement and balance sheets
Results of the discontinued operations consisted of the following:
 
Three months ended March 31,
(Dollars in thousands)
2017
 
2016
Net sales
$
68

 
$
1,103

Cost of goods sold
15

 
1,183

Gross profit (loss)
53

 
(80
)
Selling, general and administrative expense
(65
)
 
1,025

Research and development expense
—

 
68

Operating income (loss) from discontinued operations
118

 
(1,173
)
Loss on settlement of liability
(45
)
 
—

Income (loss) from discontinued operations before income taxes
73

 
(1,173
)
Income tax expense
—

 
—

Income (loss) from discontinued operations, net of taxes
$
73

 
$
(1,173
)
XML 28 R19.htm IDEA: XBRL DOCUMENT v3.7.0.1
DEBT (Tables)
 3 Months Ended
Mar. 31, 2017
Debt Disclosure [Abstract]  
Schedule of debt
 
 
Dollars in Thousands
 
 
March 31, 2017
 
December 31, 2016
Revolving Line of Credit(1)
 
$
3,243

 
$
3,243

Term Loan(2)
 
4,000

 
4,000

Convertible Promissory Notes (3)
 
125

 
571

Total debt
 
7,368

 
7,814

Current portion of long-term debt
 
(7,368
)
 
(7,814
)
Long-term debt, net of current maturities
 
$
—

 
$
—

 
(1)
Revolving Line of Credit. Amounts advanced under the Revolving Line accrue interest at an annual rate equal to the greater of (a) 6.25% or (b) the Wall Street Journal prime rate plus 3%. The current interest rate is 6.75%. As discussed below under Additional Terms, the interest rate is subject to increase if there is a default under the Loan Agreement. Interest is payable on a monthly basis, with the balance payable at the maturity of the Revolving Line. Under the Loan Agreement, we pay the Lenders a commitment fee of $20,000 on each one-year anniversary of March 13, 2013, the Effective Date, during the term of the Revolving Line. In addition, a fee of 0.5% per annum is payable quarterly on the unused portion of the Revolving Line. The Revolving Line matures on November 1, 2017.

(2)
Term Loan. We received $4.0 million under the Term Loan on the Effective Date. Pursuant to the terms of the Loan Agreement, as amended, the maturity date of the Loan Agreement was extended until November 1, 2017 and no principal payments on the Term Loan are due until such date. The current interest rate is 9.1%. As discussed below, the interest rate is subject to increase if there is a default under the Loan Agreement.

We will pay the Lenders an additional final payment of $120,000, at maturity or prepayment of the Term Loan, which has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016. In addition, if we repay the Term Loan prior to maturity, we will pay the Lenders a prepayment penalty of 1% of the total outstanding balance under the Term Loan.

Additional Terms.
The Loan Agreement contains affirmative and negative covenants. Under the Loan Agreement, we agreed not to (i) pledge or otherwise encumber our assets other than to the Lenders, (ii) enter into additional borrowings or guarantees, (iii) repurchase our capital stock, or (iv) enter into certain mergers or acquisitions without the Lenders’ consent. Additionally, the Loan Agreement contains a subjective acceleration clause at the discretion of the Lenders. As of March 31, 2017, we were not in compliance with the Loan Agreement, as amended, due to the fact that events of default existed, including our failure to make certain required monthly interest payments.

To secure the repayment of any amounts borrowed under the Revolving Line and the Term Loan, we granted the Lenders a security interest in all of our assets. The occurrence of an event of default under the Loan Agreement could result in the acceleration of our obligations under the Loan Agreement, would increase the applicable interest rate under the Revolving Line or Term Loan (or both) by 5% and would permit the Lenders to exercise remedies with respect to the collateral under the Loan Agreement. At March 31, 2017, our applicable interest rates have been increased by 5%.

(3) Convertible Promissory Notes. The Notes accrue interest at a rate of 6% per year and matured on December 31, 2016.

XML 29 R20.htm IDEA: XBRL DOCUMENT v3.7.0.1
STOCKHOLDERS' EQUITY (Tables)
 3 Months Ended
Mar. 31, 2017
Stockholders' Equity Note [Abstract]  
Schedule of stockholders' equity, including warrants and rights
Warrant Holder
 
Issue Year
 
Expiration
 
Underlying
Shares
 
Exercise
Price
Various Institutional Holders(1)
 
2013
 
January 2018
 
441,655
 
$9.00
Affiliates of Third Security, LLC(1)
 
2013
 
January 2018
 
250,000
 
$9.00
Various Institutional Holders(2)
 
2014
 
April 2020
 
374,618
 
$4.00
Various Institutional Holders(3)
 
2015
 
February 2020
 
714,780
 
$2.24
Various Institutional Holders(4)
 
2015
 
December 2020
 
122,433
 
$1.66
Various Institutional Holders(5)
 
2015
 
January 2021
 
1,161,972
 
$1.21
Affiliates of Third Security, LLC(6)
 
2016
 
January 2021
 
161,026
 
$1.21
Various Institutional Holders(6)
 
2016
 
January 2021
 
107,527
 
$1.21
 
 
 
 
 
 
3,334,011
 
 


(1)
These warrants were issued in connection with an offering which was completed in January 2013.
(2)
These warrants were issued in connection with a private placement which was completed in October 2014.
(3)
These warrants were issued in connection with an offering which was completed in February 2015.
(4)
These warrants were issued in connection with an offering which was completed in July 2015.
(5)
These warrants were originally issued in connection with the offering in July 2015, and were amended in connection with the January 2016 Offering, which was completed in January 2016.
(6)
These warrants were issued in connection with the January 2016 Offering, which was completed in January 2016.
XML 30 R21.htm IDEA: XBRL DOCUMENT v3.7.0.1
FAIR VALUE (Tables)
 3 Months Ended
Mar. 31, 2017
Fair Value Disclosures [Abstract]  
Schedule of changes in fair value of liability
During the three months ended March 31, 2017 and 2016, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following:
 
 
Dollars in Thousands
 
 
For the Three Months Ended
 
 
March 31, 2017
 
March 31, 2016
Beginning balance at January 1
 
$
—

 
$
350

Total (gains) or losses:
 

 
 
Recognized in earnings
 
—

 
(330
)
Balance at March 31
 
$
—

 
$
20

During the three months ended March 31, 2017 and 2016, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following:     
 
 
Dollars in Thousands
 
 
 
For the Three Months Ended
 
 
 
March 31, 2017
 
March 31, 2016
 
Beginning balance at January 1
 
$
582

 
$
—

 
Additions
 
—

 
1,437

 
Total (gains) or losses:
 
 
 
 
 
Recognized in earnings
 
33

 
9

 
Balance at March 31
 
$
615

 
$
1,446

 
XML 31 R22.htm IDEA: XBRL DOCUMENT v3.7.0.1
STOCK OPTIONS (Tables)
 3 Months Ended
Mar. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Summary of stock option activity
The following table summarizes stock option activity under our 2006 Equity Incentive Plan (the "Plan") during the three months ended March 31, 2017:
 
 
Number of
Options
 
Weighted-Average
Exercise Price
Outstanding at January 1, 2017
738,026

 
$
3.59

Granted
—

 
—

Forfeited
(62,739
)
 
2.12

Outstanding at March 31, 2017
675,287

 
$
3.73

Exercisable at March 31, 2017
547,957

 
$
4.25
XML 32 R23.htm IDEA: XBRL DOCUMENT v3.7.0.1
BUSINESS DESCRIPTION (Details)
$ in Thousands, shares in Millions
 3 Months Ended 9 Months Ended 12 Months Ended
Feb. 02, 2017
USD ($)
shares
Mar. 31, 2017
USD ($)
operating_segments
Mar. 31, 2016
USD ($)
Sep. 29, 2015
operating_segments
Dec. 31, 2016
USD ($)
Oct. 31, 2016
Business Acquisition [Line Items]            
Number of operating segments | operating_segments   1   2    
Working capital   $ (20,600)        
Debt settled with issuance of preferred stock and warrants   $ 0 $ 199   $ 200  
Common Stock | Maximum            
Business Acquisition [Line Items]            
Reverse stock split ratio           0.1
Common Stock | Minimum            
Business Acquisition [Line Items]            
Reverse stock split ratio           0.0333
Precipio | Common Stock            
Business Acquisition [Line Items]            
Number of shares converted, shares | shares 160.6          
Percentage of shares owned after transaction 52.00%          
Precipio | Preferred Stock            
Business Acquisition [Line Items]            
Number of shares converted, shares | shares 24.1          
Percentage of shares owned after transaction 8.00%          
Debt settled with issuance of preferred stock and warrants $ 3,000          
XML 33 R24.htm IDEA: XBRL DOCUMENT v3.7.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narratives) (Details) - USD ($)
 3 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Other current assets $ 190,000   $ 105,000
Current prepaid expense 100,000    
Other current receivables $ 100,000    
Share-based compensation arrangement by share-based payment award, expiration period 10 years    
Stock-based compensation expense $ (24,000) $ 110,000  
Unrecognized compensation expense related to unvested stock awards, not yet recognized $ 100,000    
Unvested stock options, unrecognized compensation expense weighted average recognition period 1 year    
Common stock rights issued (in shares) 2,933,106    
Deferred revenue $ 133,000   170,000
Options, warrants and conversion rights, common stock callable and antidilutive (in shares) 4,425,218 12,970,881  
Pharmacogenomic Services      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Deferred revenue $ 100,000   $ 200,000
Executive Officers      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Stock options, unvested options, vesting period 3 years    
Common stock rights issued (in shares) 83,333    
Selling, General and Administrative Expenses      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Stock-based compensation expense $ 0 $ 100,000  
Maximum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Stock options, unvested options, vesting period 3 years    
XML 34 R25.htm IDEA: XBRL DOCUMENT v3.7.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Property, Plant and Equipment) (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Accounting Policies [Abstract]    
Depreciation expense $ 0.1 $ 0.1
XML 35 R26.htm IDEA: XBRL DOCUMENT v3.7.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Intangible Assets) (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Accounting Policies [Abstract]    
Amortization expense for intangible assets $ 0.1 $ 0.1
Remaining amortization expense, 2017 0.1  
Amortization expense, 2018 0.1  
Amortization expense, 2019 (less than) 0.1  
Amortization expense, 2020 (less than) 0.1  
Amortization expense, 2021 (less than) $ 0.1  
XML 36 R27.htm IDEA: XBRL DOCUMENT v3.7.0.1
DISCONTINUED OPERATIONS (Revenues and Net Income (Loss)) (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Dec. 31, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]      
Income (loss) from discontinued operations, net of taxes $ 73 $ (1,173)  
Assets held for sale 24   $ 31
Discontinued operations      
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]      
Assets held for sale 100    
Discontinued operations | Genetic Assays and Platforms and Patient Testing      
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]      
Net sales 68 1,103  
Cost of goods sold 15 1,183  
Gross profit (loss) 53 (80)  
Selling, general and administrative expense (65) 1,025  
Research and development expense 0 68  
Operating income (loss) from discontinued operations 118 (1,173)  
Loss on settlement of liability (45) 0  
Income (loss) from discontinued operations before income taxes 73 (1,173)  
Income tax expense 0 0  
Income (loss) from discontinued operations, net of taxes $ 73 $ (1,173)  
XML 37 R28.htm IDEA: XBRL DOCUMENT v3.7.0.1
DEBT (Schedule of Debt) (Details) - USD ($)
 3 Months Ended
Mar. 31, 2017
Dec. 31, 2016
Dec. 31, 2014
Debt Instrument [Line Items]      
Total debt $ 7,368,000 $ 7,814,000  
Current portion of long-term debt (7,368,000) (7,814,000)  
Long-term debt, net of current maturities 0 0  
Term loan      
Debt Instrument [Line Items]      
Total debt 4,000,000 4,000,000  
Proceeds from issuance of long-term debt $ 4,000,000    
Current interest rate (as a percent) 9.10%    
Future debt extinguishment costs $ 120,000    
Prepayment penalty percentage of outstanding balance (as a percent) 1.00%    
Increase in interest rate in case of debt default (as a percent) 5.00%    
Convertible promissory notes      
Debt Instrument [Line Items]      
Total debt $ 125,000 $ 571,000  
Annual interest rate (as a percent)   6.00% 6.00%
Revolving credit facility | Line of credit      
Debt Instrument [Line Items]      
Total debt $ 3,243,000 $ 3,243,000  
Annual interest rate (as a percent) 6.25%    
Effective interest rate (as a percent) 6.75%    
Commitment fee amount $ 20,000    
Commitment fee (as a percent) 0.50%    
Revolving credit facility | Line of credit | Wall Street Journal prime rate      
Debt Instrument [Line Items]      
Basis spread on variable rate (as a percent) 3.00%    
XML 38 R29.htm IDEA: XBRL DOCUMENT v3.7.0.1
DEBT (Revolving Line and Term Loan) (Details) - USD ($)
 3 Months Ended
Feb. 02, 2017
Mar. 31, 2017
Mar. 31, 2016
Jan. 06, 2016
Dec. 31, 2014
Mar. 13, 2013
Debt Instrument [Line Items]            
Conversion of convertible promissory notes   $ 499,000 $ 0      
Precipio            
Debt Instrument [Line Items]            
Share price (in dollars per share) $ 0.50          
Conversion of convertible promissory notes   7,200,000        
Debt conversion, converted Instrument, interest   $ 800,000        
Precipio | Convertible Common Stock            
Debt Instrument [Line Items]            
Number of shares converted (shares) 10,400,000          
Precipio | Convertible Preferred Stock            
Debt Instrument [Line Items]            
Number of shares converted (shares) 24,100,000          
Term loan | Third Security LLC and affiliates            
Debt Instrument [Line Items]            
Face amount           $ 4,000,000
Convertible notes payable            
Debt Instrument [Line Items]            
Face amount       $ 750,000 $ 750,000  
Number of shares converted (shares)   502,786        
Revolving credit facility | Line of credit            
Debt Instrument [Line Items]            
Payment to lenders to support the amount advanced     $ 200,000      
Revolving credit facility | Line of credit | Third Security LLC and affiliates            
Debt Instrument [Line Items]            
Current borrowing capacity           $ 4,000,000
XML 39 R30.htm IDEA: XBRL DOCUMENT v3.7.0.1
DEBT (Convertible Promissory Notes) (Details)
 3 Months Ended 12 Months Ended
Jan. 13, 2017
USD ($)
shares
Dec. 31, 2016
USD ($)
shares
Mar. 31, 2017
USD ($)
shares
Mar. 31, 2016
USD ($)
Dec. 31, 2016
USD ($)
Jan. 17, 2017
Jan. 06, 2016
USD ($)
Jan. 20, 2015
USD ($)
Jan. 15, 2015
investor
Dec. 31, 2014
USD ($)
Debt Instrument [Line Items]                    
Conversion of convertible promissory notes     $ 499,000 $ 0            
Additional notes                    
Debt Instrument [Line Items]                    
Number of additional accredited investors | investor                 7  
Convertible notes payable                    
Debt Instrument [Line Items]                    
Face amount             $ 750,000     $ 750,000
Interest rate (as a percent)   6.00%     6.00%         6.00%
Number of shares converted (shares) | shares     502,786              
Long-term debt   $ 600,000     $ 600,000          
Debt instrument, default period         10 days          
Convertible notes payable | Agent Note                    
Debt Instrument [Line Items]                    
Face amount $ 446,250             $ 46,250    
Number of shares converted (shares) | shares 416,135                  
Percentage of initial note               5.00%    
Long-term debt $ 100,000                  
Accrued interest $ 100,000                  
Convertible notes payable | Additional notes                    
Debt Instrument [Line Items]                    
Face amount               $ 925,000    
Number of shares converted (shares) | shares   281,023                
Conversion of convertible promissory notes         $ 400,000          
Convertible notes payable | Additional Notes                    
Debt Instrument [Line Items]                    
Required cumulative principal payment, percent           66.67%        
Portion of principal required by deferred maturity date, percent           33.33%        
XML 40 R31.htm IDEA: XBRL DOCUMENT v3.7.0.1
CONTINGENCIES (Details) - USD ($)
$ in Thousands
Apr. 07, 2017
Mar. 06, 2017
Feb. 21, 2017
Feb. 06, 2017
Dec. 19, 2016
Nov. 30, 2016
Oct. 27, 2016
Sep. 13, 2016
Jun. 23, 2016
Feb. 25, 2016
Mar. 31, 2017
Dec. 31, 2016
Loss Contingencies [Line Items]                        
Delinquent accounts payable                     $ 600  
UNMC                        
Loss Contingencies [Line Items]                        
Damages sought in a lawsuit                   $ 700    
Contingency accrual                     400 $ 400
Accrual of possible loss in a lawsuit       $ 400                
Mount Sinai                        
Loss Contingencies [Line Items]                        
Damages sought in a lawsuit                 $ 700      
Contingency accrual                     700 700
Accrual of possible loss in a lawsuit             $ 700          
Smith                        
Loss Contingencies [Line Items]                        
Damages sought in a lawsuit         $ 2,200              
Contingency accrual                     600  
Deferred loss payment                     400  
Smith | Subsequent Event                        
Loss Contingencies [Line Items]                        
Accrual of possible loss in a lawsuit $ 600                      
XIFIN, Inc.                        
Loss Contingencies [Line Items]                        
Damages sought in a lawsuit     $ 270                  
Contingency accrual                     300 200
Science Park Development Corporation                        
Loss Contingencies [Line Items]                        
Damages sought in a lawsuit           $ 400            
Accrual of possible loss in a lawsuit   $ 400                    
CPA Global                        
Loss Contingencies [Line Items]                        
Damages sought in a lawsuit       $ 200                
Contingency accrual                     200 200
Edge BioSystems, Inc.                        
Loss Contingencies [Line Items]                        
Damages sought in a lawsuit               $ 100        
Contingency accrual                     $ 100 $ 100
XML 41 R32.htm IDEA: XBRL DOCUMENT v3.7.0.1
INCOME TAXES (Details) - USD ($)
 3 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Income Tax Disclosure [Abstract]    
Income tax expense (benefit) $ 0 $ 0
XML 42 R33.htm IDEA: XBRL DOCUMENT v3.7.0.1
STOCKHOLDERS' EQUITY (Common Stock) (Details)
 1 Months Ended 3 Months Ended 12 Months Ended
Jun. 14, 2016
USD ($)
shares
May 31, 2016
shares
Jan. 08, 2016
USD ($)
$ / shares
shares
Jan. 06, 2016
$ / shares
shares
Dec. 29, 2010
USD ($)
$ / shares
May 31, 2016
shares
Jan. 31, 2016
USD ($)
$ / shares
shares
Mar. 31, 2017
USD ($)
$ / shares
shares
Dec. 31, 2016
USD ($)
$ / shares
shares
Mar. 31, 2016
USD ($)
Dec. 31, 2016
USD ($)
$ / shares
shares
Jun. 07, 2016
shares
Jul. 07, 2015
shares
Class of Stock [Line Items]                          
Common stock, shares authorized (in shares)               150,000,000 150,000,000   150,000,000    
Initial valuation of warrant issued in conjunction with Private Placement | $     $ 1,800,000         $ 0   $ 1,827,000      
Debt settled with issuance of preferred stock and warrants | $               $ 0   199,000 $ 200,000    
Preferred stock, shares outstanding (in shares)               214,705 214,705   214,705    
Payments of stock issuance costs | $                   $ 219,000      
Stock issued for services | $ $ 89,000                        
Common stock, shares issued (in shares)               26,863,062 26,446,927   26,446,927    
Craig-Hallum Capital Group LLC                          
Class of Stock [Line Items]                          
Common stock warrant, exercise price (in dollars per share) | $ / shares             $ 4.39            
Class of warrant or right, exercise term             5 years            
Payments of stock issuance costs | $             $ 140,000            
Payments of stock issuance costs, percentage of gross offering proceeds             7.00%            
Share price (in dollars per share) | $ / shares             $ 50            
Payments of stock Issuance costs, warrant right to purchase common stock (shares)             107,527            
Sale of stock, price per share | $ / shares             $ 1.21            
Reimbursable expenses | $             $ 50,000            
Partners' capital account, units, sold in private placement (units)             3,239,827            
Craig-Hallum Capital Group LLC | Previously Reported                          
Class of Stock [Line Items]                          
Partners' capital account, units, sold in private placement (units)             2,188,177            
Vendor I                          
Class of Stock [Line Items]                          
Stock issued for services (shares)   78,000                      
Vendor II                          
Class of Stock [Line Items]                          
Stock issued for services (shares) 64,153                        
2016 Warrant                          
Class of Stock [Line Items]                          
Common stock warrant, exercise price (in dollars per share) | $ / shares               $ 1.21          
Number of shares converted, shares                     1,006,419    
Class of warrant or right, exercise term               5 years          
Stock warrant exchange amount | $               $ 1,436,882          
Price per share of stock warrants exchanged (usd per unit) | $ / shares               $ 0.50          
Series A-1 Warrant                          
Class of Stock [Line Items]                          
Exercise period not subject to cash payment       90 days                  
At the Market Offering Agreement | Craig-Hallum Capital Group LLC                          
Class of Stock [Line Items]                          
Common stock, shares authorized (in shares)                       3,500,000  
Common stock warrant, exercise price (in dollars per share) | $ / shares                 $ 4.23   $ 4.23    
Sale of stock, price per share | $ / shares                 $ 0.42   $ 0.42    
Partners' capital account, units, sold in private placement (units)                     3,362,276    
Placement fees, percentage of gross sales price                       3.25%  
Common stock, shares issued (in shares)                 1,177,849   1,177,849    
Proceeds from the issuance of stock | $                 $ 500,000        
At the Market Offering Agreement | Craig-Hallum Capital Group LLC | Previously Reported                          
Class of Stock [Line Items]                          
Partners' capital account, units, sold in private placement (units)                     3,262,088    
Series A-1 Convertible Preferred Stock and Warrants                          
Class of Stock [Line Items]                          
Conversion ratio       1                  
Series A Preferred Stock                          
Class of Stock [Line Items]                          
Common stock warrant, exercise price (in dollars per share) | $ / shares       $ 1.00 $ 2.32                
Preferred stock, shares outstanding (in shares)       0                  
Payments of stock issuance costs | $         $ 200,000                
Conversion ratio       0.3333                  
Common Stock | Craig-Hallum Capital Group LLC                          
Class of Stock [Line Items]                          
Share price (in dollars per share) | $ / shares             $ 1.00            
Common Stock | 2016 Warrant                          
Class of Stock [Line Items]                          
Common stock warrant, common stock called (in shares)               2,873,765          
Common stock warrant, exercise price (in dollars per share) | $ / shares               $ 0.25          
Number of shares converted, shares                     1,613,353    
Cash payment for portion of stock warrants exercised | $               $ 718,441          
Stock warrants settled with cash | $               $ 500,000     $ 500,000    
Security Purchase Agreement                          
Class of Stock [Line Items]                          
Private placement, net | $     2,200,000                    
Net proceeds from the issuance of stock warrants | $     $ 2,000,000                    
Security Purchase Agreement | Series A Warrants                          
Class of Stock [Line Items]                          
Common stock warrant, common stock called (in shares)               1,161,972         1,161,972
Stock warrant exchange amount | $               $ 941,197          
Exercise period not subject to cash payment               90 days          
Price per share of stock warrants exchanged (usd per unit) | $ / shares               $ 0.50          
Security Purchase Agreement | Series A Warrants | Maximum                          
Class of Stock [Line Items]                          
Common stock warrant, common stock called (in shares)               1,882,395          
Security Purchase Agreement | Series A Preferred Stock                          
Class of Stock [Line Items]                          
Private placement, net (in shares)     2,365,243                    
Dividends | $     $ 400,000                    
Class of warrant or right, number of securities called by each warrant or right (per right)     1.075269                    
Number of shares converted, shares           2,150,538              
Preferred stock, shares outstanding (in shares)               214,705          
Security Purchase Agreement | Common Stock                          
Class of Stock [Line Items]                          
Common stock warrant, common stock called (in shares)     1,773,929                    
Common stock warrant, exercise price (in dollars per share) | $ / shares     $ 0.93                    
Class of warrant or right, number of securities called by each warrant or right (per right)     0.93                    
Number of shares converted, shares           2,150,538              
Security Purchase Agreement | Common Stock | Series A Warrants                          
Class of Stock [Line Items]                          
Common stock warrant, common stock called (in shares)       1,882,395                  
Common stock warrant, exercise price (in dollars per share) | $ / shares               $ 0.25          
Cash payment for portion of stock warrants exercised | $               $ 470,599          
XML 43 R34.htm IDEA: XBRL DOCUMENT v3.7.0.1
STOCKHOLDERS' EQUITY (Common Stock Warrants) (Details) - $ / shares
 3 Months Ended
Mar. 31, 2017
Dec. 31, 2016
Class of Stock [Line Items]    
Class of stock warrants expired (shares) 3,362,276  
Common stock warrants issued (in shares) 2,933,106  
Underlying Shares   3,334,011
Private Placement    
Class of Stock [Line Items]    
Common stock warrants issued (in shares) 1,051,650  
Offering    
Class of Stock [Line Items]    
Common stock warrants issued (in shares) 1,881,456  
Various Institutional Holders; January 2018    
Class of Stock [Line Items]    
Underlying Shares   441,655
Exercise Price (in dollars per share)   $ 9
Affiliates of Third Security, LLC; January 2018    
Class of Stock [Line Items]    
Underlying Shares   250,000
Exercise Price (in dollars per share)   $ 9
Various Institutional Holders; April 2020    
Class of Stock [Line Items]    
Underlying Shares   374,618
Exercise Price (in dollars per share)   $ 4.00
Various Institutional Holders; February 2020    
Class of Stock [Line Items]    
Underlying Shares   714,780
Exercise Price (in dollars per share)   $ 2.24
Various Institutional Holders; December 2020    
Class of Stock [Line Items]    
Underlying Shares   122,433
Exercise Price (in dollars per share)   $ 1.66
Various Institutional Holders; January 2021    
Class of Stock [Line Items]    
Underlying Shares   1,161,972
Exercise Price (in dollars per share)   $ 1.21
Affiliates of Third Security, LLC; January 2021    
Class of Stock [Line Items]    
Underlying Shares   161,026
Exercise Price (in dollars per share)   $ 1.21
Various Institutional Holders; January 2021    
Class of Stock [Line Items]    
Underlying Shares   107,527
Exercise Price (in dollars per share)   $ 1.21
XML 44 R35.htm IDEA: XBRL DOCUMENT v3.7.0.1
STOCKHOLDERS' EQUITY (Preferred Stock Series A) (Details)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended
Dec. 29, 2010
USD ($)
$ / shares
shares
Nov. 30, 2011
USD ($)
Mar. 31, 2017
Director
shares
Mar. 31, 2016
USD ($)
Dec. 31, 2016
shares
Jan. 06, 2016
$ / shares
Class of Stock [Line Items]            
Preferred stock, shares authorized (in shares) | shares     15,000,000   15,000,000  
Proceeds from issuance of common stock and convertible notes | $ $ 6,000          
Payments of stock issuance costs | $       $ 219    
Minimum            
Class of Stock [Line Items]            
Number of directors | Director     2      
Series A Preferred Stock            
Class of Stock [Line Items]            
Common stock warrant, exercise price (in dollars per share) | $ / shares $ 2.32         $ 1.00
Convertible notes, number of securities called by note | shares 1,293,102          
Payments of stock issuance costs | $ $ 200          
Preferred stock | Series A Preferred Stock            
Class of Stock [Line Items]            
Preferred stock, shares authorized (in shares) | shares     3,879,307      
Private placement, net (in shares) | shares 2,586,205          
Common stock warrant, exercise price (in dollars per share) | $ / shares $ 2.32          
Preferred stock, dividend rate (percentage)     10.00%      
Preferred Stock, compound dividend rate maximum (percentage)     50.00%      
Common Stock            
Class of Stock [Line Items]            
Redemption value adjustment | $   $ 300        
XML 45 R36.htm IDEA: XBRL DOCUMENT v3.7.0.1
STOCKHOLDERS' EQUITY (Preferred Stock Series B) (Details)
$ / shares in Units, $ in Millions
Jan. 06, 2016
Mar. 05, 2014
USD ($)
$ / shares
shares
Mar. 31, 2017
$ / shares
Dec. 31, 2016
$ / shares
Jan. 24, 2013
$ / shares
shares
Class of Stock [Line Items]          
Preferred stock, par value (in dollars per share)     $ 0.01 $ 0.01  
Series B preferred stock          
Class of Stock [Line Items]          
Conversion ratio 1        
Preferred Stock | Series B preferred stock          
Class of Stock [Line Items]          
Conversion ratio 1        
Third Security LLC and affiliates          
Class of Stock [Line Items]          
Common stock warrant, exercise price (in dollars per share)   $ 11.73     $ 12.96
Common stock warrant, common stock called (in shares) | shares   1,212,665     1,097,600
Third Security LLC and affiliates | Preferred Stock | Series B preferred stock          
Class of Stock [Line Items]          
Private placement, net (in shares) | shares   1,443,297      
Preferred stock, par value (in dollars per share)   $ 0.01      
Share price (in dollars per share)   $ 4.85      
Private placement, net | $   $ 7.0      
Conversion ratio   1      
Third Security LLC and affiliates | Preferred Stock | Series B preferred stock          
Class of Stock [Line Items]          
Conversion ratio   1      
XML 46 R37.htm IDEA: XBRL DOCUMENT v3.7.0.1
STOCKHOLDERS' EQUITY (Conversion of Preferred Stock) (Details)
$ / shares in Units, $ in Millions
 12 Months Ended
Jan. 06, 2016
USD ($)
$ / shares
shares
Dec. 31, 2014
Mar. 31, 2017
$ / shares
shares
Dec. 31, 2016
$ / shares
shares
Dec. 29, 2010
$ / shares
Conversion of Stock [Line Items]          
Preferred stock, par value (in dollars per share) | $ / shares     $ 0.01 $ 0.01  
Preferred stock, shares outstanding (in shares)     214,705 214,705  
Series A Preferred Stock          
Conversion of Stock [Line Items]          
Preferred stock, par value (in dollars per share) | $ / shares $ 0.01        
Common stock warrant, exercise price (in dollars per share) | $ / shares $ 1.00       $ 2.32
Conversion ratio 0.3333        
Common stock dividend (shares) 3,681,590        
Preferred stock, shares outstanding (in shares) 0        
Series B preferred stock          
Conversion of Stock [Line Items]          
Conversion ratio 1        
Preferred stock, shares outstanding (in shares) 0        
Preferred Stock | Series A Preferred Stock          
Conversion of Stock [Line Items]          
Common stock warrant, exercise price (in dollars per share) | $ / shares         $ 2.32
Conversion ratio   4      
Number of shares converted, shares 2,586,205        
Dividends payable | $ $ 3.7        
Preferred Stock | Series B preferred stock          
Conversion of Stock [Line Items]          
Conversion ratio 1        
Number of shares converted, shares 1,443,297        
Dividends payable | $ $ 0.8        
Common Stock          
Conversion of Stock [Line Items]          
Number of shares converted, shares 2,305,354        
Common Stock | Series A Preferred Stock          
Conversion of Stock [Line Items]          
Number of shares converted, shares 862,057        
Stock dividends (shares) 793,235        
Shares, issued (shares) 6,780,179        
Common Stock | Series B preferred stock          
Conversion of Stock [Line Items]          
Number of shares converted, shares 1,443,297        
Shares, issued (shares) 4,474,825        
XML 47 R38.htm IDEA: XBRL DOCUMENT v3.7.0.1
STOCKHOLDERS' EQUITY (Preferred Stock Dividends) (Details)
Mar. 31, 2017
USD ($)
Preferred Stock  
Class of Stock [Line Items]  
Cumulative undeclared dividends, preferred stock $ 0
XML 48 R39.htm IDEA: XBRL DOCUMENT v3.7.0.1
FAIR VALUE (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended
Jan. 31, 2016
Feb. 28, 2012
Mar. 31, 2017
Mar. 31, 2016
Dec. 31, 2016
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
Common stock warrants issued (in shares)     2,933,106    
Warrants outstanding (shares)         3,334,011
2012 Warrant Liability          
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
Common stock warrants issued (in shares)   3,400,000      
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]          
Beginning balance $ 350   $ 0 $ 350  
Total (gains) or losses:          
Recognized in earnings     0 (330)  
Balance at end of period     $ 0 20  
2016 Warrant Liability          
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
Common stock warrants issued (in shares) 1,800,000        
Warrants outstanding (shares)     800,000    
Share price (in dollars per share)     $ 0.56    
Volatility (as a percent)     115.00%    
Risk-free interest rate (as a percent)     1.66%    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]          
Beginning balance $ 0   $ 582 0  
Additions     0 1,437  
Total (gains) or losses:          
Recognized in earnings     33 9  
Balance at end of period     $ 615 $ 1,446  
XML 49 R40.htm IDEA: XBRL DOCUMENT v3.7.0.1
STOCK OPTIONS (Stock Options) (Details) - Employee Stock Option - Equity Incentive Plan 2006 - USD ($)
 3 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Number of Options    
Outstanding at beginning of period (in shares) 738,026  
Granted (in shares) 0 14,000
Forfeited (in shares) (62,739)  
Outstanding at end of period (in shares) 675,287  
Exercisable at end of period (in shares) 547,957  
Weighted-Average Exercise Price    
Outstanding at beginning of period (in dollars per share) $ 3.59  
Granted (in dollars per share) 0.00  
Forfeited (in dollars per share) 2.12  
Outstanding at end of period (in dollars per share) 3.73  
Exercisable at end of period (in dollars per share) $ 4.25  
Stock options, expected to vest, outstanding (in shares) 661,914  
Stock options, expected to vest, outstanding, aggregate intrinsic value $ 0  
Stock options, expected to vest remaining contractual term 7 years 2 months  
XML 50 R41.htm IDEA: XBRL DOCUMENT v3.7.0.1
STOCK OPTIONS (Stock Appreciation Rights) (Details)
 3 Months Ended
Mar. 31, 2017
USD ($)
$ / shares
shares
Weighted-Average Exercise Price  
Unvested stock options, unrecognized compensation expense weighted average recognition period 1 year
SARs  
Number of SARs  
Exercisable (in shares) | shares 83,333
Weighted-Average Exercise Price  
Outstanding (in dollars per share) | $ / shares $ 4.32
Stock appreciation rights, aggregate intrinsic value, outstanding | $ $ 0
Unvested stock options, unrecognized compensation expense weighted average recognition period 6 years 6 months
XML 51 R42.htm IDEA: XBRL DOCUMENT v3.7.0.1
SUBSEQUENT EVENTS (Details) - USD ($)
 3 Months Ended
Apr. 13, 2017
Mar. 31, 2017
Subsequent Event [Line Items]    
Common stock warrants issued (in shares)   2,933,106
Subsequent Event    
Subsequent Event [Line Items]    
Common stock warrants issued (in shares) 1,150,000.00  
Common stock warrant, exercise price (in dollars per share) $ 0.50  
Subsequent Event | Precipio    
Subsequent Event [Line Items]    
Percentage of loan to related party 50.00%  
Secured debt $ 500,000  
Subsequent Event | Aegis Corp    
Subsequent Event [Line Items]    
Common stock warrants issued (in shares) 168,000  
Common stock warrant, exercise price (in dollars per share) $ 0.50  
Subsequent Event | Bridge Loan [Member]    
Subsequent Event [Line Items]    
Face amount $ 1,150,000.00  
Maximum additional bridge loan amount 100,000  
Proceeds from the sales of debt instrument $ 1,031,000  
Annual interest rate (as a percent) 4.00%  
Debt instrument, term 90 days  
Debt instrument, premium rate (percentage) 20.00%  
Placement fees $ 84,000  
Subsequent Event | Bridge Loan [Member] | Precipio    
Subsequent Event [Line Items]    
Face amount $ 561,500  
EXCEL 52 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 53 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 54 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 56 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 178 237 1 false 64 0 false 7 false false R1.htm 0001000 - Document - DOCUMENT AND ENTITY INFORMATION Sheet http://www.transgenomic.com/role/DocumentAndEntityInformation DOCUMENT AND ENTITY INFORMATION Cover 1 false false R2.htm 1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.transgenomic.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1001001 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICALS) Sheet http://www.transgenomic.com/role/CondensedConsolidatedBalanceSheetsParentheticals CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICALS) Statements 3 false false R4.htm 1002000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.transgenomic.com/role/UnauditedCondensedConsolidatedStatementsOfOperations UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 1005000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.transgenomic.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 5 false false R6.htm 1005001 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (PARENTHETICALS) Sheet http://www.transgenomic.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlowsParentheticals UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (PARENTHETICALS) Statements 6 false false R7.htm 2101100 - Disclosure - BUSINESS DESCRIPTION Sheet http://www.transgenomic.com/role/BusinessDescription BUSINESS DESCRIPTION Notes 7 false false R8.htm 2102100 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.transgenomic.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 2105100 - Disclosure - DISCONTINUED OPERATIONS Sheet http://www.transgenomic.com/role/DiscontinuedOperations DISCONTINUED OPERATIONS Notes 9 false false R10.htm 2107100 - Disclosure - DEBT Sheet http://www.transgenomic.com/role/Debt DEBT Notes 10 false false R11.htm 2108100 - Disclosure - CONTINGENCIES Sheet http://www.transgenomic.com/role/Contingencies CONTINGENCIES Notes 11 false false R12.htm 2109100 - Disclosure - INCOME TAXES Sheet http://www.transgenomic.com/role/IncomeTaxes INCOME TAXES Notes 12 false false R13.htm 2110100 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.transgenomic.com/role/StockholdersEquity STOCKHOLDERS' EQUITY Notes 13 false false R14.htm 2111100 - Disclosure - FAIR VALUE Sheet http://www.transgenomic.com/role/FairValue FAIR VALUE Notes 14 false false R15.htm 2112100 - Disclosure - STOCK OPTIONS Sheet http://www.transgenomic.com/role/StockOptions STOCK OPTIONS Notes 15 false false R16.htm 2114100 - Disclosure - SUBSEQUENT EVENTS Sheet http://www.transgenomic.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 16 false false R17.htm 2202201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 17 false false R18.htm 2305301 - Disclosure - DISCONTINUED OPERATIONS (Tables) Sheet http://www.transgenomic.com/role/DiscontinuedOperationsTables DISCONTINUED OPERATIONS (Tables) Tables http://www.transgenomic.com/role/DiscontinuedOperations 18 false false R19.htm 2307301 - Disclosure - DEBT (Tables) Sheet http://www.transgenomic.com/role/DebtTables DEBT (Tables) Tables http://www.transgenomic.com/role/Debt 19 false false R20.htm 2310301 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://www.transgenomic.com/role/StockholdersEquityTables STOCKHOLDERS' EQUITY (Tables) Tables http://www.transgenomic.com/role/StockholdersEquity 20 false false R21.htm 2311301 - Disclosure - FAIR VALUE (Tables) Sheet http://www.transgenomic.com/role/FairValueTables FAIR VALUE (Tables) Tables http://www.transgenomic.com/role/FairValue 21 false false R22.htm 2312301 - Disclosure - STOCK OPTIONS (Tables) Sheet http://www.transgenomic.com/role/StockOptionsTables STOCK OPTIONS (Tables) Tables http://www.transgenomic.com/role/StockOptions 22 false false R23.htm 2401401 - Disclosure - BUSINESS DESCRIPTION (Details) Sheet http://www.transgenomic.com/role/BusinessDescriptionDetails BUSINESS DESCRIPTION (Details) Details http://www.transgenomic.com/role/BusinessDescription 23 false false R24.htm 2402402 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narratives) (Details) Sheet http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesNarrativesDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narratives) (Details) Details http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesPolicies 24 false false R25.htm 2402403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Property, Plant and Equipment) (Details) Sheet http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Property, Plant and Equipment) (Details) Details http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesPolicies 25 false false R26.htm 2402404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Intangible Assets) (Details) Sheet http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Intangible Assets) (Details) Details http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesPolicies 26 false false R27.htm 2405402 - Disclosure - DISCONTINUED OPERATIONS (Revenues and Net Income (Loss)) (Details) Sheet http://www.transgenomic.com/role/DiscontinuedOperationsRevenuesAndNetIncomeLossDetails DISCONTINUED OPERATIONS (Revenues and Net Income (Loss)) (Details) Details http://www.transgenomic.com/role/DiscontinuedOperationsTables 27 false false R28.htm 2407402 - Disclosure - DEBT (Schedule of Debt) (Details) Sheet http://www.transgenomic.com/role/DebtScheduleOfDebtDetails DEBT (Schedule of Debt) (Details) Details http://www.transgenomic.com/role/DebtTables 28 false false R29.htm 2407403 - Disclosure - DEBT (Revolving Line and Term Loan) (Details) Sheet http://www.transgenomic.com/role/DebtRevolvingLineAndTermLoanDetails DEBT (Revolving Line and Term Loan) (Details) Details http://www.transgenomic.com/role/DebtTables 29 false false R30.htm 2407404 - Disclosure - DEBT (Convertible Promissory Notes) (Details) Notes http://www.transgenomic.com/role/DebtConvertiblePromissoryNotesDetails DEBT (Convertible Promissory Notes) (Details) Details http://www.transgenomic.com/role/DebtTables 30 false false R31.htm 2408401 - Disclosure - CONTINGENCIES (Details) Sheet http://www.transgenomic.com/role/ContingenciesDetails CONTINGENCIES (Details) Details http://www.transgenomic.com/role/Contingencies 31 false false R32.htm 2409401 - Disclosure - INCOME TAXES (Details) Sheet http://www.transgenomic.com/role/IncomeTaxesDetails INCOME TAXES (Details) Details http://www.transgenomic.com/role/IncomeTaxes 32 false false R33.htm 2410402 - Disclosure - STOCKHOLDERS' EQUITY (Common Stock) (Details) Sheet http://www.transgenomic.com/role/StockholdersEquityCommonStockDetails STOCKHOLDERS' EQUITY (Common Stock) (Details) Details http://www.transgenomic.com/role/StockholdersEquityTables 33 false false R34.htm 2410403 - Disclosure - STOCKHOLDERS' EQUITY (Common Stock Warrants) (Details) Sheet http://www.transgenomic.com/role/StockholdersEquityCommonStockWarrantsDetails STOCKHOLDERS' EQUITY (Common Stock Warrants) (Details) Details http://www.transgenomic.com/role/StockholdersEquityTables 34 false false R35.htm 2410404 - Disclosure - STOCKHOLDERS' EQUITY (Preferred Stock Series A) (Details) Sheet http://www.transgenomic.com/role/StockholdersEquityPreferredStockSeriesADetails STOCKHOLDERS' EQUITY (Preferred Stock Series A) (Details) Details http://www.transgenomic.com/role/StockholdersEquityTables 35 false false R36.htm 2410405 - Disclosure - STOCKHOLDERS' EQUITY (Preferred Stock Series B) (Details) Sheet http://www.transgenomic.com/role/StockholdersEquityPreferredStockSeriesBDetails STOCKHOLDERS' EQUITY (Preferred Stock Series B) (Details) Details http://www.transgenomic.com/role/StockholdersEquityTables 36 false false R37.htm 2410406 - Disclosure - STOCKHOLDERS' EQUITY (Conversion of Preferred Stock) (Details) Sheet http://www.transgenomic.com/role/StockholdersEquityConversionOfPreferredStockDetails STOCKHOLDERS' EQUITY (Conversion of Preferred Stock) (Details) Details http://www.transgenomic.com/role/StockholdersEquityTables 37 false false R38.htm 2410407 - Disclosure - STOCKHOLDERS' EQUITY (Preferred Stock Dividends) (Details) Sheet http://www.transgenomic.com/role/StockholdersEquityPreferredStockDividendsDetails STOCKHOLDERS' EQUITY (Preferred Stock Dividends) (Details) Details http://www.transgenomic.com/role/StockholdersEquityTables 38 false false R39.htm 2411402 - Disclosure - FAIR VALUE (Details) Sheet http://www.transgenomic.com/role/FairValueDetails FAIR VALUE (Details) Details http://www.transgenomic.com/role/FairValueTables 39 false false R40.htm 2412402 - Disclosure - STOCK OPTIONS (Stock Options) (Details) Sheet http://www.transgenomic.com/role/StockOptionsStockOptionsDetails STOCK OPTIONS (Stock Options) (Details) Details http://www.transgenomic.com/role/StockOptionsTables 40 false false R41.htm 2412403 - Disclosure - STOCK OPTIONS (Stock Appreciation Rights) (Details) Sheet http://www.transgenomic.com/role/StockOptionsStockAppreciationRightsDetails STOCK OPTIONS (Stock Appreciation Rights) (Details) Details http://www.transgenomic.com/role/StockOptionsTables 41 false false R42.htm 2414401 - Disclosure - SUBSEQUENT EVENTS (Details) Sheet http://www.transgenomic.com/role/SubsequentEventsDetails SUBSEQUENT EVENTS (Details) Details http://www.transgenomic.com/role/SubsequentEvents 42 false false All Reports Book All Reports tbio-20170331.xml tbio-20170331.xsd tbio-20170331_cal.xml tbio-20170331_def.xml tbio-20170331_lab.xml tbio-20170331_pre.xml true true ZIP 58 0001043961-17-000009-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001043961-17-000009-xbrl.zip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�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Ð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end